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Neural tube defects (NTDs) are among the most severe and prevalent human 
congenital malformations. Their etiology is complex and multifactorial, influenced by 
dynamically interacting genetic and environmental factors. It is well known that maternal 
dietary folate status is the greatest modifying factor associated with risk for NTD-affected 
pregnancies, and that dietary fortification of folic acid (FA) can prevent a significant 
proportion of NTDs. However, many NTDs have proven to be FA-resistant, presenting a 
need to understand mechanisms underlying these FA-resistant defects and develop novel 
intervention strategies targeting this population. A class of FA-resistant NTD mouse 
models have been developed by inactivating genes associated with mitochondrial one-
carbon metabolism (mOCM). Thus, Part One of this work sought to elucidate mechanisms 
by which impaired mOCM results in FA-resistant NTDs. By crossing mice heterozygous 
for loss of Slc25a32, a gene coding for the mitochondrial folate transporter, with mice 
heterozygous for the Crooked Tail (Cd) allele of Lrp6, a gene coding for a Wnt co-receptor, 
it was discovered that a proportion of resulting co-heterozygous offspring presented with 
 vii 
NTDs, suggesting a novel digenic interaction between Lrp6 and mOCM. Further 
experiments demonstrated that Lrp6 regulates expression of mOCM genes in mouse 
embryos, while CHO cells lacking Slc25a32 demonstrated impaired Wnt signaling rescued 
by the one-carbon donor, glycine. Building on those data, it was discovered that maternal 
glycine supplementation could prevent NTDs in Slc25a32 null embryos, and that glycine 
or serine supplementation may reduce NTDs in Lrp6 Cd mice. Part One experiments also 
demonstrated that embryonic stem cells lacking Mthfd1l, another mOCM gene, have 
proliferation defects and are sensitive to hypoxia. 
 Environmental exposure to certain pharmaceutical compounds also increases risk 
for NTDs. Part Two of this work sought to identify mechanisms of NTD pathology 
associated with two common pharmaceuticals, the anticonvulsant, valproic acid (VPA), 
and the HIV integrase inhibitor, dolutegravir (DTG). Untargeted metabolic profiling was 
performed on VPA-treated mouse embryos, and predictive biomarkers of VPA sensitivity 
were identified by comparing VPA-affected and unaffected embryos. Other experiments 
identified a novel, calcium-enhanced interaction between DTG, folate, and folate receptor, 
suggesting a plausible mechanism by which DTG may enhance NTD risk. 
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Chapter 1: Introduction 
1.1 NEURAL TUBE DEFECTS 
1.1.1 Embryology of Neural Tube Defects 
Neural tube defects (NTDs) are severe congenital defects characterized by 
anatomical anomalies of the fetal or infant central nervous system (CNS, brain or spinal 
cord). In vertebrates, the CNS arises from an embryonic structure known as the neural tube 
which, in amphibian and amniote vertebrate taxa, develops from a flat sheet of 
neuroepithelial tissue, known as the neural plate, through complex morphological tissue 
movements that ultimately result in bending and folding of the neuroepithelium into a 
closed tube (Nikolopoulou et al. 2017). These processes are collectively described as 
primary neurulation or neural tube closure (NTC).  
The complex morphogenesis of NTC requires tissue-level coordination of several 
morphological and cellular events. For example, NTC first requires elongation of the neural 
plate along the embryo’s anterior-posterior (AP) axis with simultaneous narrowing of the 
plate’s mediolateral (ML) width. This process, known as convergent extension, is 
accomplished through dynamic intercalation of neural plate cells along these two axes 
(Wallingford, Fraser, and Harland 2002; Huebner and Wallingford 2018), and requires 
coordinated mediation of cell-cell interactions and cytoskeletal dynamics by the 
Wnt/Planar Cell Polarity signaling pathway (Wallingford 2012; Butler and Wallingford 
2017). The bending and folding process that shapes the neural plate into a tube is similarly 
complex. A wedge forms along the midline of the neural plate through a cellular process 
known as apical constriction, whereby the apical surface of individual neuroepithelial cells 
constricts relative to the basal surface forming a point of bent tissue called the mediolateral 
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hinge point (MHP) (Nikolopoulou et al. 2017). This process of apical constriction is 
similarly observed at two points adjacent to either side of the MHP known as the 
dorsolateral hinge points (DLHPs) (Shum and Copp 1996). Bending at the MHP and 
DLHPs is thought to generate mechanical force necessary to fold the neural plate and bring 
the neural folds in apposition to one another allowing for subsequent fusion (Eom, 
Amarnath, and Agarwala 2013). It appears the non-neural surface ectoderm may also play 
a role in generating these mechanical forces (Nikolopoulou et al. 2019). Apical constriction 
itself is complex at the cellular level, mediated by cell-cell interactions (Baumholtz et al. 
2017), modulation of cytoskeletal dynamics (Haigo et al. 2003; Copp and Greene 2010; 
Escuin et al. 2015), and coordination of cell cycle and cell polarity (Eom, Amarnath, and 
Agarwala 2013). Final tissue fusion of the neural folds at the dorsal midline is perhaps the 
most poorly understood morphogenic aspect of NTC, but clearly requires complex and 
coordinated cell behaviors, such as cellular extension of membrane protrusions between 
the apposed tissues (Pai et al. 2012; Ray and Niswander 2012; Eom, Amarnath, and 
Agarwala 2013; Rolo et al. 2016). Disruption of any of these morphological or cellular 
functions may result in failure of NTC leading to subsequent NTDs, thus illustrating the 
embryological intricacy underlying these defects. 
Adding to this complexity, there is a fair amount of diversity among vertebrates in 
their respective processes for NTC. For example, apart from convergent extension, neural 
tube development in zebrafish does not even closely resemble any of the morphogenic 
mechanisms outlined in the above description of primary neurulation. In zebrafish, the 
neural tube forms from post-convergent extension structures known as the neural keel and 
neural rod, which hollow into a tube through polarized cell divisions at the midline (Araya 
et al. 2016). In amphibians, NTC is nearly simultaneous along the entire AP axis of the 
embryo (Nikolopoulou et al. 2017), while primary neurulation in avian models occurs in a 
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continuous, bidirectional, zipper-like fashion along the AP axis from two separate initiation 
sites (Van Straaten et al. 1996). In mice, NTC is initiated at three separate locations along 
the AP axis: closure 1 occurring at the hindbrain/cervical boundary, closure 2 at the 
forebrain/midbrain boundary, and closure 3 initiating at the most rostral tip of the forebrain 
(Shum and Copp 1996; Greene and Copp 2009). NTC in humans is highly controversial 
given an inability to study human embryos using the same tools as other animal models. 
Some argue for a single closure site model of human primary neurulation (de Bakker et al. 
2017), while others favor evidence suggesting at least two or more sites of closure initiation 
(Van Allen et al. 1993; Nakatsu, Uwabe, and Shiota 2000; O'Rahilly and Muller 2002; 
Greene and Copp 2009). 
There is also a great deal of diversity in the presentation of NTDs depending on the 
severity and location of the defect along the AP axis. In humans, anterior NTDs (referring 
to the brain) are classified as anencephaly and are usually fatal prenatally or shortly after 
birth (Wallingford et al. 2013). In mice, anterior NTDs are referred to as exencephaly. 
Posterior NTDs (referring to the spine) are called spina bifida (Wallingford et al. 2013). 
This condition is survivable, but usually requires prenatal or postnatal surgical correction; 
but even then, spina bifida patients generally suffer lifelong complications associated with 
irreversible neurological damage, including bladder dysfunction, ambulatory problems, 
and cognitive impairment (McComb 1997; Young et al. 2013). Damage caused by the spina 
bifida lesion may also result in secondary conditions, such as hydrocephalus (whereby 
impaired drainage of cerebral spinal fluid results in accumulation of fluid in the brain 
ventricles increasing intracranial pressure) and Chiari-type II malformations (whereby the 
caudal cerebellum is pulled posteriorly through the foramen magnum, disrupting normal 
cerebellar development) (McComb 1997; McDowell et al. 2018; Steele et al. 2020). It is 
also important to note that there are various forms of spina bifida as well (Centers for 
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Disease 2016). Myelomeningocele is the most severe form, characterized by protrusion 
and exposure of the spinal cord in an exposed cyst (McComb 1997). In the case of 
meningoceles, only the meninges of the spinal cord are exposed (McComb 1997), while in 
spina bifida occulta (the least severe form) there is an opening in the spine with no exposed 
neural tissue. Spina bifida occulta often goes unnoticed and undiagnosed (Centers for 
Disease 2016). It should also be noted that there is much debate about whether less severe 
subsets of spina bifida are the result of failed NTC or unrelated dysplasia of vertebrae in 
the spine (Greene and Copp 2014). The rarest, most severe, and fatal form of NTD, 
craniorachischisis, is characterized by failed NTC along the entire AP axis (Wallingford et 
al. 2013; Greene and Copp 2014). Several other birth defects of the CNS are often classified 
as NTDs, despite being cephalic disorders that likely do not occur through failed primary 
neurulation (Wallingford et al. 2013; Greene and Copp 2014). Examples include 
encephaloceles, iniencephaly, and hydranencephaly. Ultimately, the complexity of the 
cellular and molecular processes orchestrating NTC, the diverse embryology of neural tube 
development among various animal models, and the diversity of the various classifications 
of these defects illustrate the challenges of studying the underlying mechanisms of NTDs. 
1.1.2 Etiology of Neural Tube Defects 
NTDs are estimated to affect approximately 18.6 per 10,000 live births globally 
(Blencowe et al. 2018). Their etiology is complex and multifactorial, influenced by 
interacting genetic and environmental factors (Wallingford et al. 2013). Associated genetic 
factors alone are quite numerous, with over 300 genetic NTD mouse models having been 
identified thus far (Wilde, Petersen, and Niswander 2014). These NTD associated genes 
span a wide range of biological functions and pathways, including one-carbon metabolism, 
Wnt signaling, planar cell polarity, DNA repair, energy metabolism, retinoid metabolism, 
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cytoskeletal function, cell-cell junctions, and oxidative stress, among many others 
(Wallingford et al. 2013). In the last decade, NTD research funding has heavily emphasized 
genomic association studies of small-scale cohorts with some success in identifying 
associated human variants. However, the rare and diverse nature of these defects makes it 
difficult to obtain sample sizes that are large enough to elicit sufficient statistical power for 
proper risk assessment of identified variants (Steele, Kim, and Finnell 2020). Often, these 
smaller-scale studies are limited to identifying candidate genes and variants without 
conventional validation. The complex genetic architecture underlying NTDs is best 
described by the omnigenic model of inheritance (Boyle, Li, and Pritchard 2017), whereby 
several “core” variants interact with all other variants across the genome to elicit complex 
traits. This concept is best illustrated by a recent study demonstrating that accumulation of 
singleton loss-of-function variants beyond a threshold level is determinative of NTD risk, 
likely more so than any one variant in any particular gene (Chen et al. 2018). Thus 
deepening our understanding of the genetic factors underlying NTDs requires an 
understanding of how candidate variants interact in a global genomic landscape (Steele, 
Kim, and Finnell 2020). 
This complex genetic etiology is further complicated when one factors in genomic 
interactions with environmental risk factors. Many environmental risk factors for NTDs 
have been identified, including maternal nutritional status (Wallingford et al. 2013), 
antiepileptic drug exposure (Wlodarczyk et al. 2012), as well as maternal diabetes and 
obesity (Wallingford et al. 2013). The challenge lies in understanding how these 
environmental risk factors interact with underlying genetic susceptibility predisposing to 
NTDs. A classic example of this concept is illustrated in mouse models of hyperthermia-
induced NTDs which demonstrate that some mouse strains are more sensitive to heat-
induced defects than others (Finnell et al. 1986; Finnell et al. 2000). More recently, using 
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mouse models of maternal diabetes, it was demonstrated that the teratogenic potential of 
maternal hyperglycemia is exacerbated in Mthfr and Folr1 mutant mouse strains, 
demonstrating a genetic interaction between folate metabolism and diabetes (Lopez-
Escobar et al. 2019). Clearly, NTD etiology is derived from interacting genetic and 
environmental influences, and elucidating these complex gene-environment interactions is 
key to developing targeted prevention strategies rooted in a precision medicine approach 
(Steele, Kim, and Finnell 2020). 
1.1.3 Prevention of Neural Tube Defects 
As mentioned, many NTD cases are fatal; but even treatable NTDs, such as spina 
bifida, generally result in permanent damage and lifelong disability. Thus, public health 
research has emphasized prevention by identifying the underlying genetic and 
environmental risk factors. Deploying intervention strategies during the periconceptional 
period is critical since NTC occurs relatively early in development, between days 19 and 
30 of gestation for humans, often before the mother is even aware of the pregnancy. By 
1998, it was well established that low maternal folate status was a significant modifier 
contributing to NTD birth outcomes, so the Food and Drug Administration (FDA) 
instituted mandatory folic acid (FA) fortification of the US food supply resulting in a 
nationally decreased prevalence of affected pregnancies by 36% ('Prevention of neural tube 
defects: results of the Medical Research Council Vitamin Study. MRC Vitamin Study 
Research Group'  1991; 'Folic acid to prevent neural tube defects'  1991; Williams et al. 
2002; Williams et al. 2015). More than two decades later; however, FA remains the only 
effective weapon in the arsenal of NTD prevention; yet it has not come close to eliminating 
the public health burden of these debilitating defects. Despite knowing the protective 
properties of FA, many countries do not impose mandatory FA fortification; and as a result, 
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an estimated 230,000 children are born each year with folate-preventable defects 
(Kancherla et al. 2018). In addition, a significant proportion of NTDs are not preventable 
by FA fortification, with these FA-resistant NTDs occurring at an apparent baseline rate of 
5 per 10,000 live births (Heseker et al. 2009). As such, there remains a critical need to 
understand the mechanisms underlying FA-resistant NTDs and to develop novel 
intervention strategies targeting this population. 
Several alternative preventions have been proposed. Inositol, for example, has been 
advocated as a potential intervention for NTDs associated with maternal diabetes, after 
finding that myo-inositol supplementation reduced the proportion of NTD-affected 
offspring in a diabetic rat model from 20.4% to 9.5% (Reece et al. 1997). A small 
randomized pilot study was conducted in the United Kingdom comparing high risk mothers 
who had a previous NTD-affected pregnancy supplemented with FA or co-supplemented 
with FA and inositol. Three NTD recurrences were observed in the FA supplemented 
cohort, while no recurrences were observed in the co-supplemented cohort (Greene et al. 
2016). The authors are thus pursuing a larger randomized trial to confirm the efficacy of 
inositol supplementation for preventing FA-resistant NTDs (Greene, Leung, and Copp 
2017). Supplementation with the nucleotide precursors, thymidine, adenine, and guanosine 
monophosphate (GMP) were found to reduce occurrences of spina bifida, but not 
exencephaly, in the Curly tail mouse model of FA-resistant defects (Leung et al. 2013). 
Formate, a product of mitochondrial one-carbon metabolism that contributes carbon units 
to thymidine and purine synthesis, has also been demonstrated to rescue NTDs in several 
FA-resistant mouse strains lacking genes necessary for mitochondrial one-carbon 
metabolism (Momb et al. 2013; Momb and Appling 2014; Pai et al. 2015; Kim et al. 2018; 
Santos et al. 2020). Most recently, quercetin, a flavonoid compound extracted from plants, 
has been demonstrated to reduce NTDs in models of diabetic embryopathy, and it is 
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believed to function through amelioration of oxidative stress (Cao et al. 2016; Khaksary 
Mahabady et al. 2016; Tan et al. 2018). Notably, these proposed alternate interventions all 
seem to prevent NTDs in specific genetic or environmental contexts, emphasizing that a 
precision medicine paradigm may be necessary to develop future prevention strategies by 
targeting appropriate supplements to the appropriate patient based on genetics or 
environmental risk factors. 
1.2 ONE-CARBON METABOLISM 
One-carbon metabolism (OCM) is a subset of enzymatic, single-carbon transfer 
reactions mediated by the vitamin coenzyme, folate (vitamin B9). OCM has many relevant 
links to human health and disease, including cancer, birth defects, cardiovascular health, 
and cognition (Ducker and Rabinowitz 2017). One-carbon (1-C) units from serine, glycine, 
and other carbon donors are shuttled through the pathway and partitioned to various 
functions, such as de novo nucleotide synthesis, essential for DNA replication and RNA 
transcription, and the methylation cycle which contributes to epigenetic methylation of 
DNA and post-translational modifications of protein.  Additionally, some reactions driving 
OCM promote turnover of the reducing equivalents NADP+ and NAD+, synthesize ATP, 
and connect centrally to other metabolic pathways, such as amino acid metabolism, energy 
metabolism, transsulfuration/glutathione synthesis, and choline metabolism (Ducker and 
Rabinowitz 2017). Therefore, OCM influences critical cellular functions such as 
proliferation, gene expression, regulation of protein function, protein synthesis, and general 
maintenance of metabolic homeostasis and cellular redox balance. The protective influence 
of FA against NTDs, the identification of OCM mutant mouse models displaying NTD 
phenotypes, and the discovery of human OCM gene variants in NTD cases demonstrates 
the importance of this pathway in NTC (Wallingford et al. 2013; Steele, Kim, and Finnell 
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2020). That said, given the variety of biological functions connected to OCM, we lack a 
sufficient understanding of the complicated underlying mechanisms through which OCM 
contributes to NTC and by which FA elicits its protective effects (Wallingford et al. 2013). 
Furthermore, the identification of FA-resistant mouse models with functional impairment 
of OCM illustrate the necessity to better understand the role OCM plays in NTD pathology 
and prevention (Momb and Appling 2014). 
1.2.1 Folate 
Folate, or vitamin B9, is an essential vitamin that works as a coenzyme for OCM 
reactions by serving as a carrier for 1-C units and facilitating partitioning of those units to 
various functions. A variety of molecular folate species exist characterized by their varying 
oxidation states. Folic acid (FA), for example, the inexpensive synthetic form usually used 
for dietary supplementation or fortification, is an oxidized species that must be biologically 
reduced to tetrahydrofolate (THF) to be utilized for OCM. This reduction occurs through 
the dihydrofolate reductase enzyme (DHFR) in two steps. First, FA is reduced to 
dihydrofolate (DHF), a naturally occurring folate species within cells generated as a 
product of thymidine synthesis by oxidizing 1-C loaded THFs. DHFR also reduces DHF 
back to THF; thus, the natural role of DHFR is to regenerate cellular THF pools consumed 
during thymidine synthesis. Importantly, while plants are capable of photosynthesizing 
folates, animals cannot, and therefore must obtain them from their diet (Ducker and 
Rabinowitz 2017).  
THF’s molecular structure consists of a pteridine ring linked to para-aminobenzoic 
acid (Figure 1.1). The N5 nitrogen on the pteridine ring and the N10 nitrogen on the para-
aminobenzoate moiety are each capable of hosting a 1-C unit individually (i.e. 5-formyl-
THF, 5-methyl-THF, 10-formyl-THF) or together bridged through a single carbon (i.e. 
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5,10-methylene-THF and 5,10-methenyl-THF). Cellular folates are also typically poly-
glutamated (Figure 1.1), which is essential for cellular retention of folates (McBurney and 
Whitmore 1974; Taylor and Hanna 1977; Kim et al. 1996). This “poly-glutamated tail” is 
synthesized by the enzyme folylpolyglutamate synthetase (FPGS) (Shane 1989). 
Interestingly, FPGS has differentially spliced cytosolic and mitochondrial isoforms and 
poly-glutamated folates are not transported across the mitochondrial membrane, suggesting 
poly-glutamination may also play a role in the sub-cellular compartmentalization of folates 




Figure 1.1 Molecular Structure of Tetrahydrofolate (THF) 
THF is composed of a pteridine ring, a para-aminobenzoic acid moiety, and a poly-
glutamate tail. Carbon units can be carried on the N5 nitrogen (R1), on the N10 nitrogen 
(R2), or both in various oxidation states. 
(Figure from Tibbetts and Appling (2010)). 
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1.2.2 Folate Transport 
Folates are transported into cells via various folate transporters (Figure 1.2). Parts 
of this section on folate transport have been previously published in a review for which the 
dissertation author contributed in the journal Biochimie, “One-carbon metabolism and 
folate transporter genes: do they factor prominently in the genetic etiology of neural tube 
defects?” (Steele, Kim, and Finnell 2020). The previously published material will be 
denoted with quotes and additional indentation. 
1.2.2.1 Folate Receptors 
“Folate Receptors (FRs) are cysteine rich glycosylphosphatidylinositol-
anchored proteins that have a high binding affinity to folate and mediate the uptake 
of folate to cells via endocytosis-mediated internalization of receptor-folate 
complexes (Chen et al. 2013). Folate is then released to the cytoplasm of cells from 
the acidified endosome followed by FR-mediated endocytosis with the help of the 
proton-coupled folate transporter (PCFT) (Zhao et al. 2009). It has also been 
proposed that FR1 may act as a nuclear transcription factor that regulates 
expression of pluripotency factors (Boshnjaku et al. 2012; Mohanty et al. 2016). 
The expression of folate receptors is limited to the placenta, the neural tube, and 
the kidney during embryonic development, and the expression of FR1 is limited to 
the epithelial cells of the choroid plexus, lung, and renal tubular cells in adults. 
Three separate genes (FR1, 2, and 3) encode folate receptors in humans, whereas 
there are only two genes (Folr1 and Folr2) in the mouse. Folr1 deficiency in mice 
is associated with cranial neural tube defects along with heart defects, facial 
malformations, and early embryonic lethality by embryonic day E10, whereas 
Folr2 depletion in the mouse results in no significant phenotypic malformations 
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(Piedrahita et al. 1999). The Folr1 nullizygous phenotypes can be rescued with 
maternal folate supplementation in the form of folinic acid (Piedrahita et al. 1999). 
A higher concentration of FR autoantibodies in maternal serum has been suggested 
to be a risk factor in human NTDs (Rothenberg et al. 2004) and a recent report 
implies the existence of a genetic association between FRs and myelomeningocele 
with the discovery of twelve novel variants in human cases (Findley et al. 2017). 
Folate deficiency due to a brain specific loss-of-function mutation of FOLR1 in 
humans is associated with cerebral folate transport defects that cause brain 
malformations and several neurological disorders including epilepsy, which can be 
partly reversed by folinic acid treatment (Steinfeld et al. 2009).” 
1.2.2.2 Reduced Folate Carrier (SLC19A1) 
“Reduced Folate Carrier 1 (RFC1) is an anion antiporter mediating the 
intake of reduced folates at a neutral pH, such as 5-methyltetrahydrofolate (5-
methyl-THF) or 5-formyltetrahydrofolate (5-formyl-THF); however, with 
relatively low affinity for folic acid (Yang, Sirotnak, and Dembo 1984). RFC1 is 
ubiquitously expressed during early development and is expressed in human tissues 
including the brush border of the small and large intestine, the basolateral 
membrane of renal tubular epithelium, hepatocytes, choroid plexus, and retinal 
pigment epithelium. Thus, it has been considered a primary folate transporter in 
cells. Rfc1 gene inactivation in mice is embryonic lethal before E6.5 (Gelineau-van 
Waes et al. 2008). Maternal folic acid supplementation of heterozygous dams with 
low dosage extended embryo survival until E9.5-E10.5, although they presented 
with severe neural tube defects, while high-dose folic acid supplementation rescued 
Rfc1 null embryos until term (E18.5) (Gelineau-van Waes et al. 2008). A common 
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human polymorphism of RFC1 (A80G) is associated with several diseases 
including neural tube defects (De Marco et al. 2003), and recently eight rare 
variants of RFC1, including one pathogenic variant, were found in 
myelomeningocele patients (Findley et al. 2017). These findings suggest a close 
association between RFC genes and neural tube closure defects in both the human 
and mouse.”   
1.2.2.3 Proton Coupled Folate Transporter (SLC46A1)  
“PCFT is an electrogenic folate transporter that is highly expressed in the 
duodenum and jejunum in humans (Qiu et al. 2006). It has the highest affinity for 
folate at pH5.5, and also has a high affinity for 5-methyl-THF and 5-formyl-THF 
under low pH conditions. PCFT mediates the folate absorption in the brush-border 
membrane of the small intestine, which has a low pH microenvironment. It is also 
a critical folate transporter in the central nervous system, as it mediates the folate 
absorption from blood to cerebrospinal fluid in the choroid plexus. Additionally, it 
has been reported that PCFT releases folates from acidic endosomes in cultured 
cells, suggesting a supportive role of PCFT in FR1 dependent folate transport (Zhao 
et al. 2009). Loss-of-function mutations in the PCFT gene in humans is associated 
with hereditary folate malabsorption (HFM) syndrome (Qiu et al. 2006), which 
causes systemic cerebral folate deficiency (CFD). This condition responds well to 
therapeutic intervention with chronic high dose folinic acid.  Pcft null mutant mice 
show a lack of folate uptake in the intestines and low folate concentration and 
subsequent increased homocysteine levels in serum and several organs. Therefore, 
the Pcft knockout mouse may serve as a murine HFM model. Parental folate 
supplementation was shown to rescue folate deficiency-induced anemia in Pcft 
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mutant mice and increased the survival length of Pcft KO [knockout] mice (Salojin 
et al. 2011).” 
1.2.2.4 Mitochondrial Folate Transporter (SLC25A32) 
Folates enter the mitochondria through the mitochondrial folate transporter (MFT), 
coded for by the gene SLC25A32 (Figure 1.2). MFT is localized to the impermeable 
mitochondrial inner membrane. The gene was identified from a mutant Chinese Hamster 
Ovary (CHO) cell line isolated from a mutagenesis screen for glycine-requiring mutants, 
which established four complementation cell lines demonstrating glycine-auxotrophy: 
glyA, glyB, glyC, and glyD (Kao, Chasin, and Puck 1969). Many of these mutants were 
later associated with serine catabolism; for example, the glyA mutation was identified in a 
gene encoding serine hydroxymethyl transferase (SHMT) activity (Simic et al. 2002). In 
addition to glycine auxotrophy, glyB cells lacked mitochondrial folate accumulation 
(Taylor and Hanna 1982). Retroviral transduction of a human placental cDNA library into 
glyB CHO cells discovered SLC25A32 to restore glycine prototrophy and mitochondrial 
folate uptake (Titus 2000). Transfection of wildtype hamster Slc25a32 cDNA in glyB 
mutant cells accomplished the same (McCarthy et al. 2004; Perchiniak et al. 2007). These 
observations make it clear that Slc25a32 codes for a transporter that shuttles folates into 
mitochondria. Since folate is a required coenzyme for catabolism of serine into glycine by 
mitochondrial serine hydroxymethyl transferase (SHMT2), a plausible mechanism is 
evident for glycine deficiency resulting from impairment of MFT. Evidence also indicates 
that MFT may be the only transporter through which folates enter mitochondria, since the 
mitochondrial folate pool is reduced by approximately 98% in glyB compared to wildtype 
CHO cells (Titus and Moran 2000; McCarthy et al. 2004).  
 16 
Knockout of Slc25a32 in mice is embryo-lethal by E12.5 accompanied by 100% 
penetrant NTD phenotypes (Kim et al. 2018). NTDs in this model are predominantly 
anterior and are FA-resistant; however, approximately 78% could be rescued with maternal 
formate supplementation (Kim et al. 2018). Modeling suggests that THF transport by MFT 
is dependent on π-cation interactions with residue Trp142, since site-specific mutagenesis 
of Trp142 in CHO cells rendered MFT unable to facilitate mitochondrial folate uptake 
(Lawrence, Hackett, and Moran 2011). One human NTD case has been identified with two 
heterozygous loss-of-function variants in SLC25A32, both with predicted disruption of the 
Trp142 residue (Kim et al. 2018). MFT also appears capable of shuttling FAD+/NAD+-like 
substrates as well (Spaan et al. 2005), and human variants have been associated with 
riboflavin-responsive exercise intolerance (Schiff et al. 2016). Finally, SLC25A32 is 
amplified in a range of human cancers, associated with both tumor proliferation and 
reduced patient survival, making MFT a proposed druggable target for cancer therapy 
(Santoro et al. 2020). 
1.2.3 Compartmentalization of One-carbon Metabolism 
OCM is physically compartmentalized in cells between the cytosol and 
mitochondria, with both compartments having their own distinct set of enzymes capable of 
performing 1-C transfer reactions (Tibbetts and Appling 2010) (Figure 1.2). Work done 
with S. cerevisiae in the 1990s supports that compartmentalization directs the conventional 
flow of 1-C units through OCM, with mitochondrial reactions typically proceeding in the 
oxidative direction, whereby 1-C units are loaded onto THF via catabolism of serine and 
glycine. Sarcosine or dimethylglycine derived from choline metabolism may also 
contribute 1-C units. The donated 1-C units are then oxidized to single-carbon formate 
ions, which are exported to the cytosolic compartment (Barlowe and Appling 1988; 
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Pasternack, Laude, and Appling 1992; Garcia-Martinez and Appling 1993; Yang and 
MacKenzie 1993; Pasternack, Laude, and Appling 1994; Pasternack et al. 1996; Appling 
et al. 1997; Kastanos, Woldman, and Appling 1997). Cytosolic OCM reactions then 
proceed in the reductive direction for partitioning of 1-C units to purine synthesis, 
thymidylate synthesis, or methionine synthesis (Tibbetts and Appling 2010). While these 
1-C transformation reactions are reversible, an electrochemical potential between 
mitochondrial NADH and cytosolic NADPH thermodynamically favors flux of 1-C units 
from mitochondria to cytosol in the form of formate, since cytosolic 5,10-methylene-THF 
dehydrogenase (MTHFD) activity utilizes NADPH as a reductive cofactor, while 
mitochondrial MTHFD uses both NADH and NADPH (Yang and MacKenzie 1993; West, 
Horne, and Appling 1996; Shin et al. 2014; Ducker and Rabinowitz 2017; Shin, Momb, 
and Appling 2017). It is theorized that eukaryotes evolved this compartmentalized strategy 
to uncouple the redox activity of OCM’s oxidation reactions from glycolytic energy 
metabolism, which is NADH-sensitive, thus promoting cellular “robustness” (Ducker and 
Rabinowitz 2017). It should also be noted that a third compartmentalization of OCM occurs 
in the nucleus (Tibbetts and Appling 2010). MTHFD1, DHFR, SHMT1 (serine hydroxy 
methyltransferase 1), a splice variant of SHMT2 (SHMT2α), and TYMS (thymidylate 
synthase) are all capable of nuclear localization (Anderson, Woeller, and Stover 2007; 
Woeller et al. 2007; Anderson and Stover 2009; Field et al. 2014). It appears that nuclear 
compartmentalization supports the specialized purpose of enhanced and localized 
thymidylate synthesis for DNA replication during S-phase of the cell cycle (McFarlane 




Figure 1.2 Overview of One-carbon Metabolism 
“Transport of folates into the cytosol and mitochondria are depicted by the blue and 
red circles, respectively. Compartmentalization of one-carbon metabolism between 
the cytosol and mitochondria is demonstrated, with key enzymes participating in 
one-carbon reactions displayed in gold font. The glycine cleavage system (GCS) 
includes the enzymes AMT and GLDC. Carbon units, carbon donors, and carbon 
acceptors are displayed in purple font. CH3-THF = 5-methyl-THF, CH2-THF = 
5,10-methylene-THF, CH+-THF = 5,10-methenyl- THF, CHO-THF = 10-formyl-
THF, AdoMet = S-adenosylmethionine, Hcy = homocysteine. *This figure was 
modified from our collaborators’ in Momb et al. 2013.” 
(Figure from Steele, Kim, and Finnell (2020))  
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Portions of the following three sections on mitochondrial OCM, cytosolic OCM, 
and the methionine cycle have been previously published in a review for which the 
dissertation author contributed in the journal Biochimie, “One-carbon metabolism and 
folate transporter genes: do they factor prominently in the genetic etiology of neural tube 
defects?” (Steele, Kim, and Finnell 2020). The previously published material will be 
denoted with quotes and additional indentation. 
1.2.3.1 Mitochondrial One-carbon Metabolism 
“Conventionally, it is understood that the majority of carbon units enter the 
cycle in the mitochondrial compartment, and through folate-mediated one-carbon 
transfers, are increasingly oxidized to produce the single-carbon ion, formate 
(Tibbetts and Appling 2010). The mitochondria-derived formate is then exported 
to the cytosol where it serves as the predominant carbon pool for cytosolic OCM 
(Tibbetts and Appling 2010). The specific role of mitochondrial OCM is of interest 
to identifying NTD risk and prevention, since mouse knockout models of certain 
mitochondrial OCM genes result in defects that are not folate responsive and are 
instead rescued by formate supplementation. As mentioned earlier, while folic acid 
is the primary line of defense in NTD prevention, a baseline rate of 5 per 10,000 
live births have proven to be unresponsive to folate (Heseker et al. 2009). 
Therefore, variants of mitochondrial OCM genes may contribute to these 
unpreventable cases, thus increasing NTD risk regardless of maternal folate status.” 
“In the mitochondria, THF can be loaded with carbon units donated from 
serine via the activity of SHMT2 (the mitochondrial serine 
hydroxymethyltransferase), from glycine via the glycine cleavage system, and 
dimethylglycine or sarcosine by DMGDH (dimethylglycine dehydrogenase) and 
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SARDH (sarcosine dehydrogenase) respectively. While few variants in SHMT2 and 
DMGDH have been identified in human patients, at least three SARDH 
polymorphisms (rs573904, rs2797840, and rs2873817) have been identified as 
nominally associated with NTD risk (Franke et al. 2009; Piao et al. 2016).” 
Knockout of Shmt2 in mice results in embryonic lethality, growth retardation, and 
impaired mitochondrial respiration, but does not cause NTDs (Tani et al. 2018). Serine 
catabolism by SHMT2 transfers one 1-C unit to THF, forming 5,10-methylene-THF and 
glycine as products (Figure 1.2). 
Glycine itself can contribute 1-C units to mitochondrial OCM via the glycine 
cleavage system (GCS) (Figure1.2). The GCS consists of four coupled enzymes attached 
to the mitochondrial inner membrane: the P-protein (glycine decarboxylase, GLDC), which 
decarboxylates the two-carbon glycine disposing of one carbon in the form of CO2; the T-
protein (amino-methyl transferase, AMT), which transfers the remaining carbon to THF, 
forming 5,10-methylene-THF and an ammonium ion; and the L and H proteins which 
participate in an oxidation-reduction reaction essential for the H-protein’s function 
(Kikuchi et al. 2008). Knockout of Gldc or Amt in mouse embryos results in NTDs 
(Narisawa et al. 2012; Pai et al. 2015). Notably, maternal formate supplementation reduces 
the occurrence of these defects and hydrocephalus in Gldc mutant mice (Pai et al. 2015; 
Leung et al. 2017; Santos et al. 2020). 
“Furthermore, variants in AMT and GLDC that may contribute to human 
NTD risk have been identified in several studies (Narisawa et al. 2012; Pai et al. 
2015; Shah et al. 2016).” 
Dimethylglycine and sarcosine are both metabolites of choline/betaine metabolism 
and can contribute 1-C units to mitochondrial OCM via the activities of dimethylglycine 
dehydrogenase (DMGDH) and sarcosine dehydrogenase (SARDH) respectively. In the 
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absence of THF, DMGDH and SARDH still function, but produce formaldehyde as a 
byproduct of the demethylation of their respective substrates (Wittwer and Wagner 1980). 
This formaldehyde may serve as an alternative source for mitochondrial formate, since it 
can be oxidized to formate through the activity of mitochondrial aldehyde dehydrogenase 
(ALDH2) (Morrow et al. 2015; Dorokhov et al. 2015). This may explain why mitochondria 
lacking MTHFD1L are still capable of producing formate (Bryant et al. 2018). 
 “After carbon units are loaded onto THF, they are oxidized to formate by 
the actions of mitochondrial enzymes MTHFD2/2L (methylene tetrahydrofolate 
dehydrogenase2/2L) and MTHFD1L. MTHFD2 and MTHFD2L are bifunctional, 
performing both dehydrogenation of 5,10-methylene-THF to 5,10-methyneyl-THF 
and subsequent hydrolysis of that product to 10-formyl-THF.  While mitochondrial 
10-formyl-THF may have multiple fates, including synthesis of formyl-methionine 
for mitochondrial gene translation, MTHFD1L specifically converts the formyl 
group to a free formate ion, regenerating THF in the process. While no variants in 
MTHFD2 or MTHFD2L have been associated with NTD risk, a common 
insertion/deletion polymorphism in MTHFD1L (rs3832406) was found to be 
loosely associated with NTDs in a human study (Parle-McDermott et al. 2009). 
Furthermore, knockout of this gene in mice results in NTD phenotypes similar to 
null Slc25a32 phenotypes, with Mthfd1l knockouts being similarly unresponsive to 
folate supplementation and rescuable by formate (Momb et al. 2013).” 
While MTHFD2 and 2L share redundant functionality, they are expressed at 
different stages of development. Mthfd2 is expressed only in embryos, while Mthfd2l 
expression turns on between E8.5 and E10.5 in mouse embryos, remains high through the 
remainder of gestation, and is also expressed in adult tissues (Bolusani et al. 2011; Bryant 
2017). While these enzymes were originally thought to be solely NAD+-dependent, it was 
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recently demonstrated that both MTHFD2L and MTHFD2 favor NAD+ and NADP+ under 
physiologically relevant conditions, although this has not been confirmed in vivo (Shin et 
al. 2014; Ducker and Rabinowitz 2017; Shin, Momb, and Appling 2017). Shin, Momb, and 
Appling (2017) propose that MTHFD2 is co-expressed with MTHFD2L during early 
embryogenesis to drive higher rates of mitochondrial 1-C flux to meet increased demand 
for 1-C units in rapidly proliferating cells. 
MTHFD1L and the various fates for mitochondrial 10-formyl-THF will be 
discussed more thoroughly in Chapter 3. 
1.2.3.2 Cytosolic One-carbon Metabolism 
“Once carbon units are exported to the cytosol in the form of 
mitochondrially-derived formate, they re-enter the folate cycle through the activity 
of MTHFD1. MTHFD1 is trifunctional, performing all three reactions carried out 
by the combined efforts of MTHFD2/2L and MTHFD1L in mitochondria, although 
typically in the reverse direction given a favorable flux of carbon units entering the 
cytosol as formate. A meta-analysis of nine studies spanning 4,300 NTD cases 
suggested that one particular polymorphism of MTHFD1 (rs2236225) increased the 
likelihood of neural tube defects by 15-30% (Jiang et al. 2014).” 
“Cytosolic 10-formyl-THF may contribute its carbon unit to purine 
synthesis via enzymes coded for by the genes GART and ATIC, both functioning at 
different steps in purine metabolism. The GART polymorphism, rs2070388, was 
determined to have an increased odds ratio of 1.89-1.96 in NTD cases compared to 
controls in an Irish study (Pangilinan et al. 2012).” 
Cytosolic 10-formyl-THF not utilized for purine metabolism may be oxidized by 
aldehyde dehydrogenase 1-like (ALDH1L1) to CO2, regenerating THF in the process. 
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Alternatively, 10-formyl-THF could be further reduced to 5,10-methylene-THF by 
MTHFD1 (Figure 1.2). 
“Cytosolic 5,10-methylene-THF could contribute carbon units to thymidine 
synthesis via thymidylate synthase (TYMS), to glycine and serine metabolism via 
the cytosolic serine hydroxymethyltransferase (SHMT1), or it could be reduced to 
5-methyl-THF by the enzyme MTHFR (methylene tetrahydrofolate reductase) to 
feed carbon units into the methionine cycle. When examining single nucleotide 
polymorphisms associated with NTD risk under conditions of low maternal folate 
status, SHMT1 variant, rs12939757, was associated with increased NTD risk in the 
infant (Etheredge et al. 2012). Interestingly, that same study found some maternal 
variants of TYMS and MTHFR, as well one infant variant of TYMS to be slightly 
protective against NTDs (Etheredge et al. 2012). That study also observed three 
variants of MTHFD1 (rs2236224, rs2236225, and rs11627387) to increase NTD 
risk (Etheredge et al. 2012). Of all OCM genes associated with human NTD risk, 
MTHFR mutant C677T is probably the most well-studied variant, being associated 
with a two to four-fold increase in NTD risk (Yaliwal and Desai 2012). Other 
MTHFR variants, such as the A1298C mutant, have also been identified to slightly 
increase NTD risk (Yaliwal and Desai 2012).” 
1.2.3.3 The Methionine Cycle 
“Carbon units from 5-methyl-THF can be used to synthesize methionine 
from homocysteine through the methionine synthase enzyme (coded for by MTR) 
in conjunction with its cofactor, vitamin B12. Methionine synthase reductase 
(coded by MTRR) is also required to activate the methionine synthase enzyme. A 
maternal study demonstrated enhanced risk for mothers harboring the rs1808349 
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MTRR variant, as well MTHFD1 rs2236225, MTHFR rs1801133, and RFC1 
rs1051226 (Cai et al. 2019). While studies have yielded conflicting results on the 
association of certain MTR variants on NTD risk, one meta-analysis looking at the 
common A66G mutant did not find increased NTD risk across 8 studies (Zhang et 
al. 2013).” 
“While methionine can be utilized in many aspects of amino acid 
metabolism, in the methionine cycle it is converted to S-adenosylmethionine 
(SAM) by methionine adenosyl transferase 1a (MAT1A). Carbon units from SAM 
are then unloaded by various methyl transferases for methylation of various 
substrates, including DNA, lipids, and proteins. The product of these 
demethylations of SAM is S-adenosylhomocysteine [SAH], which is converted 
back to homocysteine to regenerate methionine. Alternatively, homocysteine can 
be utilized for cysteine metabolism via the transsulfuration pathway to produce the 
critical antioxidant, glutathione. Increased homocysteine levels are a common risk 
factor for NTDs (Steegers-Theunissen et al. 1994), likely because elevated 
homocysteine is a biomarker for impaired OCM.” 
1.3 PHARMACEUTICAL EXPOSURES AND NEURAL TUBE DEFECTS 
Epilepsy is a neurological disorder characterized by spontaneous, recurrent 
seizures. Most epileptics require medication with an antiepileptic drug (AED, also known 
as an anticonvulsant) in order to reduce the frequency and severity of their seizures. AEDs 
are also used in the treatment of a wide range of other conditions (Wlodarczyk et al. 2012). 
Between 7.6 and 12.7 million women in the United States have epilepsy with close to 
25,000 epileptic pregnancies each year (Meador et al. 2008); but managing epilepsy during 
pregnancy can be challenging given maternal physiologic changes that can alter 
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pharmacodynamics and effectiveness of AED medications (Wlodarczyk et al. 2012). 
Moreover, it is firmly established that in utero AED exposure greatly enhances risk for 
adverse birth outcomes, with one study reporting major congenital malformations in 6.1% 
of AED treated epileptic pregnancies compared to 2.8% of epileptic pregnancies that went 
untreated (Tomson and Battino 2009). Common congenital anomalies observed from AED 
exposures include congenital heart defects, hypospadias, facial clefts, growth retardation, 
microcephaly, and NTDs (Wlodarczyk et al. 2012). Common AEDs include 
carbamazepine, phenytoin, phenobarbital, lamotrigine, levetiracetam, topiramate, 
gabapentin, vigabatrin, and valproic acid. The mechanisms of these various drugs as well 
as animal and human epidemiological studies assessing their teratogenic are thoroughly 
reviewed in Wlodarczyk et al. (2012). For the purposes of this dissertation, only valproic 
acid will be discussed further. 
Valproic acid (VPA), marketed as Depakene and Depakote among others, is used 
widely as an anticonvulsant, a mood stabilizer, a prophylactic, and is used in some cases 
for treatment of schizophrenia (Wlodarczyk et al. 2012). It was first approved for medical 
use in 1978 as an AED and has been effective against several types of seizures (Scott 1993; 
Marson 2015). VPA’s molecular interactions will be discussed more thoroughly in Chapter 
4, but in general it is believed to prevent seizures by inhibiting sustained repetitive firing 
of neurons after depolarization by increasing recovery of voltage-activated sodium 
channels (Pugsley et al. 1999). The teratogenic effects of VPA are clear, with several 
animal studies demonstrating dose-dependent induction of developmental anomalies, 
including NTDs (Petrere et al. 1986; Finnell et al. 1988; Hendrickx et al. 1988; Binkerd et 
al. 1988; Massa et al. 2005). In humans, several epidemiological surveys have been 
performed (Wlodarczyk et al. 2012); in the Neurodevelopmental Effects of Antiepileptic 
Drugs (NEAD) study, a prospective dose-dependent study on the effects of VPA and other 
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AEDs, it was determined that adverse pregnancy outcomes were observed in 20.3% of 
VPA treated pregnancies (Meador et al. 2006), and in general, it appears VPA is associated 
with a 10 to 20 fold increased risk for having an NTD-affected pregnancy (Wlodarczyk et 
al. 2012). The mechanisms through which VPA causes birth defects are not understood. It 
has been proposed that VPA may elicit congenital malformations through its roles as a 
histone-deacetylase (HDAC) inhibitor, thus interfering with the embryo’s epigenetic 
programming (Tremolizzo et al. 2005; Lloyd 2013). But other mechanisms have also been 
proposed, including oxidative stress and interference with folate transport or OCM 
(Alonso-Aperte et al. 1999; Frey et al. 2006; Khan et al. 2011; Lloyd 2013; Fathe, Palacios, 
and Finnell 2014; Semmler et al. 2017). Moreover, there is undoubtedly an underlying 
genetic component predisposing to AED risk. Studies in mice demonstrate that VPA 
sensitivity is strain-dependent, and that this sensitivity can be mapped to a specific genetic 
locus in Swiss-Vancouver (SWV) mice (Finnell et al. 1988; Finnell et al. 1997; Beck 1999; 
Finnell et al. 2000; Beck 2001; Lundberg et al. 2004). Since, VPA and other AEDs are still 
prescribed to women of childbearing potential and discontinuing AED use during 
pregnancy may also result in adverse outcomes with respect the mother’s epilepsy 
treatment, there is a critical need to elucidate the mechanisms of VPA-induced teratology, 
understand the underlying genetics predisposing to susceptibility, and develop alternative 
AEDs with lower teratogenic potential. 
Finally, AEDs are not the only class of pharmaceuticals associated with NTDs or 
other adverse pregnancy outcomes. Many acne medications contain tretinoin, which is a 
form of retinol (vitamin A). Retinoid metabolism plays an important role in embryonic 
development, as retinoic acid acts as a morphogen patterning the AP axis of the embryo 
and regulating body axis elongation (Rhinn and Dolle 2012). There is evidence to suggest 
exposure to tretinoin during pregnancy is associated with increased risk for NTDs ('Birth 
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defects due to topical adapalene and tretinoin'  1998; Lipson, Collins, and Webster 1993). 
More recently, the antiretroviral integrase inhibitor, dolutegravir (DTG), a clinically 
preferred antiretroviral therapy against HIV, was reported to potentially increase NTD risk 
after four NTD-affected infants were born in 2018 to mothers taking DTG in Botswana 
(Zash, Makhema, and Shapiro 2018). Subsequently, the World Health Organization issued 
guidelines that DTG be avoided by women of childbearing potential (WHO 2018). As of 
yet, it is unclear how DTG, and potentially other retroviral drugs of the same class, 
contribute to NTD risk, but Chapter 5 will present work demonstrating mechanisms of 




PART ONE: MECHANISMS OF IMPAIRED MITOCHONDRIAL 
ONE-CARBON METABOLISM IN NEURAL TUBE DEFECTS 
  
 29 
Chapter 2: Mechanistic Interactions between Lrp6 and Mitochondrial 
One-carbon Metabolism in Murine Neural Tube Defects 
2.1 INTRODUCTION 
LRP6 (low-density lipoprotein receptor-related protein 6) is a Wnt pathway co-
receptor (Brown et al. 1998). Four rare missense variants of LRP6 were identified from 
192 spina bifida cases in a California cohort (Lei et al. 2015), while seven more missense 
mutations were discovered from 343 NTD cases in a Chinese study (Shi et al. 2018) and 
285 NTD cases in Italy (Allache et al. 2014). Thus, LRP6 variants may contribute to some 
proportion of the population burden of these birth defects (perhaps 1-2%). Furthermore, 
several Lrp6 mutant mouse models have been developed displaying exencephaly, 
occasional spina bifida, or other congenital anomalies (Carter et al. 1999; Pinson et al. 
2000; Kokubu et al. 2004; Carter et al. 2005; Gray and Ross 2009; Gray et al. 2010; Allache 
et al. 2014). LRP6 demonstrates a dual role in mediating both canonical and non-canonical 
Wnt signaling (planar cell polarity) by promoting canonical Wnt activity and repressing 
non-canonical Wnt activity (Schweizer and Varmus 2003; Tamai et al. 2004; Gray et al. 
2013). The Crooked Tail (Cd) Lrp6 mutant, which harbors a point mutation (G494D) and 
was originally reported to be a canonical Wnt hypermorph (Carter et al. 2005), actually 
appears to be hypomorphic with respect to canonical Wnt activity since the Cd protein 
product fails to interact with its chaperon, MESDC2, and thus cannot localize to the plasma 
membrane (Lei et al. 2015). However, the allele is a hypermorph with respect to non-
canonical Wnt activity, and it is possible that both mechanisms contribute to NTDs 
independently in Cd homozygous embryos (Gray et al. 2013). 
Curiously, Lrp6 mouse models consistently suggest an interesting interaction with 
folate and OCM. Lrp6 null embryos are FA-resistant, even to the point of FA 
supplementation resulting in increased embryonic mortality with enhanced NTD rate in the 
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viable embryos (Gray and Ross 2009; Gray et al. 2010). In contrast, the Crooked Tail (Cd) 
Lrp6 mutant is FA-responsive, displaying a dose-dependent rescue of NTD phenotypes 
with FA supplementation (Carter et al. 1999; Carter et al. 2005). Collaborative work 
between the laboratories of Richard Finnell and Elizabeth Ross have found that genetic 
impairment of folate transport, through heterozygous knockout of Folr1, in conjunction 
with heterozygosity of the Cd allele results in a 41% frequency of exencephaly (Fathe 
2014), while NTDs in Cd heterozygotes alone are a rare occurrence (Figure 2.1). It was 
recently discovered that LRP2 mediates folate uptake and endocytosis of the folate receptor 
through direct molecular interaction (Kur et al. 2014); however, no evidence has been 
discovered to suggest that LRP6 similarly interacts with FOLR1. Metabolic analysis of 
Lrp6cd/cd adult livers compared to those of wildtype mice on high and low-folate diets 
demonstrated that Lrp6cd/cd dams share a common metabolic profile with the wildtype dams 
on low-folate diets, suggesting a defect in OCM or folate metabolism (Ernest et al. 2006). 
Furthermore, metabolic analysis of Lrp6-/- embryos demonstrated decreased levels of 
methionine, homocysteine, and glutathione, which further supports that LRP6 may act as 
a critical modifier of OCM (Hansler et al. 2014). That said, the precise mechanisms through 
which this Wnt pathway co-receptor interacts with folate and OCM remains unknown. 
The experiments presented in Chapter 2 test the hypothesis that LRP6 specifically 
interacts with mitochondrial OCM. By crossing Lrp6+/cd and Slc25a32+/gt dams, it was 
discovered that a certain proportion of co-heterozygous offspring display exencephaly. 
Subsequent experiments sought to elucidate the mechanistic interactions between Lrp6 and 
mitochondrial OCM, and to investigate the efficacy of the 1-C supplements, glycine or 




Figure 2.1 Digenic Interaction Between Lrp6 Cd and Folr1 Causes Exencephaly in 
Mouse Embryos 
A) E14.5-E15.5 mouse embryos resulting from crosses between Lrp6+/cd and Folr1+/- mice. 
The genotypes are displayed below the images and two examples of Cd/Folr1 co-
heterozygotes with exencephaly are shown on the far right.  
B) Table displaying proportion of exencephaly-affected embryos from each genotype. A 
41% NTD rate was observed in Lrp6+/cd; Folr1+/- embryos.  
*Statistical significance was determined using Fisher’s Exact Test, α=0.05.  
 
The data in panel B were published in Fathe (2014). 
 32 
2.2 MATERIALS AND METHODS 
2.2.1 Mouse Work 
2.2.1.1 General 
Lrp6 Cd (Carter et al. 1999) and Slc25a32 gt (Kim et al. 2018) mice were housed 
in Baylor College of Medicine’s (BCM) Neurosensory mouse facility on 12 hour light/dark 
cycles with standard chow and maintained according to protocols approved by the 
Institutional Animal Care and Use Committee (IACUC) at BCM. For experiments 
requiring timed mating, copulation was confirmed by morning checks for vaginal plugs, 
and pregnancy was confirmed by comparing dam weight on the date the plug was observed 
to weight measured on the date of sacrifice. Euthanasia was performed with CO2 
asphyxiation followed by cervical dislocation. 
2.2.1.2 Genotyping 
Genotyping for the Lrp6 Cd and Slc25a32 gt alleles was conducted using tail snips 
(adults) or yolk sacs (embryos) digested in DirectPCR Tail Buffer (Viagen, 101-T) with 
proteinase K (Viagen, 501-PK), shaking overnight at 55⁰C. The proteinase K was quenched 
post-digestion at 95⁰C for 10 minutes, and the crude DNA extracts were centrifuged at 
13,000 rcf for 30 seconds. DNA was amplified by polymerase chain reaction (PCR) using 
LongAmp Taq 2X Master Mix (NEB, M0287) (Lrp6 Cd) or One Taq Quick-Load 2X 
Master Mix with Standard Buffer (NEB, M0486) (Slc25a32) in 25μL reactions. Primers 
used for Lrp6 Cd PCR were as follows: F – 5’-TGACAAGCCATCAAGCAGAG-3’, R – 
5’-GCTCAGAGGCTATGTGAACCA-3’. For Lrp6 Cd, the amplified PCR product was 
then digested for 2 hours at 37⁰C with Blp1 restriction enzyme (NEB, R0585). Primers 
used for Slc25a32 PCR were as follows: F – 5’-AGTGTGTGAGCCGGTGCTTT-3’, R 
(wildtype allele) – 5’-TGGGTCCTGTGGAAAGGCTA-3’, R (gt allele) – 5’-
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CCAATAAACCCTCTTGCAGTTGC-3’. The genotypes were then determined by 
agarose gel electrophoresis. 
2.2.1.3 Glycine, Serine, and Formate Supplementation Experiments 
To determine the ability of glycine to rescue NTD phenotypes in Slc25a32gt/gt 
embryos, heterozygous mating pairs were set up and pregnant dams were provided 
2500mg/kg/d glycine ad libitum in drinking water continuously until euthanized (E12.5-
E13.5). To determine the ability of glycine, serine, or formate to rescue NTD phenotypes 
in Lrp6 Cd  embryos, heterozygous mating pairs were set up and plugged dams were 
provided 2500mg/kg/d glycine, 1250mg/kg/d L-serine, or 2500mg/kg/d calcium formate 
ad libitum in drinking water until sacrifice (E12.5-E13.5). The dosages were calculated 
based on the assumption that a 25g mouse consumes 5mL of water per day (Roscoe B. 
Jackson Memorial Laboratory and Green 1966). 
2.2.2 Isolation and Culture of Mouse Embryonic Fibroblasts 
Mouse embryonic fibroblasts (MEFs) were obtained from E13.5 embryos collected 
from Lrp6+/cd x Lrp6+/cd heterozygous crosses or Lrp6+/cd x Slc25a32+/gt mating pairs. After 
euthanasia, the mice were sprayed with 70% ethanol and the uterus was removed, washed 
with 70% ethanol, then washed with sterile PBS. Embryos were washed once with sterile 
PBS and collected in 15mL conical tubes containing a volume of 0.25% Trypsin-EDTA 
sufficient to cover the embryo. The yolk sacs were reserved for genotyping. The embryos 
were then subjected to three 10-minute incubations at 37⁰C in 0.25% Trypsin-EDTA with 
vigorous homogenization through a Pasteur pipette between each incubation. The final 
homogenization was performed using a 1000μL micropipette tip. The homogenized 
suspension was centrifuged for 5 minutes at 200 rcf; the Trypsin-EDTA was then aspirated, 
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and the cell pellet was washed once with MEF cell culture media: DMEM (Gibco, 
11965118), 10% FBS, 1% Penicillin-streptomycin or Anti-Anti (Gibco, 15240112). MEFs 
from individual embryos were then plated into gelatin-coated (EMD Millipore, ES-006-B) 
10cm cell culture dishes and cultured at 5% CO2, 37⁰C. MEFs were cryopreserved after 
two passages and utilized for experiments no later than passage five. Canonical Wnt 
signaling was measured via TCF/LEF Luciferase assays as described in section 2.2.4. 
2.2.3 CHO and glyB Cell Culture 
CHO-K1 and glyB mutant CHO cells were provided by Dr. Richard Moran 
(Virginia Commonwealth University, Richmond, VA) and maintained in MEM-alpha 
media (Gibco, 12561056), supplemented with 10% FBS and 1% Penicillin-streptomycin. 
For experiments, the media was changed to a custom MEM-alpha formulation lacking 
glycine to elicit glycine-auxotrophy in glyB. Autonomous canonical Wnt signaling was 
measured via TCF/LEF Luciferase assays as described in section 2.2.4 and qPCR to 
measure Lrp6 and Wnt gene expression was performed as described in section 2.2.6. 
Supplementation experiments to rescue observed defects in autonomous Wnt signaling 
were performed by addition of 100μM palmitic acid, 0.1mM glycine, 0.4mM glycine, or 
1.6mM glycine to the custom MEM media. 
2.2.4 TCF/LEF Luciferase Assay 
Canonical Wnt activity was measured using a Dual-Luciferase Reporter Assay 
(Promega, E1910/E1960). MEFs or CHO-K1 and glyB cells were plated on day one in 24 
well plates and incubated for 24 hours in a CO2 incubator in their respective media. For 
CHO and glyB experiments, the non-customized MEM formulation was used at this stage 
of the experiment. Each treatment for each cell line was repeated in at least three replicate 
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wells. On day two, cells were transfected with 200ng of TCF/LEF LUC plasmid vector 
(expressing Firefly luciferase driven by TCF/LEF promotor) and 50ng of pRL-SV40 
control vector (expressing Renilla luciferase driven by a constitutive SV40 promoter) for 
4 hours in 500μL Opti-MEM (Gibco, 31985070) at 5% CO2, 37⁰C. Firefly luciferase 
negative controls were transfected with pRL-SV40 only. The transfection media was 
aspirated, cells were washed once with PBS, and provided complete growth media for 
overnight recovery. On day three, cells were provided experimental growth media. For 
Lrp6 Cd MEF experiments described in Section 2.3.1 and Figure 2.2., this included 
experimental media consisting of either unconditioned MEF media, or Wnt3a conditioned 
media derived from ATCC L-Wnt-3A (ATCC CRL-2647) cultures. For experiments 
utilizing MEFs derived from Lrp6+/cd x Slc25a32+/gt crosses described in Section 2.3.7 and 
Figure 2.11, this consisted of either untreated MEF media or MEF media supplemented 
with 100ng/μL Wnt3a (recombinant mouse protein). For CHO-K1 and glyB experiments 
described in sections 2.3.6 and 2.3.7 and Figures 2.10, 2.13, and 2.14, this consisted of the 
customized MEM-alpha formulation without supplementation or supplemented as 
described in Section 2.2.3. Cells were incubated in their respective experimental growth 
media for 16-18 hours at 5% CO2, 37⁰C. After which, the media was aspirated, the cells 
were washed once with PBS, covered with 100μL of passive lysis buffer (Promega, 
E1910/E1960), and rocked at room temperature for 15 minutes. Cell lysates were 
transferred to microcentrifuge tubes and centrifuged at 12,000 rcf for 1 minute at 4⁰C. 10μL 
of lysate from each sample was then transferred to a well of an opaque-bottom 96-well 
plate and luminescence was measured using a plate reader luminometer after addition of 
50μL beetle luciferin substrate mix (LARII, Promega), followed by a second reading after 
addition of 50μL coelenterazine substrate mix (Stop & Glo, Promega). The ratio of Firefly 
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luciferase luminescence was divided by the ratio of Renilla luminescence for 
normalization. 
2.2.5 Quantification of Serum Folate 
Serum was collected from wildtype and heterozygous Lrp6 Cd (n=7 Lrp6+/+, n=5 
Lrp6+/cd) and Slc25a32 gt dams (n=5 Slc25a32+/+, n=5 Slc25a32+/gt) that were 
approximately three to four months of age. Whole blood was collected from facial vein 
bleeds using a 5mm lancet. The morphotic elements were quickly removed before 
coagulation by centrifugation at 7,000 rcf for 30 seconds. The resulting serum was stored 
at -80⁰C until quantification. 
Serum folate levels were quantified using a competitive binding enzyme-linked 
immunosorbent assay (ELISA) as previously described in Cabrera et al. (2008) and Fathe, 
Palacios, and Finnell (2014). 25ng/μL folate binding protein (FBP) was plated in 1μL 
volumes onto 96 well plates and incubated overnight at 4⁰C. The wells were washed three 
times with TBS-T (Tris buffered saline with 0.05% Tween-20, pH 8.0) to remove excess 
FBP. Serial dilutions of known concentrations of folic acid (0 ng/mL to 6 ng/mL) were 
used to generate a competitive standard curve. Serum samples were diluted 1:39 in TBS-T 
containing 1% w/vol ascorbic acid (pH 3.0) and incubated at 95⁰C for 10 minutes to release 
bound folate. The samples were centrifuged for 7 minutes at 14,000 rcf and the supernatant 
was reserved and brought to neutral pH with NaOH. The folic acid serial standards and 
diluted, neutralized serum samples were supplemented 1:9 with an HRP labelled FA (FA-
HRP, Cal Bioreagents, C057). The FBP coated wells were incubated for 1 hour at room 
temperature with the standards and diluted serum samples in duplicate or triplicate wells 
for each standard or sample. The plates were then washed 3 times with TBS-T and once 
with TBS. 50 μL of HRP substrate (Super Signal ELISA Femto, Thermo Fisher, 37074) 
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was added to each well and the plates were immediately imaged using Quansys 
Biosciences’ Q-Views Imager and Software. Median pixel intensity for each well was 
exported to Microsoft Excel and the standard curve was plotted logarithmically. The folate 
concentrations in the diluted serum samples were interpolated from the logarithmic 
standard curve, multiplied by the dilution factor (40), and averaged between replicate wells 
to obtain the total serum folate (ng/mL) in each sample. 
2.2.6 RNA Extraction, qPCR, and RNA-seq 
2.2.6.1 RNA Extraction and Purification from Embryos and CHO Cells 
Total mRNA was extracted from E9.5 embryos collected from Lrp6+/cd x Lrp6+/cd 
heterozygous crosses or Lrp6+/cd x Slc25a32+/gt mating pairs. The embryos were dissected 
in PBS and placed in 100μL Tri-Reagent (Zymo, R2050), while the yolk sacs were reserved 
for genotyping. RNA was purified from the crude extracts using the Direct-zol RNA 
Miniprep Kit (Zymo, R2051) as per the manufacturer’s instructions. Total mRNA was 
extracted and purified from CHO-K1 and glyB cells using the RNeasy Minikit (Qiagen, 
74104) as per the manufacturer’s instructions. The homogenization step was performed 
using a syringe with a 20-gauge needle. The CHO-K1 and glyB RNA was extracted from 
confluent wells of a six well plate after 24 hours incubation in the custom, glycine-deficient 
MEM-alpha media described in Section 2.2.3. RNA quality and quantity were confirmed 
by a NanoDrop spectrophotometer, and all RNA was stored at -80⁰C until subsequent 
RNA-seq or cDNA synthesis. 
2.2.6.2 cDNA Synthesis and qPCR 
RNA from E9.5 Lrp6 Cd embryos (n=4 from each genotype) or from CHO-K1 or 
glyB cells (n=3 from each cell line) was reverse transcribed to cDNA using the High-
 38 
Capacity cDNA Reverse Transcription Kit (Applied Biosystems, 4368814) as per the 
manufacturer’s instructions. cDNA quality and quantity were confirmed by a NanoDrop 
spectrophotometer. Quantitative PCR (qPCR) was performed using SYBR Green PCR 
Master Mix in 10uL reactions using designed primers at 20nM each on an ABI Quantstudio 
Flex 7 thermocycler. Relative expression was determined using the comparative CT 
method. Genes targeted for qPCR in Lrp6 Cd embryos were as follows: Slc25a32, Shmt2, 
Gldc, Amt, Mthfd2l, Mthfd1l, Aldh1l2, Mtfmt, Mthfd1, Aldh1l1, Shmt1, Mthfr, Mtr, Dhfr, 
Bhmt, Folr1, Gapdh, Actb, Polm, Rpl13a, and Hprt. The primers used to amplify these 
genes are listed in Appendix I. Gapdh, Actb, Polm, Rpl13a, and Hprt were used as 
housekeeping genes. Genes targeted for qPCR in CHO-K1 and glyB were as follows: Lrp6, 
Wnt1, Wnt2, Wnt2b, Wnt3, Wnt3a, Wnt4, Wnt5a, Wnt5b, Wnt6, Wnt7a, Wnt7b, Wnt8a, 
Wnt8b, Wnt9a, Wnt9b, Wnt10a, Wnt10b, Wnt11, Wnt16, Gapdh, Actb, Polm, Rpl13a, and 
Hprt. The primers used to amplify these genes are listed in Appendix I.  
2.2.6.3 RNA-seq  
RNA from E9.5 embryos collected from Lrp6+/cd x Slc25a32+/gt crosses (n=4 per 
genotype, except for Lrp6+/cd; Slc25a32+/gt embryos where n=8, 4 with open neural tubes 
and 4 with closed neural tubes) were sequenced by a contractor, NovoGene (Beijing). 
RNA-seq data analysis was performed using kallisto and DEseq2 (Bray et al. 2016). Gene 
set enrichment analysis (GSEA) was performed using javaGSEA2-3.0 (Subramanian et al. 
2005). 
2.2.7 Statistics 
Significant changes in NTD rate for all mouse embryo data sets were determined 
by Fisher’s Exact Test (α=0.05). p-values for Hardy-Weinberg Equilibrium (p-HWE) were 
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determined by a Chi-square Test for goodness of fit. All other data were analyzed in 
Graphpad Prism (La Jolla) using unpaired t tests or one-way ANOVA with Dunnett’s 
multiple comparisons tests (α=0.05). All error bars represent mean +/- standard error of the 
mean (SEM). 
2.3 RESULTS 
2.3.1 Canonical Wnt Signaling is Impaired in Lrp6 Cd MEFs 
Since there is disagreement in the literature as to whether Lrp6 Cd is a canonical 
Wnt hypermorph (Carter et al. 2005; Shi et al. 2018) or is a model of impaired canonical 
Wnt signaling (Gray et al. 2013; Lei et al. 2015), it was first necessary to answer this 
question more definitively. Thus, a TCF/LEF luciferase assay was performed in Lrp6 Cd 
MEFs to measure canonical Wnt activity in response to the ligand, Wnt3a. The results 
confirm that the Cd allele impairs canonical Wnt/β-catenin activation of the TCF/LEF 
promotor. In Cd heterozygous MEFs, Wnt activity decreased by approximately half 
compared to wildtype, while in Cd homozygotes, canonical Wnt signaling was entirely 
ablated (Figure 2.2). These results are consistent with observations that the Cd protein 
product fails to localize to the cell membrane, and thus, cannot participate as a Wnt co-
receptor (Lei et al. 2015). This is also consistent with western blot experiments 
demonstrating decreased active β-catenin and qPCR experiments demonstrating decreased 
Axin2 expression in Cd homozygous mouse embryos (Gray et al. 2013). 
2.3.2 Digenic Interaction between Lrp6 Cd and Slc25a32 Causes NTDs in Mice 
Heterozygous crosses were performed between Lrp6+/cd sires and Slc25a32+/gt 
dams. Reciprocal crosses were also conducted (23 total litters). Exencephaly was observed 
in 14 of 52 co-heterozygous embryos (26.92%), compared to 3 out of 49 Cd heterozygotes 
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(6.12%), with zero exencephaly cases in Slc25a32 heterozygotes (Figure 2.3). Other than 
exencephaly, no other malformations were observed. Since Slc25a32 codes for a folate 
transporter and it is already known that Lrp6 Cd is folate responsive, it was considered that 
maternal genotype may influence exencephaly risk in Lrp6+/cd and co-heterozygous 
embryos. However, there were no significant differences in NTD rate between co-
heterozygous embryos in Lrp6+/cd dams and Slc25a32+/gt dams (p=0.7312, Fisher’s Exact 
Test) (Table 2.1). Furthermore, NTD rates were higher in co-heterozygotes than in any 
other genotype regardless of maternal genetics, confirming that the NTD risk is 
compounded by embryonic co-heterozygosity. A lower proportion of co-heterozygous 
embryos were observed when the dam was Lrp6+/cd, but this result was not significant 
(pHWE=0.1844) and there was no observed difference in resorption rate (p=0.8151). 
2.3.3 Serum Folate Levels in Lrp6Cd and Slc25a32 Dams 
To further evaluate possible maternal influence contributing to increased NTD risk 
in Lrp6+/cd; Slc25a32+/gt embryos, total serum folate was measured in Lrp6+/cd and 
Slc25a32+/gt dams. Serum folate levels in Slc25a32+/gt dams were comparable to that of 
wildtype dams (Figure 2.4). However, there was an approximately 30% reduction in serum 
folate for Lrp6+/cd dams compared to their wildtype counterparts (Figure 2.4). Since the 
NTD rate was not significantly lower in co-heterozygotes from Lrp6+/cd dams, this 
observed reduction in maternal folate status does not appear to have influenced NTD risk 
associated with Lrp6+/cd/Slc25a32+/gt co-heterozygosity; although, it may offer an 
explanation as to why less co-heterozygous embryos were collected from Lrp6+/cd dams if 
it enhances risk for early embryonic lethality. Further experimentation would be needed to 
answer this question. Regardless, these data further support a role for Lrp6 in regulating 
folate transport or folate-dependent metabolism. 
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Figure 2.2 Lrp6 Cd Impairs Canonical Wnt Signaling in Mouse Embryonic Fibroblasts 
Relative luciferase/renilla ratios from a TCF/LEF luciferase reporter assay in Lrp6+/+, 
Lrp6+/cd, and Lrp6cd/cd MEFs. No canonical Wnt activity was observed in response to 
unconditioned media (red), but a Cd-dependent inhibition of Wnt signaling was observed 
in response to Wnt3a conditioned media (green).  





Figure 2.3 Digenic Interaction Between Lrp6 Cd and Slc25a32 Causes Exencephaly in 
Mouse Embryos 
A) E13.5 mouse embryos resulting from crosses between Lrp6+/cd and Slc25a32+/gt mice. 
The genotypes are displayed below the images and an example of a Cd/Slc25a32 co-
heterozygote with exencephaly is shown on the far right.  
B) Table displaying proportion of exencephaly-affected embryos from each genotype. A 
26.92% NTD rate was observed in Lrp6+/cd; Slc25a32+/gt embryos.  




Table 2.1 Rate of Exencephaly in Reciprocal Crosses of Lrp6+/cd and Slc25a32+/gt Mice 
A) Proportion of exencephaly-affected embryos from each genotype in Lrp6+/cd dams. A 
20% NTD rate was observed in Lrp6+/cd; Slc25a32+/gt embryos.  
B) Proportion of exencephaly-affected embryos from each genotype in Slc25a32+/gt dams. 
A 29.73% NTD rate was observed in Lrp6+/cd; Slc25a32+/gt embryos. The difference 
between NTD rate observed in Lrp6+/cd dams and Slc25a32+/gt dams was not significant 
(p=0.7312).  






Figure 2.4 Serum Folate Status of Lrp6+/cd and Slc25a32+/gt Dams 
A) Serum folate status in Lrp6 Cd dams. 
B) Serum folate status in Slc25a32 gt dams. 
*Statistical significance determined by unpaired student’s t test, α=0.05. 
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2.3.4 Lrp6 Cd Impairs Mitochondrial OCM Gene Expression 
It was hypothesized that Lrp6 Cd may interact with Slc25a32 by impairing OCM 
gene expression. To test this hypothesis, qPCR was performed in E9.5 embryos from Cd 
heterozygous crosses comparing relative expression of OCM genes in Lrp6+/+, Lrp6+/cd, 
and Lrp6cd/cd embryos. 16 genes from OCM were measured, including Folr1, Slc25a32, 
and genes encoding cytosolic and mitochondrial OCM enzymes. Only three genes were 
observed to have significantly impaired expression associated with the Cd allele when 
normalized to multiple housekeeping genes: Slc25a32, Shmt2, and Gldc (Figure 2.5). 
Notably, each of these genes participate specifically in mitochondrial OCM, either by 
facilitating folate transport (Slc25a32) or catabolizing serine and glycine (Shmt2 and Gldc). 
Slc25a32 demonstrated an approximately 30% reduction in expression associated with Cd 
heterozygosity and an approximately 50% reduction associated with Cd homozygosity 
(Figure 2.5A), while Gldc and Shmt2 exhibited similar Cd-dependent changes in gene 
expression (Figure 2.5B and 2.5C). 
2.3.5 Gene Expression Analysis in Lrp6+/cd; Slc25a32+/gt Embryos 
RNA-seq analysis in E9.5 embryos from Lrp6+/cd x Slc25a32+/gt crosses confirmed 
reduced expression of Slc25a32 in Cd heterozygotes. More interestingly, there appeared to 
be a compounded loss in expression in co-heterozygotes, perhaps an initial reduction 
associated with loss of one functional genomic copy of Slc25a32 and an additional 
reduction associated with Cd heterozygosity (Figure 2.6). Thus, increased NTD rate in co-
heterozygotes may be the result of Slc25a32 expression dropping below a critical threshold 
for functionality. Slc25a32 was the fifth most downregulated gene out of significantly 
dysregulated genes in our RNA-seq dataset (Table 2.3). Tables 2.2 and 2.3 show the top 
20 upregulated and downregulated genes, respectively, in co-heterozygous embryos. It 
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should be noted that there did not appear to be any difference in expression of Slc25a32 
between co-heterozygotes with open and closed neural tubes (p=0.4369). 
When comparing expression of other genes between Lrp6+/cd; Slc25a32+/gt co-
heterozygotes and wildtype embryos, there was no significant differential gene expression 
when the data were corrected for false discovery rate (FDR). This is likely because the 
analysis compares gene expression in heterozygotes, and there still appears to be haplo-
sufficient functionality for both Lrp6 and Slc25a32 since most heterozygotes and co-
heterozygotes still display normal development. Thus, for gene set enrichment analysis, 
significant p-values of unpaired t tests were used to identify differentially expressed genes, 
of which there were 149 between wildtype and co-heterozygous embryos. These genes 
were over-representative of pathways associated with embryonic development and neural 
development, including pattern specification, cell fate specification and commitment, 
anterior/posterior patterning, and neuronal differentiation. Other pathways over-
represented in the differentially expressed gene set include cell-cell junctions, including 
adherens, and actin cytoskeleton (Figure 2.7). These data would suggest that increased 
NTD risk in co-heterozygous embryos is ultimately derived from disruption of the cellular 
and tissue-level morphogenic processes underlying NTC. When examining gene/pathway 
interactions underlying the patterning and cell fate processes effected in co-heterozygotes 
(Figure 2.8), several interesting genes were upregulated, including Acvr1c (codes for a 
Nodal co-receptor), Engrailed1 (En1), Pou5f1 (encodes Oct4), Tdgf1 (teratocarcinoma-
derived growthfactor 1), and Ar (androgen receptor). Tdgf1 is associated with forebrain 
defects in humans (de la Cruz et al. 2002), while En1 has been shown to interact with and 
regulate Wnt/β-catenin activity during development, including in midbrain neurons 
(Adamska et al. 2004; Bachar-Dahan et al. 2006; Alves dos Santos and Smidt 2011). 
Downregulated genes included transcription factors associated with neurogenesis, and 
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notably, Dnaic2. Mutations in this gene have been associated with primary cilia dyskinesia 
(Pennarun et al. 2000; Loges et al. 2008). Given the role of primary cilia in planar cell 
polarity, convergent extension, and NTDs (Wallingford 2012, 2006), this gene represents 





Figure 2.5 Differential Expression of Mitochondrial One-carbon Metabolism Genes in 
Lrp6 Cd Embryos 
Results of qPCR showing decreased expression of Slc25a32 (A), Gldc (B), and Shmt2 (C) 
associated with Lrp6 Cd in E9.5 embryos.  
*Statistical analysis was performed using one-way ANOVA with Dunnett’s multiple 




Figure 2.6 Slc25a32 gene expression in Lrp6 Cd/Slc25a32 Co-heterozygous Embryos 
Relative normalized counts for Slc25a32 from RNA-seq data in E9.5 embryos from 
Lrp6+/cd x Slc25a32+/gt crosses. 
*Statistical analysis was performed using one-way ANOVA with Dunnett’s multiple 
comparisons tests (α=0.05). 
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Table 2.2 Most Significantly Upregulated Genes in Lrp6 Cd/Slc25a32 Co-heterozygous 
Embryos 
Table listing the top 20 most upregulated genes (p<0.05, unpaired t test) in E9.5 Lrp6 




Rank Gene FC log2(FC) p value 
1 Foxa2 2.08297 1.058642 0.045809 
2 Muc1 2.059492 1.042288 0.0068 
3 Cdh22 1.994137 0.995765 0.02504 
4 Ptchd2 1.942395 0.957837 0.010552 
5 Fat3 1.9329 0.950767 0.032508 
6 Pak6 1.776725 0.82922 0.004818 
7 Taf4a 1.758602 0.814429 0.021336 
8 Fgf15 1.738707 0.798015 0.023123 
9 Maneal 1.696905 0.762906 0.02638 
10 Fgf1 1.690379 0.757347 0.033607 
11 H2-T24 1.667363 0.737568 0.045736 
12 Ksr2 1.651302 0.723604 0.004968 
13 Nrcam 1.638027 0.711959 0.048565 
14 Slco5a1 1.625666 0.701031 0.048449 
15 Ccdc177 1.625392 0.700788 0.041573 
16 Fgf14 1.609294 0.686428 0.0141 
17 Fut9 1.567346 0.648324 0.043016 
18 Pappa 1.558355 0.640024 0.049162 
19 Astn1 1.531194 0.614657 0.036583 
20 Fam69c 1.519873 0.603951 0.011111 
FC = fold change 
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Table 2.3 Most Significantly Downregulated Genes in Lrp6 Cd/Slc25a32 Co-
heterozygous Embryos 
Table listing the top 20 most downregulated genes (p<0.05, unpaired t test) in E9.5 Lrp6 
Cd/Slc25a32 co-heterozygous embryos compared to wildtype embryos. 
 
 
Rank Gene FC log2(FC) p value 
1 Nol3 0.542019 -0.88358 0.00388 
2 Csn3 0.555637 -0.84779 0.016555 
3 Tomt 0.572176 -0.80547 0.011916 
4 Cpa1 0.576623 -0.7943 0.01021 
5 Slc25a32 0.59679 -0.7447 0.013848 
6 Tnni2 0.600166 -0.73657 0.001456 
7 Nr4a1 0.627348 -0.67266 0.030244 
8 Wif1 0.648332 -0.6252 0.042747 
9 Nmi 0.659824 -0.59985 0.019679 
10 Vstm5 0.66008 -0.59929 0.005143 
11 Eaf2 0.67728 -0.56218 0.030031 
12 Tns2 0.684248 -0.54741 0.03393 
13 Tnfsf12 0.691433 -0.53234 0.032114 
14 Rasd1 0.6949 -0.52512 0.046668 
15 Nudt17 0.70148 -0.51153 0.034555 
16 Tmem204 0.712931 -0.48816 0.049712 
17 Tmem200b 0.714049 -0.4859 0.021364 
18 Scn1b 0.719708 -0.47452 0.02813 
19 Gja4 0.722644 -0.46864 0.037141 
20 Fcgbp 0.728235 -0.45752 0.003867 
FC = fold change 
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Figure 2.7 Gene Set Enrichment Analysis for Differentially Expressed Genes in Lrp6 
Cd/Slc25a32 Co-heterozygous Embryos 
Gene set enrichment analysis showing top 10 classifications in the biological process gene 
set (BP) and cellular component gene set (CC) between Lrp6+/+; Slc25a32+/+ and Lrp6+/cd; 
Slc25a32+/gt embryos at E9.5. The chart represents the number of dysregulated genes and 
gene ratio for each ontological category (p< 0.05). 
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Figure 2.8 Biological Process Gene/Pathway Interaction Plot for Differentially Expressed 
Genes in Lrp6 Cd/Slc25a32 Co-heterozygous Embryos 
Gene pathway interaction plot showing fold changes in gene expression between Lrp6+/+; 
Slc25a32+/+ and Lrp6+/cd; Slc25a32+/gt embryos at E9.5 in the biological process gene set. 
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2.3.6 Loss of Slc25a32 Impairs Canonical Wnt Signaling in glyB Cells 
It was also hypothesized that impairment of mitochondrial OCM could similarly 
disrupt Lrp6’s canonical Wnt activities. To address this hypothesis, canonical Wnt 
signaling was measured in CHO-K1 and glyb cells using TCF/LEF luciferase assays. It 
was discovered that CHO cells exhibit innate autonomous Wnt signaling, thus there was 
no need to stimulate with exogenous Wnts in the media. Autonomous Wnt signaling was 
reduced by approximately 70% in glyB mutants compared to wildtype CHO-K1 (Figure 
2.9) suggesting mitochondrial folate transport and mitochondrial OCM may be important 
for Wnt signaling. 
The next set of experiments were designed to determine the functional level at 
which Slc25a32 may regulate canonical Wnt signaling. First, qPCR was performed to 
compare expression of Wnt genes and Lrp6 in CHO and glyB mutants. No significant 
changes in expression were observed in any of the genes tested (Figure 2.10). Expression 
of Wnt1, Wnt2, Wnt2b, Wnt3, and Wnt3a were either expressing below the limit of 
detection or not at all. Thus, it appears Slc25a32 may not be essential for Wnt gene 
expression. The next hypothesis was that Slc25a32 may be required for Wnt/β-catenin 
signal transduction. This experiment was conducted using MEFs derived from crosses 
between Lrp6+/cd and Slc25a32+/gt mice, which do not exhibit autonomous Wnt signaling. 
Canonical Wnt stimulation was observed upon addition of 100ng/μL Wnt3a. A 50-60% 
reduction in canonical Wnt activity was detected in Lrp6+/cd and Lrp6+/cd; Slc25a32+/gt 
MEFs, but no reduction was observed in Slc25a32+/gt MEFs (Figure 2.11). If anything, 
losing one copy of Slc25a32 may have slightly enhanced Wnt signal transduction, although 
not significantly. These results suggest that impairment of Wnt signal transduction in 
Lrp6+/cd; Slc25a32+/gt MEFs is elicited solely as a result of the Cd genotype and is not 
influenced by Slc25a32. 
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Finally, Wnts must undergo post-translational palmitoylation before they can be 
secreted (Takada et al. 2017; Parchure, Vyas, and Mayor 2018). Since palmitate synthesis 
requires acetyl-CoA derived from the mitochondrial citric acid cycle, it was hypothesized 
that impaired palmitate synthesis in glyB stemming from defective mitochondrial 
metabolism may impair Wnt secretion and thus Wnt signaling. This hypothesis was tested 
by supplementing CHO and glyB cells with 100μM palmitic acid. Palmitate 
supplementation did appear to enhance canonical Wnt signaling in wildtype CHO, 
however, glyB cells remained unresponsive (Figure 2.12). This result supports that Wnt 
secretion may be impaired in glyB, but not as a result of palmitate deficiency. It is possible 
that other processes, such as palmitoylation itself by the palmitoleoyltransferase, PORCN, 
may be impaired, although further experimentation would be needed to confirm this 
hypothesis. 
2.3.7 Glycine Restores Canonical Wnt Signaling in glyB Cells 
Since glyB cells are glycine auxotrophs, and glycine is known to rescue 
proliferation defects observed in glyB (McCarthy et al. 2004), it was hypothesized that 
glycine may also rescue autonomous Wnt signaling defects in glyB. A glycine dose 
response assay was set up to test this hypothesis. While concentrations of glycine normally 
found in cell culture media (0.4mM) had no effect, four-fold excess glycine (1.6mM) was 
sufficient to restore the autonomous Wnt defects observed in glyB mutants back to levels 




Figure 2.9 Impairment of Autonomous Canonical Wnt Signaling in glyB Mutant CHO 
Cells 
Relative luciferase/renilla ratios from a TCF/LEF luciferase reporter assay in CHO-K1 and 
glyB mutant CHO cells.  




Figure 2.10 Expression of Wnt Genes in glyB Mutant CHO Cells 
Heat map showing relative gene expression of Lrp6 and Wnt genes in CHO-K1 and glyB 
cells. Each square represents the relative, comparative CT value for separate biological 
replicates. No significant changes in gene expression were observed. 




Figure 2.11 Slc25a32 Genotype Does Not Influence Canonical Wnt Signal Transduction 
in Mouse Embryonic Fibroblasts 
Relative luciferase/renilla ratios from a TCF/LEF luciferase reporter assay using MEFs 
obtained from Lrp6+/cd x Slc25a32+/gt crosses after incubation with 100ng/μL Wnt3a for 
18 hours. Changes in canonical Wnt activity were observed in Lrp6+/cd and Lrp6+/cd; 
Slc25a32+/gt MEFs, but no reduction was observed in Slc25a32+/gt MEFs. 





Figure 2.12 Palmitic Acid Enhances Autonomous Wnt Signaling in CHO-K1, but not 
glyB 
Relative luciferase/renilla ratios from a TCF/LEF luciferase reporter assay in CHO-K1 and 
glyB mutants after incubation with 100μM palmitic acid for 18 hours. Changes in canonical 
Wnt activity were observed in palmitate-treated CHO-K1, but not in palmitate-treated 
glyB. 





Figure 2.13 Glycine Rescues Wnt Signaling in glyB Mutant CHO Cells 
Relative luciferase/renilla ratios from a TCF/LEF luciferase reporter assay in CHO-K1 and 
glyB mutants after incubation with serial dilutions of glycine supplemented media (0.1mM, 
0.4mM, and 1.6mM). 1.6mM glycine restored autonomous canonical Wnt activity in glyB 
mutant CHO cells. 
*Statistical significance was determined using unpaired t tests, α=0.05. 
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2.3.8 Glycine Rescues NTDs in Mouse Embryos Lacking Slc25a32 
It was previously shown that Slc25a32gt/gt embryos exhibit 100% penetrant NTDs 
(Figure 2.14B), which could be rescued with maternal calcium formate supplementation 
(Kim et al. 2018). Since glycine rescued auxotrophy and Wnt signaling in glyB cells, which 
are essentially Slc25a32 knockouts, it was hypothesized that glycine could similarly rescue 
NTDs in Slc25a32 knockout mouse embryos. To test this hypothesis, heterozygous 
Slc25a32 mating pairs were set up and pregnant dams were provided 2500mg/kg/d glycine 
throughout gestation. Of 11 Slc25a32gt/gt embryos at E13.5, only two exhibited NTDs 
(18.18%) (Figure 2.14C). One of those two embryos was severely underdeveloped and 
displayed craniorachischises. The other had a mostly closed neural tube, except in the 
midbrain/forebrain where the entire anterior of the embryo was deformed and the neural 
tube was open (Figure 2.14A). This embryo also had a facial cleft. The distribution of 
genotypes among the glycine supplemented offspring did not follow typical Hardy-
Weinberg equilibrium (p-HWE=0.0098), with genotype distribution skewed towards 
wildtype embryos (Slc25a32+/+=29 (39%), Slc25a32+/gt =34 (46%), Slc25a32gt/gt =11 
(15%)). There was also a high rate of resorption (18.68%). This would suggest that while 
glycine does appear to rescue NTDs in viable Slc25a32gt/gt embryos, it may also decrease 
knockout embryo viability. This phenomenon will be reviewed more thoroughly in the 
discussion (Section 2.4).  
2.3.9 Preliminary: Glycine and Serine Prevent NTDs Associated with Lrp6 Cd 
Based on the foregoing results, it appears Lrp6 interacts with mitochondrial OCM, 
and that this interaction is important for proper NTC. As such, it was hypothesized that, in 
addition to the previously demonstrated ability of folic acid to reduce NTD rates in Lrp6 
Cd embryos (Carter et al. 1999), maternal supplementation of 1-C supplements, such as 
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formate, may also prevent NTDs in Cd mice. To test this hypothesis, heterozygous Cd 
mating pairs were set up and pregnant dams were provided 2500mg/kg/d calcium formate, 
2500mg/kg/d glycine, or 1250 mg/kg/d L-serine throughout gestation. The serine dosage 
was half that of formate and glycine because serine provides two 1-C units to mitochondrial 
OCM, while formate and glycine only provide one. Formate, glycine, and serine did not 
reduce the occurrence of exencephaly in Lrp6cd/cd embryos, as approximately 50% of Cd 
homozygotes presented with exencephaly in un-supplemented and all supplemented litters 
(Figure 2.15A). However, in our colony, we do observe a proportion of heterozygous Cd 
embryos that present with exencephaly (approximately 20%), as long as the mice are 
maintained on their DBA/2; A/J background. Preliminarily, it was observed that the 
proportion of Cd heterozygotes presenting exencephaly phenotypes decreased in glycine 
and serine supplemented litters to only 5.88% and 6.38%, respectively. However, formate 
supplementation was unable to produce the same results (Figure 2.15B). It is important to 
emphasize that these data are preliminary, as a large enough sample size has not yet been 
collected to make appropriate statistical inferences. If confirmed, these data would suggest 
that glycine and serine may serve as alternate intervention strategies for human NTDs 
associated with deleterious, heterozygous LRP6 variants, and further support a mechanism 




Figure 2.14 Maternal Glycine Supplementation Rescues Neural Tube Defects in 
Slc25a32gt/gt Embryos 
A) Images of E13.5 Slc25a32gt/gt embryos from glycine supplemented dams. The embryo 
on the left exhibited an open cranial neural tube and a facial cleft. The embryos on the right 
appeared developmentally normal. 
B) Table illustrating normal mendelian distribution and 100% penetrant NTDs in un-
supplemented Slc25a32gt/gt embryos. *Data previously published in Kim et al. (2018). 
C) Table illustrating decreased prevalence of NTDs in glycine supplemented 
(2500mg/kg/d) Slc25a32gt/gt embryos. The genotypes did not follow a mendelian 
distribution. *p-HWE was calculated using a Chi-square goodness of fit test (α=0.05). 
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Figure 2.15 Preliminary Data: Effect of Supplementation with One-carbon Donors on 
NTD-rate in Lrp6 Cd Embryos 
A) Effect of maternal calcium formate (2500mg/kg/d), glycine (2500mg/kg/d), and L-
serine (1250mg/kg/d) supplementation on NTD rate in Lrp6cd/cd embryos. 
B) Effect of maternal calcium formate (2500mg/kg/d), glycine (2500mg/kg/d), and L-
serine (1250mg/kg/d) supplementation on NTD rate in Lrp6+/cd embryos. The occurrence 
of exencephaly decreased in glycine and serine supplemented dams (5.88% and 6.38%, 
respectively). 
*Statistical significance was calculated using Fisher’s Exact Test (α=0.05). Note: These 





The work presented here demonstrates mechanistic interactions between Lrp6 and 
mitochondrial OCM in mouse NTDs. Heterozygous crosses between Lrp6 Cd and 
Slc25a32 gt mice strains demonstrated that co-heterozygous embryos were at increased 
risk for developing exencephaly. It was further shown that these defects arose as a result 
of the embryonic genotype and did not depend on maternal genotype, strain background, 
or serum folate status. The approach of investigating digenic interactions using this co-
heterozygous mouse model represents a practical strategy for dealing with the complex 
genetic architecture underlying NTDs. Traditionally, NTD-associated genes are studied 
using single-gene mouse knockout models, of which hundreds have been identified (Harris 
and Juriloff 2007, 2010). However, actual human NTD cases are complex, and it is unlikely 
that patients would be homozygous for a deleterious variant, and even less likely that such 
a condition could be considered a preventable birth defect. Variants contributing to 
preventable human NTDs are generally heterozygous and their risk is determined by 
interaction with other genetic variants and environmental factors. That said, mouse models 
that replicate this reality of the human condition are exceedingly rare, although not unheard 
of. For example, it was  found that digenic heterozygosity for deleterious planar cell 
polarity pathway mutants are found in human NTD cases, and is replicable in mouse 
models (Wang et al. 2018). Therefore, utilization of such a model that more accurately 
reflects human NTD pathology is a rare opportunity allowing for an innovative approach. 
It remains to be seen whether these Lrp6 Cd/Slc25a32 gt co-heterozygotes represent a FA-
resistant NTD model, but since Lrp6 Cd dams were shown to have a lower serum folate 
status but did not present with increased NTD rate, it is inherently plausible. 
When exploring the mechanisms underlying this interaction, it was discovered that 
Lrp6 Cd impairs mitochondrial OCM gene expression at the levels of mitochondrial folate 
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transport, serine catabolism, and glycine catabolism in embryos. It was further discovered 
that in co-heterozygous embryos Slc25a32 expression was reduced even further compared 
to both Lrp6 Cd heterozygotes and Slc25a32 heterozygotes. These data suggest that 
mitochondria in Cd mutant embryos may have both a lower total folate level and a reduced 
capacity to perform 1-C transfer reactions necessary to load 1-C units onto THF. Further 
experiments are required to confirm that these observed reductions in gene expression 
translate to impaired OCM. Future experiments will measure total folate and distribution 
of folate species within the mitochondrial folate pool comparing wildtype, Lrp6 Cd 
heterozygous, and Cd/Slc25a32 co-heterozygotes. In addition, measuring formate 
production in isolated mitochondria and heavy isotope labelled 1-C tracing from serine and 
glycine in embryos will inform as to whether there is reduced production of mitochondria-
derived 1-C units and reduced incorporation of these units into purine synthesis, pyrimidine 
synthesis, and the methionine cycle consistent with this hypothesis. 
This work also explored an alternative hypothesis as to the mechanisms underlying 
these interactions: that mitochondrial OCM may conversely regulate canonical Wnt 
signaling. The link between OCM and Wnt signaling has been known for a while, but little 
progress has been made in mechanistically linking these two pathways. Gray et al. (2010) 
showed that FA supplementation enhanced Wnt signaling in NIH-3T3 cells up to 4μg/mL, 
but that FA attenuated Wnt signaling at higher concentrations (above 10μg/mL). However, 
the design of this experiment only looked at Wnt transduction from exogenous Wnt3a and 
used supraphysiological concentrations of FA. It was also recently shown that impairing 
OCM through methionine deprivation or methotrexate, a DHFR inhibitor, resulted in 
impaired Wnt signaling in HEK-293T (Albrecht, Bui, and De Robertis 2019); however, 
this result was also obtained using exogenous Wnt3a. Our experiments in Slc25a32+/gt 
MEFs did not indicate a reduction in response to exogenous Wnts resulting from a single 
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copy loss of Slc25a32; however, it may be the case that a single copy of Slc25a32 is haplo-
sufficient for OCM’s Wnt-modulating properties. Even so, that previously published work 
and our findings that glyB mutant CHO cells, which are mitochondrial folate transporter 
mutants, have reduced capacity to generate autonomous Wnt signaling, shows consistent 
support for the hypothesis that impaired OCM may disrupt Wnt signaling, indicating a 
possible mechanism through which impaired OCM may cause NTDs. Future experiments 
are needed to determine whether the observed impairment of Wnt signaling in glyB cells 
translates to Slc25a32 knockout mouse embryos. Perhaps the most interesting discovery in 
this particular line of experimentation was that glycine could rescue the autonomous Wnt 
defects observed in glyB. What role does mitochondrial-derived glycine play in Wnt 
signaling? Glycine is an amino acid, and thus essential for protein synthesis, but it plays 
important roles in many other biochemical processes, including purine and glutathione 
synthesis. Ducker et al. (2016) found that glycine was required to support growth of 
mitochondrial OCM knockout cells lacking MTHFD2 and SHMT2, but that glycine’s 
essential function was not to provide 1-C units since these cell lines could not be rescued 
with formate supplementation. Similarly, we found that formate was not capable of 
rescuing autonomous Wnt defects in glyB mutants (data not shown), suggesting 
mitochondrial glycine’s contribution to Wnt activity is not as a 1-C donor. Ducker et al. 
(2016) proposed that mitochondrial glycine supports cellular redox homeostasis through 
glutathione synthesis based on metabolic analysis of glycine-deprived SHMT2 knockout 
cells and the observation that glutathione or N-acetylcysteine supplementation rescued 
growth deficiencies in SHMT2 knockouts similarly to glycine. There is a lot of literature 
linking oxidative stress and Wnt signaling, with some literature suggesting that oxidative 
stress suppresses canonical Wnt activity, while in other models, oxidative stress appears to 
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enhance canonical Wnt signaling (Ebrahimi et al. 2018; Zhang, Tannous, and Zheng 2019). 
Thus, further experimentation may be needed to test this hypothesis in glyB cells. 
Notably, the experiments presented in this chapter demonstrated that maternal 
glycine supplementation could rescue NTDs in Slc25a32 knockout embryos similarly to 
formate as previously described by Kim et al. (2018). These results would suggest that 1-
C units are not the only product of mitochondrial OCM required for NTC. Indeed, it seems 
difficult to imagine a mechanism by which glycine could provide 1-C units for purine and 
pyrimidine synthesis under conditions of total ablation of mitochondrial folate, since 
glycine contributes its 1-C unit to OCM via folate-dependent mitochondrial glycine 
cleavage. While it is possible there is still a certain level of folate in the mitochondria to 
serve as a glycine cleavage cofactor, there is no evidence to support that folates enter 
mitochondria by any other mechanism than MFT. Ducker et al. (2016) demonstrated that, 
in cell culture at least, ablation of mitochondrial OCM is compensated for via reversal of 
cytosolic 1-C flux, i.e. cytosolic OCM flows in the oxidative direction providing 1-C units 
from catabolized serine for purine and pyrimidine synthesis. While there is no evidence 
that this mechanism is applicable in embryos, excess glycine would certainly counteract 
cytosolic serine catabolism by stoichiometrically favoring serine synthesis via SHMT1. 
This may explain why we did not observe a typical mendelian distribution of knockout 
Slc25a32 genotypes upon maternal glycine supplementation, as it is possible that excess 
glycine may be embryotoxic under conditions of impaired mitochondrial OCM. Glycine 
supplementation of Slc25a32 knockout cells was shown to elicit cytostatis by opposing de 
novo purine and thymidine synthesis (Steven Gross, Weill-Cornell Medical College, 
personal communication). Moreover, cancer cells appear to consume serine in preference 
to glycine for maximal proliferation, and excess glycine or depleted serine results in 
impaired flux of glycine to purine synthesis, thus depleting cellular nucleotide pools and 
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inhibiting proliferation (Labuschagne et al. 2014). Notably, exogenous formate counteracts 
glycine-induced inhibition of cancer proliferation (Labuschagne et al. 2014). While these 
results would suggest glycine as a potential anti-cancer therapeutic, they also indicate that 
glycine as an intervention strategy for FA-resistant NTDs may be problematic. Either way, 
the discovery that glycine rescues NTDs in the viable Slc25a32 knockout embryos reveals 
novel insights into the mechanisms of mitochondrial OCM in neural tube development. 
Further experimentation is needed to elucidate the reasons as to why glycine is essential 
for NTC, whether it be important for canonical Wnt signaling, as a 1-C donor as certainly 
demonstrated in glycine cleavage mutants (Pai et al. 2015; Leung et al. 2017), or by other 
mechanisms such as direct incorporation into purine synthesis, glutathione metabolism, or 
as an amino acid for protein synthesis. The arguments presented herein pose one further 
question: would co-supplementation of glycine and formate, or glycine and serine, in 
Slc25a32 knockout embryos prove to be a more effective intervention strategy than formate 
or glycine alone? Further experiments are needed to answer this question. 
Finally, the preliminary data suggesting glycine or serine supplementation may 
reduce occurrence of NTDs approximately three to four-fold in Cd heterozygous embryos 
supports a role for Lrp6 in mitochondrial OCM. Interestingly, formate did not elicit the 
same effect. While providing exogenous formate as a source of 1-C units may rescue 
proliferation defects and NTDs associated with total ablation of mitochondrial formate 
production, it may be counterproductive under conditions of only moderately impaired 
mitochondrial OCM flux, such as we hypothesize in Lrp6 Cd heterozygotes. The gene 
expression data presented in Figures 2.6 and 2.7 support that mitochondrial folate transport, 
mitochondrial serine catabolism, mitochondrial glycine synthesis, and mitochondrial 
glycine catabolism would be impaired in Lrp6 Cd heterozygotes. Logically, providing 
excess folate, serine, or glycine would more directly rescue these deficiencies than excess 
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formate. Furthermore, Ducker et al. (2016) demonstrated that formate supplementation was 
antagonistic in SHMT2 knockout HEK-293T cells. Thus, serine and glycine may be more 
suitable intervention strategies for rescuing NTDs associated with Lrp6-induced 
impairment of mitochondrial OCM.  
It is important to note that we were surprised to observe Cd heterozygotes with 
exencephaly, as this was not reported in any of the previously published literature on Lrp6 
Cd. We were initially concerned, since previous experiments crossed this line to Folr1 and 
Slc25a32 knockout lines, that a breeding mistake had somehow introduced a Folr1 or 
Slc25a32 knockout allele into our colony. However, after genotyping several litters, we 
were able to rule out this possibility. Thus, it is possible the Lrp6 Cd mouse strain has 
undergone some amount of genetic drift in the 21 years since this line was first generated 
(Carter et al. 1999). Interestingly, the approximately 20% occurrence of NTDs in Cd 
heterozygous embryos seems to depend on the genetic background. This strain was 
originally identified in a mixed DBA/2; A/J background (Carter et al. 1999), and to the best 
of our knowledge, no other genetic strain has been introduced into our Cd colony. We 
noticed that when Lrp6 Cd is crossed to the C57/BL6 background, the background hosting 
the Slc25a32 knockout, the observed rate of NTDs in Cd heterozygous embryos drops to 
around 6.12% (Figure 2.3); and when Lrp6 Cd is crossed to the LM/BC background, the 
background hosting the Folr1 knockout, we do not observe any NTDs in Cd heterozygous 
embryos (Figure 2.1). Thus, the NTD risk associated with Cd heterozygosity is clearly 
influenced by genetic modifiers in the host strain.  
Ultimately, the data presented in this chapter support a mechanism of interaction 
between Lrp6 and mitochondrial OCM. Understanding the biology and biochemistry 
underlying this interaction may support the efficacy of alternative intervention strategies 
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such as dietary fortification of glycine or serine for the prevention of human NTDs 
associated with LRP6 variants or other models of impaired mitochondrial OCM. 
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Chapter 3: Characterization of Murine Embryonic Stem Cells Lacking 
Mthfd1l 
3.1 INTRODUCTION 
10-formyl-tetrahydrofolate (10-formyl-THF) is the most oxidized folate species 
harboring a 1-C unit, and is synthesized in mitochondria from 5,10-methylene-THF via a 
two-step process by the bifunctional enzymatic activities of MTHFD2 or MTHFD2L, two 
members of the methylene tetrahydrofolate dehydrogenase (MTHFD) family (Tibbetts and 
Appling 2010; Shin et al. 2014). 10-formyl-THF can be utilized for one of three fates in 
mitochondria (Figure 3.1). First, the formyl group may be transferred to methionyl-tRNA 
formyltransferase to produce N-formylmethionyl-tRNA, which is the essential initiator 
tRNA in mitochondrial protein translation (Minton et al. 2018; Morscher et al. 2018). 
Alternatively, 1-C units from 10-formyl-THF could be completely oxidized to CO2 by 
aldehyde dehydrogenase 1-like 2 (ALDH1L2) simultaneously producing NADPH 
(Krupenko et al. 2010; Strickland et al. 2011); in this case, the 1-C units are no longer 
available for subsequent OCM. Finally, the formyl group could be converted to free 
formate by the monofunctional, mitochondrial 10-formyl-THF synthetase, MTHFD1L, 
and utilized for cytosolic OCM. In fact, up to 75% of 1-C units in the cytosol are derived 
from mitochondrial formate (Pike et al. 2010). Thus, MTHFD1L is essential for cytosolic 
OCM. 
Mouse embryos lacking the gene, Mthfd1l, were found to be non-viable beyond 
E12.5 and phenotypically presented severe developmental delay, orofacial clefts, and 
NTDs (Momb et al. 2013; Shin et al. 2019). Maternal supplementation with exogenous 
formate decreased the prevalence and severity of the observed phenotypes and prolonged 
viability (Momb et al. 2013). The human gene, MTHFD1L, has been implicated in birth 
defects as well. Three alleles in a common polymorphism, rs3832406, were identified in 
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an Irish population with variable influences on risk for NTDs, and an additional single-
nucleotide polymorphism in the 3’ UTR of MTHFD1L was also associated with these same 
congenital anomalies (Parle-McDermott et al. 2009; Minguzzi et al. 2014). One of the 
rs3832406 alleles was further found to slightly enhance maternal risk of having a neural 
tube defect-affected infant in a U.S. Hispanic cohort (McKenzie 2018). Another 
MTHFD1L variant, rs11754661, was associated with Alzeheimer’s Disease in a Han 
Chinese population (Ren et al. 2011; Ma et al. 2012), while a study in Hungary and the 
United Kingdom demonstrated strong association between MTHFD1L variant, 
rs11754661, and ruminative response style, suggesting the gene may play a role in the 
etiology of depression and other disorders associated with mental and cognitive health 
(Eszlari et al. 2016). Yet another polymorphism, rs6922269, has been associated with 
patient outcomes after acute coronary syndrome (Palmer et al. 2014; Hubacek et al. 2015). 
Finally, the most recent line of published research sharply focuses on this enzyme’s role in 
cancer progression and metabolism, suggesting MTHFD1L may be a strong candidate 
target for future therapeutic strategies (Lee et al. 2017; Yang et al. 2018; Agarwal et al. 
2019; Eich et al. 2019; Li et al. 2019). Given, the extensive and diverse roles for MTHFD1L 
thus far associated with human health outcomes, understanding the underlying mechanisms 
through which MTHFD1L influences normal cellular metabolism and function is of critical 
interest. 
To investigate these questions, a functional analysis of mouse embryonic stem (ES) 
cells lacking Mthfd1l was performed. Consistent with impaired de novo nucleotide 
metabolism, we observed proliferation defects in the Mthfd1l knockout ES cells compared 
to wildtype, which could be rescued with either exogenous formate, or co-supplementation 
with hypoxanthine and thymidine. We also observed that ES cells lacking Mthfd1l were 
sensitive to hypoxia in a gene dose-dependent manner, and that this sensitivity was related 
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to cell survival, not proliferative capacity. Finally, we found evidence in mouse embryo 
gene expression analysis suggesting a metabolic switch in catabolism of mitochondrial 10-
formyl-THF away from MTHFD1L-dependent formate synthesis occurring between E8.5 
and E10.5. The implications and relevance of these findings related to underlying 





Figure 3.1 Fates for 10-formyl-THF in Mitochondrial One-carbon Metabolism  
THF = tetrahydrofolate; tRNA-fMET = N-formylmethionyl-tRNA; MTFMT = methionyl-
tRNA formyltransferase; ALDH1L2 = aldehyde dehydrogenase 1-like-2; MTHFD1L = 




3.2 MATERIALS AND METHODS 
3.2.1 Mouse Embryonic Stem Cell Culture 
Mouse ES cell lines were generated as described by Nichols et al. (2009) from 
Mthfd1l+/+, Mthfd1l+/z, and Mthfd1lz/z mouse embryos (described in Momb et al. (2013)) 
and cryopreserved in liquid nitrogen for long term storage. ES cells were maintained on 
gelatin coated plates (EMD Millipore, ES-006-B) with daily feedings of 2i media, which 
consisted of a 50:50 mix of Neurobasal (Gibco, 21103049) and DMEM/F-12 (Gibco, 
11320082) supplemented with 0.5x Ndiff Neuro-2 (EMD Millipore, SCM012), 0.5x B-27 
(Gibco, 17504044), 3µM CHIR 99021 (Cayman Chemical, 13122), 1µM PD03259010 
(Sigma, PZ0162), 100µM 2-mercaptoethanol (Gibco, 21985023), and 50 ng/mL 
recombinant mLIF (EMD Millipore, LIF2050). The cells were passaged as needed using 
Accutase (EMD Millipore, SF006) for 3 minutes at 37°C.  
3.2.2 Embryonic Stem Cell Growth Curve Analysis 
Since DMEM/F-12 contains thymidine and hypoxanthine, which would prevent the 
cells from utilizing de novo nucleotide synthesis in favor of nucleotide salvage, 
DMEM/F12 was replaced with DMEM (Gibco, 11965118) in the 2i cocktail for the growth 
curve experiments. The cells were gradually weaned onto this modified 2i media for two 
days leading up to the experiments by reducing the ratio of Ham’s F-12 (Gibco, 11765054) 
by half with each feeding. Mthfd1l+/+ and Mthfd1lz/z ES cells were plated in 6-well cell 
culture plates at a density of 30,000 cells per well. The cells were cultured for five days in 
the modified 2i media containing DMEM, and the media was either left un-supplemented 
or supplemented with 400μM sodium formate, or 30μM hypoxanthine and 3μM thymidine 
based on the conventional media formulation for Ham’s F-12. Each day, three replicate 
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wells from each genotype and treatment were harvested with Accutase and counted by 
hemocytometer. 
3.2.3 Hypoxia Experiments 
3.2.3.1 CyQUANT Assay 
Hypoxic cell culture conditions were generated by culturing cells in a humidified, 
one-shelf C-chamber (Biospherix, C174) placed inside a 37°C cell culture incubator. 
Oxygen was regulated using the ProOx P110 oxygen controller (Biospherix, P110) using 
a custom gas mixture of 5.55% CO2 balanced with nitrogen. The purpose of the custom 
gas mixture is to maintain a 5% CO2 environment as ambient oxygen gets displaced. 
Mthfd1l+/+, Mthfd1l+/z, and Mthfd1lz/z ES cells were plated in 96-well plates at a 
density of 6,000 cells per well, with three replicate wells per genotype. The cells were 
allowed to attach overnight and subsequently placed at either 1% O2 or ambient incubator 
O2 (approximately 18-19%) conditions for 48 hours. The media was then removed, and the 
cells were gently washed once with PBS. The plates were then frozen at -80°C for one hour 
and allowed to thaw at room temperature. Relative cell density in each well was then 
measured using the CyQUANT Cell Proliferation Assay (Thermo Fisher, C7026) via a 
fluorescent 96-well plate reader. 
3.2.3.2 EDU Proliferation Assay 
Mthfd1l+/+, Mthfd1l+/z, and Mthfd1lz/z ES cells were plated in 6-well plates at a 
density of 200,000 cells per well, with three replicate wells per genotype. An additional 
well of Mthfd1l+/+ was utilized as a negative control. The cells were allowed to attach 
overnight and subsequently placed at 1% O2 for 24 hours. At the 22 hour mark, EdU 
(ethynyl deoxyuridine) was quickly added without changing the media to each well at a 
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final concentration of 10μM (from a 10mM stock) and the cells were allowed to incubate 
for an additional 2 hours at 1% O2. Afterwards, cells were lifted with Accutase, washed 
once with PBS, fixed, permeabilized, and the incorporated EdU was labelled using the 
Click-iT Plus EdU Flow Cytometry Assay Kit (Life Technologies, C10633) as per 
manufacturer protocols. The fixative and saponin-based permeabilization buffer were 
supplied as part of the kit. Negative control wells were treated with EdU, washed, fixed, 
and permeabilized the same as all other samples, but were not treated the Alexa Fluor 647 
picolylazide detection reagent. Cells were then washed twice in 5mL of PBS, incubated 
with Hoescht 33342 (1μg/mL) in PBS for 10 minutes, and washed again with 5mL of PBS. 
Cells were then placed in 1mL of PBS while EdU and Hoescht incorporation were 
measured via fluorescence-based flow cytometry using an Attune NXT (T103) Cell 
Analyzer in BCM’s Cytometry and Cell Sorting Core. The plots in Figure 3.4A represent 
concatenations of three replicates. Between 7,000 and 10,000 cells were analyzed for each 
replicate. 
3.2.3.3 Cellular Viability Assay 
Mthfd1l+/+, Mthfd1l+/z, and Mthfd1lz/z ES cells were plated in 6-well plates at a 
density of 200,000 cells per well, with three replicate wells per genotype. Two additional 
wells of Mthfd1l+/+ were utilized as positive and negative controls. The cells were allowed 
to attach overnight and subsequently placed at 1% O2 for 24 hours. The cells were lifted 
with Accutase, washed once with PBS, resuspended in 1mL of PBS and 1mL of 2X 
LIVE/DEAD Cell Imaging Kit 488 probe (Life Technologies, R37601) was added to each 
well, except for the negative control. The positive controls were heated at 42°C for 10 
minutes to induce cell death prior to adding probe. The cells were then incubated at room 
temperature for 15 minutes followed by two 5mL washes with PBS. The cells were then 
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incubated with Hoescht 33342 (1μg/mL) in PBS for 10 minutes and washed once more 
with 5mL of PBS. Cells were then placed in 1mL of PBS while FITC and Hoescht 
fluorescence were measured via flow cytometry using an Attune NXT (T103) Cell 
Analyzer in BCM’s Cytometry and Cell Sorting Core. The plots in Figure 3.5A represent 
concatenations of three replicates. Between 7,000 and 10,000 cells were analyzed for each 
replicate. Gates were established using the positive and negative controls. 
3.2.4 Mouse Embryo Gene Expression Analysis Between E8.5 and E10.5 
C57/BL6 mice were obtained from BCM’s Center for Comparative Medicine, were 
housed in BCM’s Neurosensory mouse facility on 12-hour light/dark cycles with standard 
chow and maintained according to protocols approved by the Institutional Animal Care 
and Use Committee (IACUC) at BCM. Timed mating and euthanasia were performed as 
described in Section 2.2.1. Embryos were collected from pregnant dams at E8.5, E9.5, and 
E10.5. Total mRNA was extracted as described in Section 2.2.6 using Tri-reagent. cDNA 
synthesis and qPCR were also performed as described in Section 2.2.6. The following 
genes were targeted for qPCR: Slc25a32, Shmt2, Shmt1, Mthfd2L, Mthfd1L, Mthfd1, Folr1, 
Gapdh, Actb, Aldh1l1, and Aldh1l2. Differential gene expression was determined using the 
comparative CT method with Gapdh and Actb used as housekeeping genes. 
3.2.5 Statistics 
All statistical analyses were performed using GraphPad Prism (La Jolla). Statistics 
comparing genotypes and treatments at each time point for the ES cell growth curve 
analysis were conducted using student’s t tests (α=0.05). Statistical significance for the 
CyQUANT, EdU, and cellular viability assays were determined using two-way ANOVA 
with Dunnett’s multiple comparisons tests (α=0.05). Significant differences in embryo 
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gene expression between E8.5 and E10.5 was determined by one-way ANOVA with 
Dunnett’s multiple comparisons tests (α=0.05). All error bars represent mean +/- standard 
error of the mean (SEM). 
3.3 RESULTS 
3.3.1 Embryonic Stem Cell Growth Curve Analysis 
We initially did not observe proliferation defects in our ES cell lines, which was 
not consistent with previous observations in Mthfd1lz/z MEFs (Bryant 2017) and CRISPR-
mediated knockouts of mitochondrial OCM in HEK-293T cells (Ducker et al. 2016). It was 
hypothesized that the standard 2i media formulation may provide sufficient levels of 
hypoxanthine and thymidine for the cells to utilize nucleotide salvage for purine and 
pyrimidine synthesis. To test this hypothesis, a modified 2i media was formulated lacking 
hypoxanthine and thymidine (see Section 3.2.2). Consistent with the hypothesis, ES cells 
lacking Mthfd1l grew significantly slower in this modified 2i media (Figure 3.2). 
Differences between the number of Mthfd1l+/+ cells and Mthfd1lz/z cells were statistically 
significant at every timepoint measured between days two and five of the experiment, and 
the ratio of wildtype to knockout cells increased each day. Formate supplementation did 
improve growth of knockout cells, although formate-supplemented knockouts never 
completely caught up to wildtype ES cells. It should also be noted that formate 
supplementation in Mthfd1l+/+ significantly impaired growth, although not comparably to 
total loss of Mthfd1l (data not shown).  Notably, Mthfd1lz/z cells co-supplemented with 




Figure 3.2 Growth Curves Comparing Mthfd1l+/+ and Mthfd1lz/z Embryonic Stem Cells 
Growth curves of un-supplemented Mthfd1l+/+ and Mthfd1lz/z ES cells cultured in modified 
2i media lacking hypoxanthine and thymidine over five days. Growth of formate 
supplemented (400μM sodium formate) Mthfd1lz/z cells and Mthfd1lz/z cells co-
supplemented with hypoxanthine (30μM) and thymidine (3μM) is also displayed. 
*Statistical significance was determined by student’s t tests (α=0.05). *, p<0.05. **, 
p<0.01. ***, p<0.001. 
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3.3.2 Embryonic Stem Cells Lacking Mthfd1l are Sensitive to Hypoxia 
Given the role of mitochondrial OCM in mediating cellular redox balance, it was 
hypothesized that Mthfd1lz/z ES cells may exhibit hypoxia-specific phenotypes. To test this 
hypothesis, Mthfd1l+/+, Mthfd1l+/z, and Mthfd1lz/z ES cells were cultured at 1% O2, and a 
CyQUANT proliferation assay was performed. It is important to note that while the 
CyQUANT kit is marketed as a “proliferation assay,” the detection method relies on DNA 
content; thus, this assay can only detect cellular density and is not able to discern between 
proliferation rate and cell viability. After 48 hours under ambient O2 conditions in a normal 
CO2 cell culture incubator (O2 = approx. 18-19%), there were no differences in cell 
numbers between Mthfd1l+/+, Mthfd1l+/z, and Mthfd1lz/z ES cells (Figure 3.3). This 
experiment was performed in standard 2i media to differentiate between mitochondrial 
OCM’s role in producing purines and pyrimidines from its supportive role in cellular redox 
homeostasis. Thus, those observations are consistent with our previous observations 
regarding proliferation in these ES cells under those conditions. At 1% O2 however, 
wildtype cells performed better compared to wildtype cells at ambient oxygen (Figure 3.3). 
This is consistent with observations that many cell lines, including stem cells and primary 
cells, perform better at lower than atmospheric oxygen, possibly because these conditions 
are more physiologically relevant and cells are genetically designed to adapt under these 
conditions (Bates 2012). Interestingly, an Mthfd1l genotype-dependent reduction in cell 
density was observed under these hypoxic conditions, with Mthfd1l+/z performing half as 
well as wildtype, and Mthfd1l knockouts performing substantially poorer (Figure 3.3). 
Thus, it appears Mthfd1l may be critical for cellular adaptation to hypoxia. 
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3.3.3 Hypoxia Sensitivity in Mthfd1l Embryonic Stem Cells is Characterized by 
Viability Defects 
We wanted to see whether this observed hypoxia sensitivity associated with 
Mthfd1l genotype was a result of impaired cellular proliferation or decreased viability. An 
EdU cell proliferation assay was performed on Mthfd1l+/+, Mthfd1l+/z, and Mthfd1lz/z ES 
cells cultured at 1% O2. After 2 hours EdU exposure, no significant differences were 
observed between genotypes in the proportions of cells at each phase of the cell cycle 
(G0/G1, S, and G2) (Figure 3.4). Thus, it was concluded that hypoxia sensitivity was not 
caused by impaired proliferative capacity. 
However, in the viability assay, only 83.29% (+/- 1.24%) of Mthfd1lz/z cells 
clustered with the viable negative controls, compared to 86.25% (+/- 0.57%) in Mthfd1l+/z 
cells and 90.67% (+/- 0.08%) in Mthfd1l+/+ cells (Figure 3.5). This result was statistically 




Figure 3.3 Hypoxia Sensitivity in Mthfd1lz/z Embryonic Stem Cells  
CyQUANT proliferation assay showing relative cellular abundance (based on sample DNA 
content) in Mthfd1l+/+, Mthfd1l+/z, and Mthfd1lz/z ES cells cultured for 48 hours under at 
ambient O2 or 1% O2. 
*Statistical significance was determined using two-way ANOVA with Dunnett’s multiple 
comparisons tests (α=0.05). *, p<0.05. **, p<0.01. ***, p<0.001. 
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Figure 3.4 Effect of Hypoxia on Proliferation of Mthfd1lz/z Embryonic Stem Cells  
A) Concatenated scatter plots of flow cytometry data from EdU proliferation assays 
conducted in Mthfd1l+/+, Mthfd1l+/z, and Mthfd1lz/z ES cells cultured for 24 hours at 1% O2. 
The gated cell populations shown in red, green, and blue represent cells in G0/G1, S-phase, 
and G2 of the cell cycle, respectively. 
B) Stacked column chart showing the average (n=3) proportions of cells in each phase of 
the cell cycle based on EdU incorporation.  
*Statistical significance was determined using two-way ANOVA with Dunnett’s multiple 
comparisons tests (α=0.05). *, p<0.05. **, p<0.01. ***, p<0.001. ****, p<0.0001. 
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Figure 3.5 Effect of Hypoxia on Viability of Mthfd1lz/z Embryonic Stem Cells  
A) Concatenated scatter plots of flow cytometry data from viability assays conducted in 
Mthfd1l+/+, Mthfd1l+/z, and Mthfd1lz/z ES cells cultured for 24 hours at 1% O2. The gated 
cell populations shown in blue and red represent viable and non-viable cells respectively 
as confirmed by positive and negative controls. 
B) Stacked column chart showing the average (n=3) proportions of viable and non-viable 
cells based on FITC signal.  
*Statistical significance was determined using two-way ANOVA with Dunnett’s multiple 
comparisons tests (α=0.05). *, p<0.05. **, p<0.01. ***, p<0.001. ****, p<0.0001. 
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3.3.4 Changes in Gene Expression Suggest Metabolic Switch in Mitochondrial 10-
formyl-THF Utilization in Mouse Embryos Between E8.5 and E10.5 
Since the window of mouse embryo development between E8.5 and E10.5 is a time 
of drastic changes, both in terms of vascularization and neural tube closure, we decided to 
look at expression of mitochondrial and cytosolic OCM genes during this timeframe. Of 
the genes examined, six were differentially expressed between E8.5 and E10.5 (Figure 3.6). 
Downregulation of the folate receptor, Folr1, after neural tube closure was already known 
(Piedrahita et al. 1999), and thus serves as a validation of the results. Notably, Shmt2 
expression decreased between E8.5 and E10.5, but Shmt1 expression did not. This may 
suggest a reduction in mitochondrial serine catabolism. More interestingly, we observed 
decreased expression of Mthfd1l and Mthfd1, consistent with results published in Shin et 
al. (2014).  Decreased expression of these genes occurred concomitant with substantial 
increases in Aldh1l1 and Aldh1l2 expression. The diametrical changes in gene expression 
between these two classes of enzymes with a common substrate suggest a change in 
embryonic utilization of 10-formyl-THF between E8.5 and E10.5. MTHFD1L and 
MTHFD1 direct interconversion of formate and 10-formyl-THF between the mitochondria 
and cytosol, allowing for direction of 1-C units from 10-formyl-THF into continued 
utilization by OCM; but ALDH1L1 and ALDH1l2, both catalyze the irreversible oxidation 
of the formyl group to CO2 (see Figure 3.1). This result taken with decreased expression 
of Shmt2 suggests mouse embryos may decrease mitochondrial OCM activity after neural 




Figure 3.6 Expression of One-carbon Metabolism Genes in C57 Mouse Embryos 
Between E8.5 and E10.5 
Gene expression of OCM genes in C57/BL6 mouse embryos at E8.5, E9.5, and E10.5. 
 
*Statistical significance was determined using one-way ANOVA with Dunnett’s multiple 






The growth curve analysis in ES cells lacking Mthfd1l demonstrates that this gene 
is essential for ES cell growth in a manner dependent on purine and pyrimidine metabolism. 
It is notable that no proliferation defects were observed in Mthfd1l knockout cells on 
standard 2i media. Modifying the media to remove Ham’s F12, which contains thymidine 
and hypoxanthine induced an apparent deficiency in knockout cells compared to wildtype. 
This suggested that thymidine and hypoxanthine would be sufficient to restore normal 
proliferation in knockout cells, likely because thymidine could be used directly in 
pyrimidine metabolism, and hypoxanthine could promote purine synthesis via nucleotide 
salvage. This hypothesis was confirmed when co-supplementation of hypoxanthine and 
thymidine restored growth in knockout ES cells back to wildtype levels. This raises the 
question as to whether hypoxanthine and thymidine supplementation, or supplementation 
with other nucleotides or nucleobases can rescue NTDs in Mthfd1l knockout mouse 
embryos. It was previously demonstrated that supplementation of nucleotides could rescue 
NTDs in the FA-resistant Curly Tail mice (Leung et al. 2013). In Mthfd1l knockout mice, 
maternal supplementation with a “cocktail” of various nucleotides was not capable of 
preventing any of the observed phenotypes, nor was thymidine supplementation (Jessica 
Momb, The University of Texas at Austin, personal communication). However, 20mg/kg/d 
of hypoxanthine did prevent up to 20% of NTDs in the Mthfd1l knockouts (Jessica Momb, 
The University of Texas at Austin, personal communication). However, Dr. Momb did not 
test tandem supplementation with hypoxanthine and thymidine as we tested here in the ES 
cell experiment. Thus, the efficacy of these two compounds as co-supplements for NTD 
prevention remains an open question in this model and a project for future exploration. 
Formate supplementation also rescued growth defects observed in Mthfd1l knockout ES 
cells as expected, although not as efficiently. More interestingly, formate inhibited growth 
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in wildtype cells, which is consistent with observations in Ducker et al. (2016) where 
formate supplementation impaired growth in mitochondrial OCM mutant HEK-293T cells. 
Bryant et al. (2018) found that formate and co-supplemented hypoxanthine and thymidine 
were effective at rescuing growth defects in Mthfd1lz/z MEFs, supporting our observations 
in ES cells, while thymidine supplementation on its own did not rescue growth deficiency 
in Mthfd1lz/z MEFs. Bryant et al. (2018) also performed metabolic analysis of Mthfd1lz/z 
embryos with and without calcium formate supplementation. They found that formate 
supplementation restored metabolic imbalance in energy metabolism and a few amino acid 
pathways. However, it appeared general 1-C metabolic pathways such as methane 
metabolism and serine/glycine/threonine metabolism were still significantly perturbed. For 
example, formate did not restore relative abundances of glycine (which was diminished in 
Mthfd1lz/z embryos) and serine (which accumulated in Mthfd1lz/z embryos). Thus, while 
formate may rescue cytosolic OCM and its constituent functions, the defect in 
mitochondrial OCM remains. We therefore hypothesized that ES cells lacking Mthfd1l may 
display other phenotypes under conditions of mitochondrial stress, such as hypoxia. 
The developing mammalian embryo is a hypoxic environment (Chen, Fujinaga, and 
Giaccia 1999; Burton and Jaunaiux 2001; Dunwoodie 2009), particularly around the time 
of neural tube closure as hypoxia-dependent vascularization of the embryo occurs around 
that time, at least in the mouse (Walls et al. 2008). While hypoxia may be a normal, and 
possibly even required aspect of development, hypoxia does require unique metabolic 
adaptations that are necessary to maintain cellular redox balance under hypoxic conditions 
(Miyata, Takizawa, and van Ypersele de Strihou 2011). Recent research in cancer 
metabolism suggests mitochondrial OCM may play a role in cellular adaptation to hypoxia, 
supporting tumor growth and survival (Martinez-Reyes and Chandel 2014). Ye et al. 
(2014) found that in hypoxia-resistant, myc-amplified neuroblastoma cells, there was 
 89 
significantly enhanced expression of SHMT2, which was induced by hypoxia-inducible 
factor (HIF1α). Ablation of this SHMT2 activity resulted in hypoxia-sensitivity and 
oxidative stress. Moreover, MTHFD1L itself appears to be implicated as hypoxia-sensitive 
in the literature. The prokaryotic equivalent enzyme that performs 10-formyl-THF 
synthetase activity, Fhs, is more commonly found in anaerobic bacteria and facultative 
anaerobes, but does not appear to be required for aerobic species (Sah et al. 2015). 
Moreover, it was found that transformation with the fhs gene conferred a metabolic 
advantage to Escherichia coli under anaerobic conditions (Sah et al. 2015). Thus, we 
hypothesized that ES cells lacking Mthfd1l may also exhibit hypoxia sensitivity. 
While Mthfd1l knockout cells exhibited no observable phenotypes at ambient O2 
so long as they received hypoxanthine and thymidine supplemented media, cell survival 
was impacted in a genotype-dependent manner under hypoxic conditions (1% O2). We also 
ruled out the possibility that this phenotype was associated with Mthfd1l’s role in formate 
synthesis and nucleotide metabolism, since the knockout cells did not appear to be 
proliferating slower under hypoxia compared to wildtype cells but were in fact less viable. 
Recently, it was shown that knockdown of MTHDF1L in human tumor squamous cell 
carcinoma resulted in reduced NADPH and increased reactive oxygen species under stress 
conditions, including hypoxia and glucose deprivation (Li et al. 2019). Our data also 
support a role for MTHFD1L in maintaining cellular redox homeostasis under hypoxic 
stress and potentially other forms of oxidative stress. Work on mitochondrial OCM mutant 
mouse models have thus far focused on mitochondrial OCM as a source for 1-C units 
involved in purine, thymidine, and methionine metabolism. However, the role of 
mitochondrial OCM in redox homeostasis and its implications for NTC have been largely 
ignored. While that is understandable given how difficult redox experiments can be to 
control, especially in vivo, a developing body of evidence supports that mitochondrial 
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OCM’s redox properties may be critical to understanding this pathway’s role in neural tube 
development. 
Finally, the changes in OCM gene expression observed between E8.5 and E10.5 in 
mouse embryos suggests that embryonic utilization of 10-formyl-THF may shift during 
this timeframe from favoring mitochondrial formate synthesis at E8.5, to aldehyde 
dehydrogenase activity at E10.5. While these data may be considered preliminary, since 
more evidence beyond gene expression would be needed to confirm this hypothesis, there 
are two possible explanations as to why this may be a beneficial metabolic switch for 
embryos. First, the enzymatic activity of ALDH1L1 and ALDH1L2 catalyzes the 
irreversible oxidation of the formyl group from 10-formyl-THF to CO2, regenerating THF 
in the process. This reaction utilizes NADP+ as a cofactor and yields one molecule of 
NADPH. Thus, this switch may reflect the embryo’s metabolic requirements for reducing 
equivalents during the transition from predominantly anaerobic to aerobic metabolism. 
Furthermore, Ducker et al. (2016) demonstrated that in cell culture, mitochondrial OCM 
flux exceeds demand for cytosolic 1-C units, and that the rate of mitochondrial formate 
excretion was closely linked to expression of mitochondrial OCM genes, specifically 
MTHFD2, SHMT2, and MTHFD1L. While these observations have not been confirmed in 
vivo, it seems a reasonable hypothesis that embryonic demand for 1-C units may decrease 
after NTC. If that is the case, mitochondrial OCM continuing to produce more formate 
beyond 1-C demand may lead to accumulation of formate, which can be toxic in the 5-
30mM range via inhibition of cytochrome c oxidase (Nicholls 1975; Pietzke, Meiser, and 
Vazquez 2020). Thus, disposing of 1-C units by shuttling them into complete oxidation by 
ALDH1L1 and ALDH1L2 may be a metabolic strategy to cope with decreased 1-C 
demand. Pursuing this hypothesis in future experiments may yield insight into the role of 
mitochondrial OCM both during NTC and at other stages of development.  
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PART TWO: MECHANISMS OF NEURAL TUBE DEFECTS 
CAUSED BY PHARMACEUTICAL EXPOSURE TO VALPROIC 
ACID OR DOLUTEGRAVIR 
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Chapter 4: Identifying Predictive Biomarkers of Valproic Acid 
Sensitivity in Neural Tube Defect-affected and Unaffected Murine 
Embryos 
4.1 INTRODUCTION 
The teratogenic mechanism by which valproic acid (VPA) causes neural tube 
defects (NTDs) and other congenital anomalies remains an unanswered question. 
Preventing VPA-induced NTDs (or other AED-induced defects for that matter) while still 
enabling women of childbearing potential to safely benefit from the therapeutic properties 
of these drugs requires us to understand the underlying mechanism of action. That said, 
even the therapeutic mechanism of VPA is debatable (Lloyd 2013). Enhancing γ-
aminobutyric acid (GABA) concentrations within the brain (Johannessen and Johannessen 
2003), and reduction of excitatory neurotransmission through inhibition of voltage gated 
sodium channels (Pugsley et al. 1999; Large et al. 2009) or reduction in synaptic aspartate 
levels (Morland, Nordengen, and Gundersen 2012) have all been proposed. Ultimately, 
several undefined mechanisms may contribute to VPA’s anticonvulsant effects (Lloyd 
2013). 
Several potential mechanisms of VPA teratogenesis are being researched. 
Physiologically, around 97% of the drug is metabolized in the liver through uridine 
diphosphate glucuronidation, β-oxidation, and cytochrome P450 activity (Sankar 2007). It 
appears that VPA is asymmetrically distributed across the placenta, with higher 
concentrations of VPA accumulating in the embryo than in maternal blood, possibly 
resulting in a toxic dose for the embryo despite a conventionally safe dose for the mother 
(Vajda 2012). Even managing maternal dose can be tricky during pregnancy, since plasma 
concentrations of VPA may decrease by up to 50% (Sabers and Tomson 2009; Wlodarczyk 
et al. 2012). It has also been demonstrated that VPA functions as a histone-deacetylase 
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(HDAC) inhibitor, which suggests VPA may disrupt epigenetic regulation of embryonic 
gene expression (Lloyd 2013). Other evidence indicates VPA may cause oxidative stress. 
For example, hepatic metabolism of VPA results in several reactive compounds including 
4-ene VPA, which can undergo β-oxidation to form the reactive species (E)-2,4-diene VPA 
which competes with the glutathione redox cycle by oxidizing NADPH (Liu et al. 2009). 
It has also been suggested that VPA may antagonize the activities of folate and OCM by 
directly antagonizing the folate receptor (Fathe, Palacios, and Finnell 2014) or through 
antagonism of DHFR, thus depleting cellular folate pools (Hsieh et al. 2012). Regardless, 
given the extensive metabolic activity of VPA and its constituent metabolites, a 
metabolism-dependent mechanism of VPA sensitivity is highly plausible. 
Moreover, there is undoubtedly an underlying genetic component predisposing to 
AED risk. Studies in mice demonstrate that VPA sensitivity is strain-dependent, and that 
this sensitivity can be mapped to a specific genetic locus in Swiss-Vancouver (SWV) mice 
(Finnell et al. 1988; Finnell et al. 1997; Beck 1999; Finnell et al. 2000; Beck 2001; 
Lundberg et al. 2004). Even within the same litter, not all VPA-exposed embryos develop 
NTDs. For example, DBA/2J mice appear entirely resistant to VPA, while about 20% of 
LM/BC and C57/BL6 embryos develop NTDs. SWV mouse embryos appear even more 
susceptible displaying a 35% occurrence of NTDs after VPA exposure (Finnell et al. 1988; 
Lundberg et al. 2004). Regardless, elucidating the underlying genetic or metabolic factors 
contributing to risk for valproate-affected pregnancies may lead to development of non-
teratogenic anticonvulsants, novel prevention strategies, or more targeted methods for 
managing epileptic pregnancies. 
Previous metabolomic studies have been performed in mice comparing VPA-
treated and untreated embryos (Akimova et al. 2017). However, as mentioned, less than 
half of exposed embryos actually develop NTDs; thus, these studies did not adequately 
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discern between metabolic alterations caused by VPA exposure and metabolic alterations 
associated with VPA sensitivity. No comparison has yet been made between VPA-treated 
embryos that developed NTDs and those that did not. Using tandem liquid 
chromatography-mass spectrometry (LC-MS), we performed an untargeted metabolomic 
profiling of murine C57/BL6 embryos (a moderately sensitive strain) exposed in utero to 
VPA on gestational day E8.5 and compared metabolic alterations between VPA-affected 
(developed an NTD) and unaffected embryos at gestational days E9.5 (26 hours post 
exposure), and E10.5 (50 hours post exposure). Moreover, by observing metabolic 
variation between untreated control embryos and VPA-treated embryos on E8.5 (two hours 
post exposure and prior to neural tube closure) we identified predictive biomarkers 
associated with VPA exposure that may be determinative of sensitivity to VPA-induced 
NTDs. 
4.2 MATERIALS AND METHODS 
4.2.1 VPA Treatment and Embryo Collection 
C57/BL6 mice were obtained from BCM’s Center for Comparative Medicine and 
were housed on 12-hour light/dark cycles with standard chow (5V5R, Lab Supply) and 
maintained according to protocols approved by the Institutional Animal Care and Use 
Committee (IACUC) at BCM. Timed crosses were performed, and copulation was 
confirmed by morning checks for vaginal plugs. Pregnancy was confirmed by comparing 
dam weight on the date the plug was observed to weight measured on gestational day E8.5. 
Pregnant dams were euthanized using CO2 asphyxiation followed by cervical dislocation. 
At 11 AM on gestational day E8.5, 9 pregnant dams received an intraperitoneal injection 
of a 600mg/kg dose of VPA dissolved in PBS. 9 pregnant control dams did not receive the 
injection. Embryos were collected from three dams of each treatment group on E8.5 at 1 
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PM, two hours post-injection. Embryos were also collected from three dams of each 
treatment group 26 hours post-injection (E9.5) and 50 hours post-injection (E10.5). E 9.5 
and E10.5 embryos were scored as being VPA-affected if they presented with an open 
neural tube, and unaffected if they presented with a closed neural tube and otherwise 
normal development. Somite number was counted at each timepoint. E8.5 embryos could 
not be scored as the process of neural tube closure is still ongoing at that time. 22 VPA-
treated embryos were collected at E8.5. 24 VPA-treated embryos were collected at E9.5, 
of which 6 were scored as affected (25%). 26 VPA-treated embryos were collected at 
E10.5, of which 5 were scored as affected (19.2%). 
Upon dissection, the embryos were washed once in sterile milli-Q water and snap 
frozen in liquid nitrogen. All VPA-treated embryos and 8 untreated control embryos from 
each timepoint were selected for metabolomics. Metabolites were extracted in a 1:1 
aqueous methanol solution with 10mM chloroform, which was then evaporated using a 
refrigerated speed vac at -5⁰C. 
4.2.2 Liquid Chromatography-Mass Spectrometry (LC-MS) 
An untargeted metabolomic analysis of polar fraction extracts was performed on a 
Hybrid quadrupole-Orbitrap mass spectrometer (Q Exactive, Thermo Scientific, Waltham, 
MA, USA) hyphenated with a Thermo Scientific Accela 1250 UHPLC system via 
electrospray ionization source, simultaneously operating in positive/negative polarity 
switching ionization mode. To ensure consistency in data acquisition over the entire batch, 
quality control (QC) samples, prepared for each group and pool of all samples, were run 
every 8 samples.  
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4.2.3 Data Analysis and Statistics 
All raw MS datasets were processed using Sieve 2.2 (Thermo Fisher Scientific) and 
features with a coefficient of variation (CV) lower than 25% in the QC samples were 
considered for further analysis. Peaks were scaled and normalized according to a PQN 
algorithm (Dieterle et al. 2006) and features were then mined against an in house database 
of accurate masses and retention times generated in the Stefano Tiziani laboratory  (The 
University of Texas at Austin, Dell Medical School) through the IROA300 (Lu, 
Solmonson, et al. 2017) Mass Spectrometry Metabolite Library of Standards (MSMLS; 
IROA Technologies, Bolton, MA) using the same experimental conditions used for data 
acquisition of this dataset. In addition, databases of accurate masses taken from the KEGG 
database and the Human Metabolome database were also mined. Univariate (student’s t 
test)  and multivariate (principal component analysis) statistical data analyses were 
performed using statistics and bioinformatics toolboxes for MATLAB as described in the 
following publications: (Lodi et al. 2011; Tiziani et al. 2011; Lodi et al. 2013; Tiziani et 
al. 2013; Kang et al. 2014; Sweeney et al. 2016; Lodi et al. 2017; Lu, Salmoson, et al. 
2017), or in Microsoft Excel with Analyze-It statistical package. Statistical significance 
was set at p<0.05. False discovery rate (FDR) was calculated using the Benjamini-
Hochberg method (Benjamini and Hochberg 1995). Pathway analyses were performed 
using MetaboAnalyst (McGill University, Montreal, Canada). 
4.3 RESULTS 
4.3.1 Comparison of Affected and Unaffected Embryos at E9.5 and E10.5 
All putatively identified metabolites (based on exact mass) and confirmed MS 
peaks were plotted in heat maps following hierarchical clustering (Figures 4.1 and 4.2). 
Major metabolic alterations were observed between gestational days E8.5 and E10.5 for 
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control as well as VPA-treated embryos (See Appendix II for a list of significantly altered 
metabolites between E8.5, E9.5, and E10.5 in VPA-treated embryos). To better visualize 
the extent of the metabolic differences between the control and treated embryos at each 
gestational day, principal component analysis (PCA) was performed using all putatively 
identified MS peaks for all embryo samples and different groups (control and treated) 
separately (Figure 4.3). It can be clearly seen in Figure 4.3A that control and treated embryo 
groups at each gestational day overlap with one another indicating metabolic similarity 
among them, whereas clear separation between each gestational day of the control and 
treated embryo groups indicates significant metabolic changes between different 
embryonic developmental stages. That said, overall metabolism of VPA-affected and 
unaffected embryos was remarkably similar (Figure 4.3B). 
A more detailed analysis of metabolic alterations in VPA treated embryos at 
gestational day E10.5 (compared to E8.5) indicated accumulation of citrate cycle 
metabolites (citrate, fumarate and malate) as well as hydroxyglutarate. Significant effects 
on glycolysis and the pentose phosphate pathway (PPP) were observed with accumulation 
of glucose, fructose-1,6-biphosphate, glycerol-2-phosphate, phosphoenolpyruvate, 
nucleotides (mono-, di-, and tri-phosphates), and  downregulation of ribose-5-phosphate, 
glycerate, inosine, xanthine, hypoxanthine, uracil, uric acid, uridine, cytidine and 
thymidine. Similarly, accumulation of glycine, serine and methionine suggests alteration 
of one-carbon metabolism and nucleotide biosynthesis. Upregulation of NAD+, NADH, 
tryptophan, kynurenine and hydroxykynurenine indicates modulation of de novo NAD+ 
biosynthesis (Appendix II). 
In addition, we performed an in-depth analysis of the metabolic differences 
between VPA-affected and unaffected embryos at gestational days E9.5 and E10.5.  As 
mentioned earlier, the PCA plot demonstrated little to no variation between E9.5 and E10.5 
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embryos classified as affected or unaffected (Figure 4.3B). Confirming this assessment, 
univariate statistical analyses (student’s t tests) uncovered very few metabolites 
significantly altered between VPA-affected and unaffected embryos at these two 
timepoints. There was significant downregulation of the nucleotide diphosphate, adenosine 
diphosphate, the nucleotide-sugar, uridine 5-diphosphogalactose, the pentose-phosphate 
intermediate, ribose 5-phosphate, and the glycolysis pathway intermediates, 
phosphoenolpyruvic acid and fructose-1,6-biphosphate (Figure 4.4). We also found 
significantly decreased abundance of methionine at E10.5 concomitant with a significant 
increase in 2-ketobutyric acid, a metabolite produced during conversion of cystathionine 
to cysteine (Figure 4.4G and 4.4H). These data suggest persistent disruption of cysteine 
and methionine metabolism in VPA-affected embryos, even as late as 50 hours post 
exposure. 
4.3.2 Metabolic Effects of VPA in E8.5 Embryos 
Previous metabolomic analyses of VPA-treated embryos only examined metabolic 
alterations at E9.5 when VPA-induced defects become apparent (Akimova et al. 2017). 
However, in our analysis, we noticed the greatest variation between VPA-treated and 
untreated embryos was observable at E8.5 (two hours post-injection). Thus, it appears VPA 
induces large-scale metabolic changes very quickly, within a few hours of exposure, and 
analyzing metabolic alterations at that timepoint would be more informative. We therefore 
compared metabolism at E8.5 between VPA-treated embryos and untreated controls. 
Seventy-five metabolites of significantly differential abundance were identified in 
E8.5 VPA-treated embryos after adjusting for false discovery rate (FDR) (Appendix III). 
Pathway analysis revealed that pyrimidine and purine metabolism were the most 
overrepresented pathways, with 10 and 12 altered metabolites respectively (Table 4.1). 
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Purines and pyrimidines in their nucleobase or glycosylated nucleoside forms were 
significantly upregulated, while their mono-, di-, and tri-phosphate nucleotide analogs 
were significantly downregulated (Appendix III), suggesting impairment of nucleoside 
kinase activity, which are ATP-dependent enzymes. There were also a significant number 
of dysregulated amino acids, explaining enrichment of the pathway aminoacyl-tRNA 
biosynthesis. There were six metabolites of differential abundance representing cysteine 
and methionine metabolism (Table 4.1), including upregulation of S-adenosyl-
homocysteine and methionine, and downregulation of taurine, hypotaurine, and oxidized 
glutathione (Appendix III), suggesting impairment of homocysteine and cysteine 
catabolism via the transsulferation pathway. 
4.3.3 Predictive Biomarkers of VPA Sensitivity in E8.5 Embryos 
Scoring E8.5 embryos as either VPA-affected or unaffected through observation of 
overt phenotypes is not possible since NTDs cannot be confirmed prior to neural tube 
closure, which occurs between E9.0 and E9.5 in mouse embryos (Greene and Copp 2009). 
However, there were disappointingly few metabolites differentiating VPA-affected and 
unaffected embryos at E9.5 and E10.5. Since E8.5 is a more developmentally critical 
timepoint to assess metabolic influence on neural tube closure, and since VPA seemed to 
induce the largest metabolic alterations at that time, we sought to identify metabolites at 
E8.5 that might be predictive of VPA sensitivity. 
To address this challenge, we performed a multivariate analysis of all MS peaks for 
VPA-treated and untreated embryos at E8.5 only (Figure 4.5). We noticed that the greatest 
stratification between control embryos (n=8) and treated embryos (n=22) occurred along 
principal component 2 (PC2). While their ranges overlapped, with approximately half of 
treated embryos clustering within the range of the controls, the other half clustered outside 
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that range. This alone, however, cannot be predictive of VPA-sensitivity since NTD-
affected embryos only accounted for 19.2% and 25% of E10.5 and E9.5 embryos, 
respectively. Thus, using the standard deviation (σ) of the controls, we looked for a number 
of standard deviations along PC2 outside the range of the control embryos that isolated 
approximately that proportion of treated embryos (Table 4.2). We found that 5 treated 
embryos (22.73%) clustered more than five standard deviations from the range of the 
controls (Figure 4.5 and Table 4.2). Assuming that embryos with the greatest metabolic 
deviation from controls are more sensitive to VPA, we categorized these embryos as likely 
affected. Treated E8.5 embryos that clustered within five standard deviations of the control 
range were categorized as likely unaffected. Hierarchical clustering of confirmed 
metabolite peaks in E8.5 embryos demonstrated that the five likely affected embryos 
clustered together with a distinguished metabolic signature relative to the other treated 
embryos and the controls (Figure 4.6). Only one other embryo classified as likely 
unaffected appeared hierarchically related to these likely affected embryos and we noted 
that this embryo was the next closest in the PCA (Figure 4.5) to the likely affected embryos. 
We next compared MS peaks between the likely affected and likely unaffected E8.5 
embryos and identified 31 metabolites of significantly differential abundance after 
adjusting for FDR (Appendix IV). Pathway analysis showed that purine and pyrimidine 
metabolism were not overrepresented, as was the case when comparing all VPA-treated 
embryos with controls. Instead, glyoxylate/dicarboxylate metabolism and the 
mitochondrial citrate cycle were significantly affected (Table 4.3). The metabolites of 
differential abundance in these pathways were oxaloacetate, citrate/isocitrate, succinate, 
fumarate, and D-glyceric acid (Figure 4.7). Each of these metabolites was found to be 
significantly reduced in likely affected embryos compared to likely unaffected embryos; but 
notably, only oxaloacetate was significantly reduced in likely unaffected embryos 
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compared to untreated controls. Thus, impairment of the other citrate cycle intermediates 
may be uniquely predictive markers of VPA sensitivity. 
While cysteine and methionine metabolism were not significantly overrepresented 
in the pathway analysis, we did observe a notable number of metabolites with differential 
abundance representing this pathway (Appendix IV). These metabolites included 
methionine and serine, which were upregulated, and the downregulated metabolites, 
taurine and 2-sulfinoalanine (also known as L-cysteine sulfinic acid) (Figure 4.8). Serine 
is required for conversion of homocysteine to cystathionine while 2-sulfinoalanine is an 
intermediate in the catabolism of cysteine to taurine. Notably, these two metabolites were 
dysregulated in likely affected embryos, but not likely unaffected embryos relative to 
untreated controls. 
Since metabolites that are significantly altered in likely affected embryos but not in 
likely unaffected embryos are arguably more predictive of VPA sensitivity, we sought to 
identify all metabolites that were of differential abundance in likely affected embryos 
compared to likely unaffected embryos, but not in the likely unaffected group compared to 
untreated controls. The goal in this case was to differentiate between metabolic alterations 
associated with VPA exposure and those associated with VPA sensitivity. We identified 
14 metabolites that met these criteria (Table 4.4). Notably, all of the upregulated 
metabolites are amino acids, suggesting accumulation of these compounds possibly 
through impaired catabolism. This hypothesis is supported when examining the 
downregulated metabolites, which predominantly appear to be products of catabolism or 
intermediates of catabolic pathways. Notably, among these downregulated metabolites are 
the citrate cycle intermediates, succinate, fumarate, and citrate/isocitrate. Moreover, the 
catabolic “waste” compounds, urate and its oxidation product allantoin, were two of the 
most significantly depleted metabolites. 
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Arginine was the most significantly accumulated metabolite in likely affected 
embryos (Table 4.4). Interestingly, arginine abundance was highly distinguishing between 
likely affected embryos and both untreated controls and likely unaffected embryos (Figure 
4.9A). It is notable that the only embryo from the likely unaffected group that falls within 
the range of the likely affected embryos in terms of arginine abundance was the one that 
was hierarchically related to the likely affected group in Figure 4.6. Thus, it appears 
accumulation of arginine is the most predictive biomarker indicative of VPA sensitivity, 
and the strongest component associated with the distinguishing metabolic signature of 
likely affected embryos as determined by hierarchical clustering. 
Arginine is converted to citrulline either indirectly via the urea cycle or directly 
through the activity of nitric oxide synthase (NOS) enzymes. NOS catalyzes the oxygen 
dependent conversion of arginine to citrulline, producing nitric oxide (NO) as a byproduct. 
Citrulline was not identified in our analysis looking for markers specifically associated 
with VPA sensitivity, but only because the metabolite was excluded after correcting for 
FDR. When we examined the MS peaks for citrulline, we found that the metabolite was 
significantly reduced in likely affected embryos compared to both likely unaffected 
embryos and untreated controls (Figure 4.9B). Since interconversion of arginine and 
citrulline is performed by NOS and may therefore be a readout of NO levels, we looked at 
the arginine/citrulline ratio for each individual embryo. We found that the 
arginine/citrulline ratio was increased nearly four-fold in likely affected embryos compared 
to the likely unaffected group, and nearly 10-fold compared to untreated controls (Figure 
4.9C). Comparatively, embryos classified as likely unaffected only showed a 2.5-fold 
increase compared to controls. These data would suggest VPA impairs NOS enzyme 
activity and subsequent NO production (Figure 4.9D), and that the severity of this 
impairment may be predictive of VPA sensitivity.  
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Figure 4.1 Hierarchical Clustering of Putatively Identified Metabolites in Control and 
VPA-treated Embryos 
Untargeted hierarchical clustering of all putatively identified MS peaks in VPA-treated and 
control embryos at E8.5, E9.5, and E10.5, and in QC samples. Clustering was performed 
by Pearson correlation using complete linkage 
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Figure 4.2 Hierarchical Clustering of Confirmed Metabolites in Control and VPA-treated 
Embryos 
Untargeted hierarchical clustering of all confirmed MS peaks in VPA-treated and control 




Figure 4.3 Principal Component Analysis of All Confirmed Peaks in Control and VPA-
treated Embryos 
A) Principal component analysis of all confirmed MS peaks comparing control (C) and 
VPA-treated (T) embryos at each time point (E8.5, E9.5, and E10.5). The largest variation 
observed between control and VPA-exposed embryos occurred at E8.5, two hours post-
injection. 
B) Principal component analysis of all confirmed MS peaks comparing affected (A) and 
unaffected embryos (U) at each timepoint (E8.5, E9.5, and E10.5) in VPA-treated embryos 




Figure 4.4 Metabolites of Differential Abundance in VPA-affected and Unaffected 
Embryos at E9.5 and E10.5 
MS peak areas from VPA-treated embryos at E9.5 and E10.5 comparing differential 
abundance of metabolites between affected and unaffected embryos. These metabolites 
included (A) adenosine diphosphate, (B) uridine 5-diphosphogalactose, (C) ribose 5-
phosphate, (D) aspartate, (E) fructose 1,6-bisphosphate, (F) phosphoenolpyruvate, (G) 
methionine, and (H) 2-ketobutyric acid. *Statistical significance was determined by 
unpaired t tests with Welch’s correction (α=0.05).  
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Table 4.1 Pathway Analysis Comparing VPA-treated and Untreated Embryos at E8.5 
Metabolic pathways found to be significantly altered in VPA-treated E8.5 embryos 















Pyrimidine metabolism 39 10 5.33E-06 4.48E-04 0.38282 
Purine metabolism 66 12 2.63E-05 0.001105 0.14111 
Aminoacyl-tRNA 
biosynthesis 
48 9 2.36E-04 0.0066 0 
Alanine, aspartate and 
glutamate metabolism 
28 6 0.00136 0.028553 0.71235 
Arginine biosynthesis 14 4 0.003011 0.046515 0.19289 
Cysteine and 
methionine metabolism 
33 6 0.003323 0.046515 0.19088 




Figure 4.5 Principal Component Analysis of All Confirmed Peaks in E8.5 Embryos 
Principal component analysis of confirmed MS peaks in E8.5 embryos comparing 
untreated controls (n=8) and VPA-treated embryos (n=22). The component predicting 
greatest variance between treated and untreated embryos was principal component 2 (PC2). 
The mean (𝑋) and ranges of the controls and VPA-treated embryos along PC2 are displayed 
to the right, along with the standard deviation (σ) of the controls along PC2. Five VPA 
treated embryos (black circle), representing 22.73% of VPA-treated embryos, were found 
to cluster more than five standard deviations outside the range of the controls. These 
embryos were classified as likely affected.  
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Table 4.2 Proportion of VPA-treated Embryos Clustering More Than a Given Number of 
Standard Deviations Outside the Range of Control Embryos on PC2 
Criteria for differentiating VPA-affected and unaffected embryos at E8.5 based on the 
principal component analysis from Figure 4.5. Embryos clustering more than five standard 
deviations from the controls were classified as likely affected (approximately 22.73% of 
embryos). 
 
Mean of Controls (PC2) -0.16614  
Mean of Treated (PC2) 0.061777  
Standard Deviation of Controls (PC2) 0.056313  
Range of Controls (PC2) -0.23734 -0.05725 
    
σ from Max of 
Controls 
No. of Treated 
Embryos 
Percentage of Treated 
Embryos 
1 10 45.45455  
2 9 40.90909  
3 7 31.81818  
4 7 31.81818  
5 5 22.72727  
6 3 13.63636  





Figure 4.6. Hierarchical Clustering of Confirmed Metabolite Peaks in E8.5 Embryos 
Untargeted hierarchical clustering of confirmed MS peak areas for 136 metabolites in both 
VPA-treated (n=22) and untreated control (n=8) embryos at E8.5. Metabolites are clustered 
in the rows and columns represent individual embryos. Each column is marked with a color 
coding (bottom) signifying the classification of the corresponding embryos as control 
(grey, n=8), likely affected (orange, n=5), or likely unaffected (green, n=17). The row and 
column dendrograms represent clustering by Pearson correlation using complete linkage. 
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Table 4.3. Pathway Analysis Comparing Likely Affected and Likely Unaffected Embryos 
at E8.5 
Metabolic pathways found to be significantly altered in likely affected E8.5 embryos 
compared to likely unaffected VPA-treated embryos at E8.5. Pathway analysis was 
















biosynthesis 48 8 
2.02E-06 1.70E-04 0.16667 
Alanine, aspartate and 
glutamate metabolism 28 6 
1.03E-05 4.32E-04 0.29407 
Glyoxylate and 
dicarboxylate 
metabolism 32 5 
3.07E-04 0.008585 0.17726 
Citrate cycle (TCA 
cycle) 20 4 
4.98E-04 0.01045 0.27074 
Arginine biosynthesis 14 3 0.002241 0.031448 0.07614 
Phenylalanine, tyrosine 
and tryptophan 
biosynthesis 4 2 
0.002246 0.031448 1 
* Match status reflects the number of altered metabolites identified in each pathway. 
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Figure 4.7. Metabolites of Differential Abundance Related to the Citrate Cycle and 
Glyoxylate/Dicarboxylate Metabolism in E8.5 Embryos 
MS peak areas from VPA-treated embryos at E8.5 comparing differential abundance of 
metabolites between control (n=8), likely affected (n=5), and likely unaffected (n=17) 
embryos. These metabolites were associated with the citrate cycle and 
glyoxylate/dicarboxylate metabolic pathways, and included (A) oxaloacetate, (B) 
citrate/isocitrate, (C) succinate, (D) fumarate, and (E) D-glyceric acid.  





Figure 4.8. Metabolites of Differential Abundance Related to Cysteine and Methionine 
Metabolism in E8.5 Embryos 
MS peak areas from VPA-treated embryos at E8.5 comparing differential abundance of 
metabolites between control (n=8), likely affected (n=5), and likely unaffected (n=17) 
embryos. These metabolites were associated with cysteine and methionine metabolism, and 
included (A) methionine, (B) serine, (C) 3-sulfino-L-alanine (also known as L-cysteine 
sulfinic acid), and (D) taurine.  
*Statistical significance was determined by unpaired t tests with Welch’s correction 
(α=0.05).  
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Table 4.4 Metabolites of Differential Abundance Only in Likely Affected E8.5 Embryos 
Metabolites found to be significantly altered in likely affected E8.5 VPA-treated embryos 
compared to likely unaffected VPA-treated embryos, but not significantly altered in 
unaffected embryos compared to untreated controls. 
 
 





Arginine 3.12 1.644898 0.01124 0.214088 
D-Tryptophan 2.20 1.139785 1.58E-05 0.070694 
L-Tyrosine 1.81 0.858123 0.001362 0.063553 
L-Serine 1.63 0.701088 0.001515 0.822323 
L-Threonine/L-Allothreonine 1.40 0.489917 0.008042 0.224635 
D-Alanine 1.38 0.464912 0.015809 0.405604 
3-Sulfino-L-Alanine 0.57 -0.81135 0.012647 0.094568 
D-Glyceric Acid 0.54 -0.88308 0.025359 0.103572 
3-Hydroxy-3-Methylglutarate 0.52 -0.95715 0.016398 0.074156 
Succinate 0.51 -0.98357 0.02518 0.110221 
Fumarate 0.47 -1.082 0.011435 0.606414 
Allantoin 0.41 -1.27858 0.004987 0.47988 
Isocitric Acid/Citric Acid 0.39 -1.34976 0.000644 0.080757 
Urate 0.27 -1.89217 0.008476 0.183783 




Figure 4.9 Differential Abundance of Arginine and Citrulline in Likely Affected E8.5 
Embryos 
MS peak areas from VPA-treated embryos at E8.5 comparing differential abundance of 
(A) arginine and (B) citrulline between control (n=8), likely affected (n=5), and likely 
unaffected (n=17) embryos. (C) The ratio of the metabolites arginine and citrulline in 
control, likely affected, and likely unaffected embryos. The ratio was highest in the embryos 
classified as likely affected suggesting impairment of arginine-citrulline interconversion. 
Statistical significance was determined by unpaired t tests with Welch’s correction 
(α=0.05). (D) Proposed model of VPA-sensitivity predicted by impairment of nitric oxide 
synthase (NOS) enzymes. 






Figure 4.10 Ablation of UDP Glucuronic Acid in VPA-exposed E8.5 Embryos 
MS peak areas for UDP glucuronic acid in VPA-exposed E8.5 embryos compared to 
untreated controls. 





Figure 4.11 Decrease in Itaconate Abundance in VPA-treated E8.5 Embryos 
MS peak areas for itaconate in VPA-exposed E8.5 embryos compared to untreated 
controls. 





Figure 4.12 Correlation of Arginine and Methionine Abundance in E8.5 Embryos 
 
Scatter plot demonstrating correlation between MS peak areas of arginine and methionine 
in E8.5 embryos. Arginine and methionine abundance are highly correlated in untreated 
control embryos. 





In a previous study, Akimova et al. 2017, our group demonstrated that VPA 
exposure in mouse embryos on gestational day E8.5 resulted in very little metabolic 
alteration by E9.5 compared to control embryos, so long as the mice were fed a diet with a 
standard amount of folic acid (2 ppm) (Akimova et al. 2017). In fact, only two metabolites 
were demonstrated to have statistically significant abundance, adenine and thymine 
(Akimova et al. 2017). It is important to note that Akimova et al. found that a high folic 
acid diet (10 ppm) resulted in more severe metabolic alterations associated with VPA 
exposure, alterations predominantly related to nucleotide, carnitine, and one-carbon 
metabolisms. They also found that VPA-treated embryos on the high folic acid diet had 
more severe developmental anomalies and developmental delay characterized by lower 
somite number (Akimova et al. 2017). We did observe marginally lower somite numbers 
at E9.5 and E10.5 in VPA-treated embryos, but no difference in somite number was 
observed at E8.5 (data not shown). Since mice in our study were fed a chow with 3.6 ppm 
folic acid, considerably lower than 10 ppm, the fact that we did not observe metabolome 
wide changes in the VPA-treated embryos at those timepoints appears consistent with 
previous results. Moreover, the previous study only looked at metabolism in VPA-treated 
embryos that had NTDs, thus excluding apparently non-sensitive embryos from analysis 
(Akimova et al. 2017). Since the goal of our current study was to identify metabolism 
indicative of VPA sensitivity, we considered it more prudent to compare affected and 
unaffected embryos.  
Adenosine diphosphate, uridine 5-diphosphogalactose, fructose 1,6-bisphosphate, 
and phosphoenolpyruvate were decreased in affected embryos both at E9.5 and E10.5. 
Downregulation of the latter two metabolites would suggest persistent impairment of 
glycolysis in NTD embryos, while changes in nucleotide diphosphates are consistent with 
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observations from Akimova et al (Akimova et al. 2017). The decrease in uridine 5-
diphosphogalactose is likely related to VPA’s suppression of uridine diphosphate 
glucuronidase activity (Wlodarczyk et al. 2012), consistent with our observation that 
uridine diphosphoglucuronic acid (UDP glucuronic acid) was completely ablated in all 
VPA-treated embryos at E8.5 (Figure 4.10). We also found that aspartate levels were 
decreased in E10.5 affected embryos relative to unaffected embryos, but that there was no 
apparent difference at E9.5. While we found aspartate was not significantly different 
between VPA-treated embryos and controls at either timepoint, it is still difficult to draw 
conclusions from these results regarding aspartate as a marker for VPA sensitivity. We also 
observed an interesting relationship between methionine and cysteine metabolism at E10.5. 
Methionine abundance was decreased in affected embryos at E10.5, while a product of 
homocysteine and cysteine metabolism, 2-ketobutyrate was increased. This would suggest 
that at this timepoint, affected embryos are favoring utilization of homocysteine for 
transsulfuration of cysteine as opposed to regeneration of methionine. This result is 
interesting since the opposite effect was observed at E8.5, where we saw increased 
methionine in VPA-treated embryos along with decreased abundance of cysteine 
metabolism intermediates.  
That said, given the small number of altered metabolites and large-scale shifts in 
metabolism between E8.5 and E10.5 (Appendix II), it is ultimately difficult to extract 
informative insights by comparing affected and unaffected embryos at E9.5 and E10.5. 
First, there were few observed VPA-affected metabolic alterations at those gestational 
dates, and while using those timepoints does allow for direct scoring of embryos as affected 
or unaffected based on visual observations, it is important to note that the VPA-induced 
defects have already occurred by E9.5. Thus, we cannot be certain that we are measuring 
metabolism associated with VPA sensitivity or metabolism associated with NTDs 
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themselves. As such, we chose to focus the rest of our analysis on E8.5 embryos, not only 
because it is a more developmentally relevant timepoint, but also because we noticed VPA 
had the greatest influence on embryonic metabolism at that time, likely because it was the 
earliest timepoint collected post exposure. After all, the half-lives of VPA and its 2-ene-
VPA metabolite are only 0.8 and 1.2 hours, respectively (Nau and Zierer 1982; Nau 1985). 
We first examined metabolic alterations between control and VPA-treated embryos 
at E8.5 since, to our knowledge, no previous metabolomic study at that timepoint has been 
published. We observed large-scale changes in embryonic metabolism associated with 
acute VPA exposure, predominantly in purine and pyrimidine metabolism. This is 
consistent with observations in Akimova et al. where it was hypothesized impairment of 
purine and pyrimidine synthesis through disrupted one-carbon metabolism may be 
causative of VPA-induced NTDs (Akimova et al. 2017). However, our findings do not 
support this hypothesis since we actually observed increased abundance of purine and 
pyrimidines and their nucleoside analogs; it was their phosphate-linked nucleotide analogs 
that were depleted as a result of VPA exposure. Phosphorylation of nucleosides to 
manufacture nucleoside monophosphates, diphosphates, and triphosphates is mediated by 
nucleoside kinases, and it is ultimately an ATP-dependent process (Lehninger, Nelson, and 
Cox 2013). Thus, the observed alterations in purine and pyrimidine metabolism do not 
appear to be a result of disrupted purine and pyrimidine synthesis but may actually be 
suggestive of dysfunctional energy metabolism. 
While comparing untreated controls and VPA-treated embryos can be revealing as 
to how VPA exposure influences global metabolism, the ultimate goal of our study was to 
identify markers specifically associated with VPA-sensitive embryos. To address this 
challenge, we initially employed a machine learning algorithm that attempted to predict 
VPA-affected and unaffected embryos at E8.5 using metabolites of differential abundance 
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identified at E9.5. However, this approach did not yield a satisfyingly predictive model as 
it estimated approximately 60% of E8.5 embryos would be affected. We know this cannot 
be the case since we only observe around 20-25% of E9.5 and E10.5 embryos with NTDs. 
It is possible this strategy failed due to the lack of metabolic variation observed between 
affected and unaffected embryos at E9.5 and E10.5, even between control and VPA-treated 
embryos for that matter, and of course the large metabolome-wide shifts observed between 
gestational timepoints. These factors likely hampered the robustness of the model. We thus 
decided to employ a more conventional strategy by isolating a proportion of E8.5 embryos 
that demonstrated the greatest separation from untreated control embryos in a basic 
multivariate analysis. We found that approximately 23% (five embryos) of the treated E8.5 
group clustered more than five standard deviations away from control embryos, and thus 
made a quantitative assumption that these five embryos are likely affected, based on them 
demonstrating the greatest metabolic sensitivity to VPA. We believe our five-standard 
deviation cutoff was ultimately conservative, as at least one other embryo lying within the 
cutoff appeared metabolically related to the selected embryos (Figure 4.6). 
The metabolic signature that characterized the likely affected embryos was strongly 
distinguished by increased abundance of several amino acids, particularly arginine, and 
decreased abundance of citrate cycle intermediates. Despite altered purine and pyrimidine 
metabolism being the most impactful markers of VPA exposure, disruption of these 
pathways was not associated with VPA sensitivity in the likely affected cohort. That said, 
it is notable that decreased abundance of urate and allantoin were two makers strongly 
indicative of VPA sensitivity. Urate is a product of purine catabolism and allantoin is an 
oxidative product of urate synthesized via the enzyme urate oxidase (Lehninger, Nelson, 
and Cox 2013). Humans lack functional urate oxidase, but can still produce allantoin from 
urate non-enzymatically in the presence of free radicals (Grootveld and Halliwell 1987). 
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In fact, urate acts as an antioxidant due to its capacity for free radical scavenging, and is 
endogenously produced in response to oxidative stress caused by hypoxia (Baillie et al. 
2007). The developing mammalian embryo constitutes a hypoxic environment, especially 
around the time of neural tube closure (Chen, Fujinaga, and Giaccia 1999), and hypoxia-
induced oxidative stress has been implicated as a mechanism of NTDs associated with 
diabetes (Li et al. 2005). While it is unknown how important urate’s antioxidant properties 
are during this critical window of development, it is conceivable that reduced capacity to 
handle VPA-induced oxidative stress may distinguish between VPA-sensitive and resistant 
embryos. This hypothesis is supported by a previous study which demonstrated that 
coadministration of VPA with antioxidants was ameliorative with respect to both oxidative 
stress and unsavory developmental and morphological endpoints, including NTDs (Tung 
and Winn 2011). Regardless, it is a notable observation that purines accumulated in VPA-
treated embryos but that their catabolic product, urate, was diminished only in apparently 
sensitive embryos, suggesting impairment of purine catabolism may be a marker of VPA 
sensitivity. 
Decreased abundance of citrate cycle intermediates was also a unique predictor of 
VPA-sensitive embryos. It has been previously demonstrated that VPA may reduce 
excitatory neuronal activity by inhibiting Krebs’s cycle and impairing production of ATP 
(Johannessen et al. 2001), and that VPA inhibits mitochondrial uptake of pyruvate (Aires 
et al. 2008). It is notable, however, that disruption of most of these citrate cycle 
intermediates, specifically succinate, fumarate, and citrate/isocitrate, was exclusive to 
VPA-sensitive embryos. We also observed VPA-dependent reduction of another citrate-
related metabolite, itaconate, which was significantly reduced in all VPA-treated embryos, 
but more so in the likely affected group (Figure 4.11). Itaconate is a metabolite of cis-
aconitate, the intermediate of interconversion of citrate and iso-citrate, and plays a role in 
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metabolic reprogramming of macrophages during an inflammatory response (Ferreira, 
Netea, and Dominguez-Andres 2019; O'Neill and Artyomov 2019). It has also been shown 
that itaconate modulates redox metabolism through activation of nuclear factor erythroid 
2-related factor 2 (Nrf2) in models of oxidative reperfusion injury (Cordes et al. 2020; Yi 
et al. 2020). Since inhibition of Nrf2 has been linked to NTDs (Liu et al. 2018), and 
activation of Nrf2 has been shown to prevent NTDs in certain models (Dong, Reece, and 
Yang 2016), itaconate deserves further exploration as a possible mechanistic component 
of VPA-sensitive NTDs. Even so, a metabolic profile associated with an impaired citrate 
cycle has implications for both central energy production and oxidative metabolism that 
may be explanatory of VPA sensitivity. 
The marker most strongly associated with the distinguished metabolic signature of 
likely affected embryos at E8.5 was accumulation of arginine and subsequent depletion of 
citrulline as demonstrated by the 10-fold elevation of the arginine/citrulline ratio. NO is 
synthesized by NOS enzymes, of which there are several isoforms, by NADPH-dependent 
reduction of arginine and molecular oxygen to produce citrulline and NO as products 
(Groves and Wang 2000). Our data suggest the severity of VPA-induced NOS inhibition 
may be determinative of VPA sensitivity (Figure 4.9D). Recent evidence has emerged 
indicating functional interaction between VPA and NO synthesis; although in some models 
VPA appears to attenuate NO production, while in other cases it has an enhancing effect 
(Mairuae and Cheepsunthorn 2018; Nieto-Patlan et al. 2019; Okubo et al. 2019). 
Coadministration of VPA with a NOS inhibitor, L-NAME, in mice at E8 was shown to 
enhance VPA’s teratogenic effects, resulting in a four-fold increase in NTDs and an 18% 
increase in skeletal defects (Tiboni, Chiarelli, and Verrotti 2013). It is also known that 
exposing chick embryos to exogenous NO induces NTDs through inhibition of vitamin 
B12-dependent methionine synthase, and that these defects can be rescued with folic acid 
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supplementation (Weil et al. 2004). Inhibition of NOS enzymes in chick embryos also 
causes NTDs through modulation of methionine synthase activity (Nachmany et al. 2006). 
Since we observed elevated methionine in likely affected embryos and a reduction 
in markers associated with homocysteine metabolism, we looked deeper into the 
relationship between arginine and methionine in our dataset. We found that abundance of 
arginine and methionine was highly correlated in untreated control embryos at E8.5, but 
less so in VPA-treated embryos (Figure 4.12). As arginine levels increased, so too did 
levels of methionine, but their relationship became increasingly uncoupled as these two 
metabolites increased in abundance. Likely affected embryos showed the highest levels of 
both metabolites, but the correlation between their relative abundances was ablated (Figure 
4.12). These data would suggest that arginine metabolism and methionine synthesis are 
coupled in embryos at this developmental stage, and that this coupling is most likely 
mediated by NO-dependent modulation of methionine synthase activity. Further 
experimentation is needed to confirm this mechanism of VPA sensitivity. It is also 
interesting to note that NO is reported to play a role in modulating metabolic 
reprogramming in inflammatory macrophages via the citrate cycle and itaconate (Bailey et 
al. 2019). Thus, it is possible that each of these aspects characterizing the unique metabolic 
signature in VPA-sensitive embryos may be functionally linked to one another through 
nitric oxide. Either way, the predictive biomarkers of VPA-sensitivity identified in our 
study point to impairment of NOS and subsequent NO production as a novel mechanism 
of VPA teratogenicity that warrants further experimental exploration. 
To conclude, our metabolomic comparison of VPA-affected and unaffected murine 
embryos identified predictive biomarkers of VPA sensitivity associated with the citrate 
cycle, urate, cysteine and methionine metabolism, and arginine-dependent nitric oxide 
synthesis. The findings presented herein lay a groundwork for future studies exploring 
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metabolic mechanisms of VPA sensitivity and may help to identify underlying components 
of genetic susceptibility to VPA-induced congenital defects. Understanding these 
susceptibilities may allow for more informed decisions regarding the safe use of VPA or 
other AEDs during pregnancy, the design of alternative AEDs with lower teratogenic 
potential, or the development of intervention strategies that may reduce the risk of adverse 
pregnancy outcomes associated with VPA and other AEDs. 
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Chapter 5: Calcium Enhances Interactions Between Folate, FOLR1, 
and the Integrase Inhibitor, Dolutegravir 
5.1 INTRODUCTION 
The work in this chapter represents the dissertation author’s contribution to a 
research article published in the journal AIDS, “The antagonism of folate receptor by 
dolutegravir: developmental toxicity reduction by supplemental folic acid.” (Cabrera et al. 
2019). The previously published material will be denoted with quotes and additional 
indentation. 
“Dolutegravir (DTG) is the clinically preferred integrase inhibitor, available 
as a single agent (Tivicay, ViiV Healthcare, Brentford, UK) for use with other 
antiretroviral therapy (ART) medications, and available in combination 
formulation (e.g., Triumeq, ViiV Healthcare) for HIV ART. A teratogenic risk for 
DTG was recently reported after neural tube defects (NTDs) were observed in four 
infants from mothers who had been taking DTG at the time of conception in 
Botswana (Zash, Makhema, and Shapiro 2018). The WHO subsequently provided 
guidelines that DTG use be avoided by women of childbearing potential unless they 
used adequate contraception methods (WHO 2018).” 
“Preclinical studies reported DTG was administered orally at up to 
1000mg/kg daily, in rats and rabbits, during the period of organogenesis, days 16-
17 and 16-18, respectively. Although not statistically significant, examination of 
these data indicates one occurrence (1/167) of cranioschisis (anterior NTD) at 
40mg/kg in rabbits (Oral Study For Effects of S-349572 Sodium on Embryofetal 
Development in Rabbits). There was also a rat pup with meningocele, that is spina 
bifida, at 1000mg/kg in study SG10306 (Reproductive and Developmental 
Toxicity: Effects on Pre and Post-Natal Development Including Maternal Function, 
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in Rats). An ongoing observational human cohort study in Botswana reported a six 
to nine-fold increase for NTD risk in the offspring of mothers receiving DTG (Zash, 
Makhema, and Shapiro 2018; Zash 2018).” 
In Cabrera et al. (2019), we demonstrated developmental toxicity in zebrafish 
(Danio rerio) exposed to 100μM DTG beginning between one and five hours post 
fertilization, with 80-100% embryo mortality. However, mortality was reduced to 0-7.69% 
in D. rerio embryos co-exposed to 60ng/mL folic acid. We also hypothesized that DTG is 
a FOLR1 antagonist and demonstrated that DTG produces partial antagonism “with an 
unadjusted half-maximal inhibitory concentration (IC50) of approximately 4.4 μmol/L” 
using a FOLR1-folate binding microtiter assay. The dissertation author designed and 
performed cell culture experiments building on these results and found that DTG inhibited 
cellular folate uptake in NIH-3T3 cells and in a human placental trophoblast cell line 
(HTR-8/SVneo). Using fluorescently labelled folic acid, it was demonstrated that 
therapeutic concentrations of DTG result in dose-dependent cytotoxicity, altered 
localization of cellular folate, and enhanced cellular folate binding, but only in cell culture 
media and not in buffered saline. These results suggested that an ingredient in cell culture 
media modifies DTG-folate interactions, and calcium was subsequently identified to be the 
modifying factor. Using the FOLR1-folate binding microtiter assay, it was discovered that 
calcium enhances both FOLR1-folate interactions and FOLR1-folate-DTG interactions. 
The data generated by these experiments are presented herein, and the implications of these 
findings regarding plausible mechanisms of DTG’s contribution to NTD risk are discussed. 
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5.2 MATERIALS AND METHODS 
5.2.1 General Cell Culture 
HTR-8/SVneo (ATCC, CRL-3271) (Graham et al. 1993) human trophoblast cells 
were cultured under standard conditions (5% CO2, 37⁰C) in RPMI media with 5% FBS. 
NIH-3T3 and HeLa cells were cultured under standard conditions in DMEM with 10% 
FBS. Experiments were carried out in folic acid-free RPMI 1640 or DMEM with 1% FBS 
to limit the contribution of undefined folate in the serum. Depending on the experiment, 
unlabeled folic acid or labelled folic acid was added back to the media at concentrations 
specified by the described experimental parameters. 
5.2.2 Microscopy and Image Analysis 
“Live cell imaging using near-infrared-labeled folate (50 nmol/l, 
FolateRSense 680; Perkin Elmer, Waltham, Massachusetts, USA), prepared in 
DPBS [or folic acid-free media] with 1% FBS, was used to determine the impact 
of DTG on folate interactions [in cell culture]. Cations, Ca+2, Fe+3, Mg+2, and K+, 
were prepared from calcium chloride (1.8 mmol/l), iron III sulfate (250 nmol/l), 
magnesium sulfate (810 μmol/l), or potassium chloride (5.3 mmol/l). These ion 
concentrations are typical for cell culture media or serum. Folic acid (0-60 ng/ml) 
and DTG (0-100 μmol/l) were likewise dissolved in DPBS with 1% FBS for testing. 
Following incubation (1 h) with test compounds, cells were washed in DPBS with 
1% FBS. Live-cell nuclei were stained using Hoechst 33342 (1 μg/ml, 10 min) 
(Thermo Fisher Scientific, Waltham, Massachusetts, USA). Images were captured 
and analyzed on the Operetta High Content Imaging System (Perkin Elmer).” 
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5.2.3 Quantification of Cellular Folate Uptake 
NIH-3T3 or HTR-8/SVneo were cultured for 24 hours in 80% confluent 6-well 
plates in their respective folic acid-free media with 100nM unlabeled folic acid added back. 
Low-folate controls were cultured with only 10nM folic acid. Cells received either 2μM, 
10μM, or 20μM DTG or were left untreated except with DMSO as a vehicle control. There 
were six replicates for each control and treatment group. After 24 hours, cells were lifted 
with 0.05% Trypsin-EDTA, washed twice with PBS and then lysed in TBS-T with 0.1% 
ascorbic acid by boiling (described in Chapter 2, Section 2.2.5). The resulting protein pellet 
was reserved for protein quantification using a DC Protein Assay (BioRad, 5000111). 
Relative folate was quantified in the supernatant of each lysate using the FOLR1 
competitive microtiter binding assay methods described in Chapter 2, Section 2.2.5. 
Samples were normalized to total protein for relative comparison. 
5.2.4 Microtiter Assay for FOLR1 Antagonism 
The FOLR1 competitive microtiter binding assay was also used to test calcium-
dependent modulation of DTG-FOLR1 antagonism as described in Chapter 2.  
“For all testing, stock DTG solutions were prepared at 100 mmol/l in 
dimethyl sulfoxide (DMSO). DTG was diluted (1:1000, producing 100 μmol/l 
DTG, 0.1% DMSO) into tris-buffered saline with 0.01% Tween-20 (TBS-T), and 
serial diluted (1:1) in TBS-T for testing. Vehicle dilutions were done in parallel 
with 0.1% DMSO serial diluted into TBS-T. Based on the results of in-vitro studies, 
calcium was also examined for interactions with FOLR1-folate binding by DTG. 
Calcium was tested by adding serial diluted calcium chloride (0, 0.125-2 mmol/l) 
to the competitive binding buffer [TBS-T, DTG, folic acid-horseradish peroxidase 
(FA-HRP, Ortho Clinical Diagnostics, Raritan, New Jersey, USA)].” 
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More specifically, large volume serial dilutions of calcium chloride (0, 0.125-2 
mM) were made in TBS-T/1:10 FA-HRP (competitive binding buffer). Four separate serial 
dilutions of DTG (0, 0.25-32μM) were made into each calcium-competitive binding 
solution. At least three replicates of each combination were conducted. These samples were 
plated into FOLR1 labelled 96-well assay plates, which were then incubated, washed, 
imaged, and analyzed as described in Chapter 2, Section 2.2.5. 
5.2.5 Statistics 
All statistical analyses were performed using GraphPad Prism (La Jolla). Statistical 
significance was determined by one-way ANOVA with Dunnett’s multiple comparisons 
tests (α=0.05).  
5.3 RESULTS 
5.3.1 Dolutegravir Inhibits Cellular Folate Uptake and Elicits Cytotoxicity 
Consistent with our findings that DTG antagonizes folate binding to FOLR1, we 
observed a dose-dependent decrease in cellular folate uptake in HTR-8/SVneo and NIH-
3T3 cells (Figure 5.1). In both cell lines, relative cellular folate in the 10nM (low) folic 
acid controls was lower compared to cells exposed to 100nM folic acid. Mean relative 
cellular folate decreased as DTG exposure increased. Notably, relative cellular folate in 
NIH-3T3 cells appeared to be more strongly disrupted by DTG than in HTR-8/SVneo. In 
NIH-3T3, mean cellular folate was decreased to 83%, 50%, and 9% in 2μM, 10μM, and 
20μM DTG-treated samples, respectively, compared to that of unexposed cells. In HTR-
8/SVneo, mean cellular folate was decreased to 93%, 87%, and 78% in 2μM, 10μM, and 
20μM DTG-treated samples, respectively, compared to that of unexposed cells. While the 
observed decrease in HTR-8/SVneo was not statistically significant, the general decreasing 
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trend was still present. As to why NIH-3T3 were more sensitive to DTG, obviously there 
is the underlying genetic history, the fact that these cells were derived from separate 
individuals, and the fact that these cells are completely different cell types all likely 
factoring into the explanation. However, these results may also be explained by our 
subsequent findings that calcium modulates DTG-FOLR1-folate interactions at 
physiological concentrations, since DMEM, the base media for NIH-3T3, contains 1.8mM 
Ca+2, while RPMI 1640, the base media for HTR-8/SVneo only contains 0.42mM Ca+2. 
Regardless, the data obtained from both cell lines confirm that DTG inhibits cellular folate 
uptake. 
We also observed that DTG elicited a dose-dependent cytotoxicity in HTR-
8/SVneo. After 24 hours of exposure to 2.5μM, 5μM, 10μM, or 20μM DTG, nuclear area 
decreased to 98%, 92%, 88% and 60%, respectively compared to that of control cells 
(Figure 5.2A). Nuclear contraction is often associated with apoptotic and pre-apoptotic 
cells (Tone et al. 2007). Furthermore, we observed a dose-dependent decrease in the 
number of cells in each imaged well, suggesting a decrease in overall cellular viability. We 
do not believe cellular proliferation was a contributing factor, because these experiments 
were performed under low folate (100nM) and serum starvation conditions (1% FBS). 
5.3.2 Calcium Modifies Cellular Folate Distribution in Dolutegravir-treated Cells 
Based on our findings that DTG was a FOLR1 antagonist, we hypothesized that by 
using a near-IR-labeled folic acid, we could visualize decreased cellular folate in cells. 
Surprisingly, we found that when we performed the labelling experiment with HeLa cells 
in PBS, we did not observe any detectable differences in signal intensity per cell with or 
without DTG exposure (2.5μM, 5μM, 10μM, or 20μM), nor was there a dose response, at 
least after one hour of co-exposure. However, when we repeated the experiment in cell 
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culture media, we observed a dramatic change in cellular folate distribution concomitant 
with DTG exposure (Figure 5.3). In PBS and media, the labelled folate appeared to 
distribute evenly throughout the cytosol, and in PBS this was the case even with 20μM 
DTG. However, in cell culture media with 20μM DTG, we observed that labelled folate 
appeared highly restricted to small puncta of intense near-IR signal within cells. It is not 
clear whether these puncta represent clustered folate-receptor-DTG complexes on the cell 
surface, in the cytosol, or possibly within sub-cellular compartments. It might be the case 
that these folate-receptor-DTG complexes sequester folate and disrupt its sub-cellular 
distribution, possibly by blocking internalization of folate receptor, preventing release of 
internalized folate from endosomes, or decreasing solubility of folate. Either way, it 
appears that some component of cell culture media that is lacking in PBS modifies DTG-
folate interactions. 
Since DTG and similar drugs target HIV integrases through binding of cations in 
the integrases’ active sites (Song et al. 2015), we hypothesized that metal cations in cell 
culture media, of which there are five (Ca+2, Fe+3, Mg+2, K+, and Na+), are the modifying 
factors affecting DTG-folate interactions. To test this hypothesis, we repeated the near-IR 
folic acid labelling experiment of HeLa cells in PBS but added back concentrations of these 
individual cations to see which, if any, elicited the phenotypes observed in cell culture 
media upon DTG treatment. We excluded Na+ from this experiment since it is present in 
both PBS and the media. Only coadministration of Ca+2 and DTG reproduced the altered 
cellular folate distribution observed in cell culture media (Figure 5.4). It also appeared that 
calcium enhanced folate levels within the cells. The total near-IR signal associated with 
the labelled folate increased 180% compared to DTG-treated cells that received no cations 
(Figure 5.5). Comparatively, iron and magnesium resulted in 32% increases, while 
potassium elicited a 30% increase. To be certain that this was not a HeLa-specific 
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phenomenon, we repeated the experiment using HTR-8/SVneo using 20μM DTG in PBS 
for one hour, with and without calcium chloride (1.8mM). We observed the same increase 
in cellular folate accumulation and punctate distribution of labelled folate within cells 
(Figure 5.6). These results suggest that calcium cations are a modifier of DTG-folate 
interactions at the cellular level.  
5.3.3 Calcium Enhances Interactions Between Folate, FOLR1, and Dolutegravir 
Building on these findings, we hypothesized that calcium may modify DTG’s 
antagonism of FOLR1. To test this hypothesis, we repeated the competitive microtiter 
binding assay using calcium chloride-supplemented competitive binding buffer. We did 
not observe any changes in binding of FA-HRP to FOLR1 or DTG’s antagonism of said 
binding at 0.125mM or 0.5mM Ca+2. At 2mM, however, calcium enhanced FA-HRP 
binding to FOLR1 by 42.3% even in the absence of DTG (Figure 5.7). It was further 
observed that DTG enhanced this effect up to a certain concentration, such that at 4μM 
DTG, binding of FA-HRP to FOLR1 was two-fold higher compared to 0μM DTG. At 
higher concentrations of DTG, however, 8-32μM, it appears DTG became 
stoichiometrically superior and it was clear that increasing concentrations of DTG resulted 
in antagonistic properties. These data confirm that calcium enhances both folate-FOLR1 
interactions as well as folate-FOLR1-DTG interactions at physiologically relevant 
concentrations. It also appears that calcium’s ability to modify these interactions is 
dependent on the stoichiometric ratios of the reactants. 
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Figure 5.1 Effect of Dolutegravir on Cellular Folate Uptake in HTR-8/SVneo and NIH-
3T3 
Charts depicting dose-dependent reduction in relative cellular folate after 24 hours DTG 
exposure in HTR-8/SVneo (A and B) and NIH-3T3 (C and D). 
*Statistical significance was determined using one-way ANOVA with Dunnett’s multiple 
comparisons tests (α=0.05). n=6 for all groups. *, p<0.05. **, p<0.01. ***, p<0.001. ****, 
p<0.0001. 
 
(Figure from Cabrera et al. (2019)) 
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Figure 5.2 Therapeutic Concentrations of Dolutegravir Cause Cytotoxicity in HTR-
8/SVneo  
A) Dose-dependent contraction of nuclear area in HTR-8/SVneo after 24 hours DTG 
exposure. 
B) Dose-dependent reduction in total cell count in HTR-8/SVneo after 24 hours DTG 
exposure. 
*Statistical significance was determined using two-way ANOVA with Dunnett’s multiple 
comparisons tests (α=0.05). *, p<0.05. **, p<0.01. ***, p<0.001. ****, p<0.0001. 
 
(Figure from Cabrera et al. (2019)) 
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Figure 5.3 Dolutegravir Modifies Cellular Folate Distribution in a Media-Dependent 
Manner 
Microscopy images demonstrating disrupted cellular folate distribution after one hour of 
20μM DTG exposure in HeLa cells in cell culture media (C and D) but not PBS (A and B). 
Scale bars represent 100μm 
Red = FolateRSense 680 labelled folic acid (Perkin Elmer) 




Figure 5.4 Effect of Various Cations on Cellular Folate Binding in Dolutegravir-exposed 
HeLa Cells – Microscopy Images 
Microscopy images demonstrating effect of various cations [(A) potassium chloride 
(5.3mM), (B) magnesium sulfate (810 μM), (C) iron III sulfate (250nM), (D) no cation 
control and (E) calcium chloride (1.8mM)] on cellular folate uptake and distribution in 
HeLa cells after one hour of 20μM DTG exposure in PBS. 
Scale bars represent 200μm 
Red = FolateRSense 680 labelled folic acid (Perkin Elmer) 
Blue = Hoescht 33342 nuclear label 
 
(Figure from Cabrera et al. (2019))  
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Figure 5.5 Effect of Various Cations on Cellular Folate Binding in Dolutegravir-exposed 
HeLa Cells – Quantification 
Quantification of FolateRSense 680 signal demonstrating effect of various cations 
[potassium chloride (5.3mM), magnesium sulfate (810 μM), iron III sulfate (250nM), and 
calcium chloride (1.8mM)] on cellular folate uptake in HeLa cells after one hour of 20μM 
DTG exposure in PBS. 
*Statistical significance was determined using one-way ANOVA with Dunnett’s multiple 
comparisons tests (α=0.05). n=6 for negative and no cation controls. n=12 for all cation-
treated groups. *, p<0.05. **, p<0.01. ***, p<0.001. ****, p<0.0001. 
 
(Figure from Cabrera et al. (2019))  
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Figure 5.6 Calcium Modifies Cellular Folate Binding in Dolutegravir-exposed HTR-
8/SVneo 
Microscopy images demonstrating effect of A) no calcium and B) calcium (calcium 
chloride, 1.8mM) on cellular folate uptake and distribution in HTR-8/SVneo after one hour 
of 20μM DTG exposure in PBS. 
Scale bars represent 200μm 
Red = FolateRSense 680 labelled folic acid (Perkin Elmer) 





Figure 5.7 Calcium Enhances Folate-FOLR1-Dolutegravir Interactions 
“Calcium (2mM) modified folate binding to FOLR1 in the microtiter 
protein-ligand binding assay. In the presence of Ca+2 (2mM) and absence of DTG, 
folate receptor bound 42.3% more FA-HRP. The response to DTG in the presence 
of 2mM Ca+2 appeared biphasic. The dolutegravir-Ca-FOLR1 interaction below 
4μM increased folate binding, but at concentrations above 4μM, the binding fell to 
77%, or decreased -23% compared to untreated wells.” 
 





“Adverse interactions with DTG have been reported clinically with 
coadministered polyvalent cations, including calcium and iron (Tivicay, 09/2018, 
Summary of Effect of Coadministered Drugs on the Pharmacokinetics of 
Dolutegravir). The clinical concern is that coadministration can result in decreased 
DTG uptake and lower serum concentrations (Song et al. 2015). The increase in 
folate binding in cells with DTG (< 4 μmol/L) was unexpected based on the 
FOLR1-folate binding microtiter assay. The increase in folate-FOLR1 interactions 
(+42.3%) produced by calcium alone appears biologically relevant to folate-
FOLR1 interactions. This interaction is supported by another report that indicated 
calcium chloride (1 mmol/L) resulted in doubling of folate binding to rat intestinal 
mucosal cells (Colman, Hettiarachchy, and Herbert 1981).” The studies in HeLa 
cells and HTR-8/SVneo demonstrate that calcium is indeed a modifier of cellular 
folate binding, and the resulting cytotoxicity observed is supported by “a red blood 
cell study that reported DTG produces cytotoxicity in the presence of extracellular 
calcium (Al Mamun Bhuyan et al. 2016).” Furthermore, “the microtiter assay 
reproduced the increased folate binding observed in the cell culture assay[s] with 2 
mmol/L [Calcium].” These concentrations are physiologically relevant, as 
extracellular calcium in blood is approximately 2mM. “These data indicate that 
calcium is a modifier of FOLR1-folate binding, and we propose DTG chelation of 
calcium modifies FOLR1 interactions and cytotoxicity.” 
“Mechanistically, DTG binds to magnesium at the active site of the HIV 
integrase enzyme, thereby preventing integration of viral DNA into the host 
genome. Drugs in this class are unfortunately susceptible to cation interference if 
coadministered with mineral supplements of antacids (Song et al. 2015). The results 
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support the increased folate detected in the trophoblast model [and HeLa cell 
model] is a result of DTG-Ca-FOLR1-folate interactions, and the increase in signal 
represents localized increased concentrations of DTG and folate due to interaction 
with FOLR1. As soluble calcium increases folate-FOLR1 interactions and also 
interactions with DTG, the resulting chelation decreases DTG-Ca-FOLR1-folate 
solubility. This model is consistent with nuclei contraction and decreased cell 
numbers observed when DTG was coadministered with calcium and folate. We 
propose the increase in FOLR1-folate binding in cells exposed to DTG is due to 
DTG binding of calcium, and calcium-responsive FOLR1-folate binding, 
producing DTG-FOLR1-folate or DTG-Ca-FOLR1-folate complexes with limited 
DTG-folate solubility and increased cytotoxicity. The FOLR1 epitopes involved in 
DTG or Ca+2 binding, structural and stoichiometric interaction of these molecules, 
and testing of other ART medications for similar interactions are open topics for 
future studies.” 
“We have previously reported that homozygous deletion of Folr1 in mice 
is lethal, but folate supplementation if Folr1 mutants produces a range of 
developmental defects that vary by genetic background and range from lethality, to 
NTDs, to complete rescue (Piedrahita et al. 1999; Cabrera 2018). Based on these 
results, we propose the recommended folic acid (2-3 mg/kg) content in laboratory 
animal chow may limit the developmental toxicity of DTG. We propose future 
mammalian animal testing of DTG developmental toxicity is warranted, but 
preimplantation, peri-implantation, and post-implantation DTG exposure should be 
explored in studies using both low-folate diet (e.g. 0.3 mg/kg) and standard-folate 
diet to examine folate responsive defects and folate masking of DTG developmental 
toxicity. Furthermore, as more human cohort data is generated, or additional 
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clinical studies are performed on DTG, biological interactions and clinical 
correlations between natural folate intake, supplemental folic acid, fortified diets, 
calcium intake and resultant DTG, folate, and calcium in blood and serum should 
be investigated. It has been previously reported that in human populations where 
folate fortification is in place, the prevalence of folate deficiency is approximately 
0.1% or one per 1000 individuals, but in unfortified populations, the base line 
incidence may be more than 20%, one in five, or possibly higher (Rogers et al. 
2018). This 100-200-fold difference in the incidence of folate deficiency lowers the 
average serum folate, increases NTD risk and may also increase the risk of NTDs 
associated with early gestational in-utero DTG exposure. According to a WHO 
review from 1993 to 2005, 42% of pregnant women had iron-folate-related anemias 
worldwide and almost 90% of anemic women reside in Africa or Asia (Sanghvi, 
Harvey, and Wainwright 2010). On the other hand, preclinical animal studies are 
expected to approach 0% folate-deficient on standard diets, because they all have 
adequate folate intake. We propose the combination of fortified diets coupled to a 
critical period in zebrafish that parallels pre-gastrulation mammalian embryos 
(Carnegie Stage <8) limited previous detection of DTG-induced developmental 
toxicity. The data reported in this study indicate that the research and medical 
communities should consider folic acid supplementation and maternal folate status 
as a major modifier of DTG-induced developmental toxicity. The results from these 
studies are also expected to inform and guide future animal models and clinical 
studies of DTG-based ART in women of childbearing age.” 
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Chapter 6: Summary and Future Directions 
6.1 PART ONE SUMMARY 
Part One of this dissertation explored mechanisms of impaired mitochondrial OCM 
in NTDs using mouse and stem cell knockout models of the mitochondrial genes, Slc25a32 
and Mthfd1l. In Chapter 2, a novel digenic interaction was identified between Slc25a32 
and the Wnt co-receptor encoding gene, Lrp6. By crossing Slc25a32+/gt mice with Lrp6+/cd, 
it was discovered that a proportion of resulting co-heterozygous offspring presented with 
NTDs, suggesting the point of Lrp6-folate interactions may be in mitochondrial OCM. 
Further experiments demonstrated that Lrp6 regulates expression of mitochondrial OCM 
genes in mouse embryos, while CHO cells lacking Slc25a32 demonstrated impaired 
autonomous Wnt signaling that could be rescued with glycine. Building on that data, it was 
discovered that maternal glycine supplementation could prevent NTDs in Slc25a32 null 
embryos similarly to formate as previously reported (Kim et al. 2018); and preliminary 
data suggests that glycine or serine supplementation may reduce NTD risk associated with 
Cd heterozygosity. Thus, the experiments in Chapter 2 clearly identify a mechanistic 
interaction between canonical Wnt signaling and mitochondrial OCM and suggests that 
glycine or serine may serve as novel intervention strategies for NTDs arising from human 
LRP6 variants or other mitochondrial OCM interactors. Future experiments will explore 
more detailed mechanisms underlying this interaction, and the efficacy of glycine and 
serine as NTD preventative supplements. For example, this dissertation demonstrated that 
mitochondrial OCM gene expression is impaired in Lrp6 Cd embryos at the level of 
mitochondrial folate transport, serine catabolism/glycine synthesis, and glycine 
catabolism. While expression levels of mitochondrial OCM genes have previously been 
shown to modify 1-C flux in cell culture (Ducker et al. 2016), it has not been demonstrated 
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in embryos. Thus, 1-C flux and incorporation analyses in Lrp6 Cd embryos using 
deuterium-labelled serine and 13C-labelled glycine may inform as to whether these 
observed changes in gene expression translate to impaired OCM (Ducker and Rabinowitz 
2017; Leung et al. 2017). Furthermore, it has not been shown that the observed Lrp6-
dependent reduction in expression of Slc25a32 results in reduced abundance in 
mitochondrial folate pools to any significant degree. Thus, mitochondrial folate levels and 
speciation in Lrp6 Cd embryos should be quantified to answer this question. β-catenin 
activity in Slc25a32 null and heterozygous embryos should be measured to determine if 
MFT-dependent Wnt signaling is replicated in vivo. Finally, it has yet to be determined if 
NTDs resulting from Lrp6/mitochondrial OCM mutants are FA-resistant, whether Lrp6 
can interact with other mitochondrial OCM genes (such as Mthfd1l), or whether glycine, 
serine, or formate can rescue NTDs associated with compound Lrp6/mitochondrial OCM 
mutations. Thus, future experiments will explore these questions. 
In Chapter 3, it was demonstrated that ES cells lacking Mthfd1l have proliferation 
defects and are sensitive to hypoxia. It was notable that co-supplementation with 
hypoxanthine and thymidine appeared more efficient than formate at rescuing proliferation 
defects associated with loss of Mthfd1l. Thus, future experiments may look into the efficacy 
of hypoxanthine and thymidine as co-supplements for prevention of NTDs in the Mthfd1l 
knockout mouse model. Chapter 3 experiments also demonstrated that ES cells lacking 
Mthfd1l display hypoxia sensitivity in a manner independent of Mthfd1l’s role in nucleotide 
metabolism and proliferation. ES cells displayed a hypoxia-induced decrease in cell 
viability that was determined by Mthfd1l gene dosage, with nulls being most sensitive. 
These results imply alternative mechanisms by which Mthfd1l or impaired mitochondrial 
OCM may cause NTDs apart from simply insufficient production of formate for cytosolic 
1-C units. These alternate mechanisms may include mitochondrial OCM’s role in 
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producing the reducing equivalents NADPH and NADH, as well as supporting glutathione 
synthesis, thus modulating cellular redox balance. While the cancer research-community 
has already been exploring these mechanisms in their models, deciphering these same 
mechanisms in embryos is much more challenging. Finally, Chapter 3 identified changes 
in murine embryonic expression of mitochondrial OCM genes, specifically down 
regulation of Shmt2, Mthfd1l, and Mthfd1, concurrent with upregulation of Aldh1l1 and 
Aldh1l2, between E8.5 and E10.5. These changes suggest a metabolic switch away from 
production of mitochondrial 10-formyl-THF and utilization of 10-formyl-THF for formate 
synthesis and cytosolic OCM after NTC. Future experiments will explore whether these 
changes in gene expression translate into actual changes in metabolism, and to determine 
the factors driving and requiring this theorized metabolic switch. 
6.2 PART TWO SUMMARY 
Part Two of this dissertation explored mechanisms through which pharmaceutical 
exposures to VPA or DTG may cause NTDs. For Chapter 4, by comparing metabolites of 
differential abundance between VPA-affected and unaffected embryos, we were able to 
identify metabolic markers that are predictive of VPA sensitivity. Our results confirmed 
previous reports that VPA disrupts embryonic purine and pyrimidine metabolism, but we 
found that this alone was not associated with VPA sensitivity. Metabolites in affected 
embryos suggest impairment of nitric oxide synthase enzymes as a mechanism for 
valproate-induced neural tube defects. Disruption of the citrate cycle and alterations in 
amino acid interconversion were also predictive, especially methionine and cysteine 
metabolism. These results identify previously unexplored metabolic mechanisms through 
which valproic acid may cause congenital defects, thus establishing a groundwork for 
further investigation that could evolve strategies for preventing these defects. Future 
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experiments will test mechanistic hypotheses prioritized based on the findings presented in 
this study. Moreover, since some mouse strains are more resistant than others, an 
alternative future approach could be to perform a comparative metabolic analysis in 
embryos after VPA exposure in a relatively sensitive strain, such as SWV, and a relatively 
VPA-resistant strain, such as LM/BC. Ultimately, identifying mechanisms underlying 
VPA-sensitivity in NTDs may lead to the development of novel intervention strategies or 
alternative, nonteratogenic pharmaceuticals for treatment of epilepsy in women of 
childbearing potential. 
The work presented in Chapter 5 explored mechanisms underlying interactions 
between folate, FOLR1, and the HIV integrase inhibitor, DTG. The cell culture 
experiments built on the findings of Cabrera et al. (2019) that DTG is a folate receptor 
antagonist at therapeutic concentrations. It was discovered that an unknown component in 
cell culture media modifies cellular folate distribution and uptake in the presence of DTG, 
and subsequent experiments demonstrated that calcium was the modifying component. 
Using a competitive folate binding assay, it was demonstrated that calcium enhances DTG-
FOLR1-folate interactions, and it was proposed that these interactions may not only 
antagonize folate uptake but may also sequester sub-cellular folate and reduce 
bioavailability of folates by decreasing their solubility. While Cabrera et al. (2019) 
demonstrated developmental toxicity in zebrafish resulting from DTG exposure, and that 
supplemental FA reduced said toxicity, more teratology and human epidemiological 
studies are needed to assess NTD risk associated with DTG. Future experiments are 
planned to assess developmental toxicity in mouse embryo models using dams on low-
folate diets, thus more adequately accounting for DTG-folate interactions compared to the 
initial teratology studies performed for the drug’s approval. The role of calcium as a 
modifier will also be assessed in these studies. 
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Ultimately, the work presented in this dissertation identifies new mechanisms 
through which impaired mitochondrial OCM or drug exposure to VPA or DTG may cause 
NTDs. Building on the work presented here may eventually lead to novel strategies for the 




APPENDIX I: PRIMERS FOR QPCR 
Table I.1 Primers for qPCR 
Gene (species) Forward Primer (5’ to 3’) Reverse Primer (5’ to 3’) 
Actb (C. griseus) ATGACGATATCGCTGCGCTC GCCACAGGATTCCATACCCAG 
Actb (M. musculus) CCACCATGTACCCAGGCATT AGGGTGTAAAACGCAGCTCA 
Aldh1l1 (M. musculus) TCTTTGACCTTGGGTGCCTT GAACACACCCACCACCTCAT 
Aldh1l2 (M. musculus) TGAAGCGAAGCACTCAACCC TTGAAATAAACCCGGCTGGTG 
Amt (M. musculus) ATGCAGGACAAGGTCAAGGAG GTGGGTCCTTGCAGAGCTAACA 
Bhmt (M. musculus) GAGGCAGTTCGTCAGCTTCA GCTTCGTTGACTTTCTGCCC 
Dhfr (M. musculus) GACGGCAATCCTAGCGTGAA CTCGTTCCTGAGCGGAGGC 
Folr1 (M. musculus) ACAAGAAAGGAGGCTGACGG CCGAGGTTTAGTGGCCTGAA 
Gapdh (C. griseus) CCTGGAGAAACCTGCCAAGTA CGGTGTGGGGGTTATTGGAC 
 
Gapdh (M. musculus) GCACAGTCAAGGCCGAGAAT GTGGTTCACACCCATCACAA 
Gldc (M. musculus) AGAAGCCACAGAAATCGCCA AGCCACATACCCTCTTGCAC 
Hprt (C. griseus)  GCAGCGTTTCTGAGCCATTG 
 
CATCATCGCTAATCACGACGC 
Hprt (M. musculus) ACAGGCCAGACTTTGTTGGA ACTTGCGCTCATCTTAGGCT 
Lrp6 (C. griseus) TGGATGGACAACACCGACAG CGGTCCAATACATAAATCCTTC 
Mtfmt (M. musculus) GTGTACCACAGACCATCGCA ATCCAGCCATCCTTACAGCG 
Mthfd1 (M. musculus) GACCCAGACAGACAAGGCTC TGGTGGGTTCAGTCTTCTCA 
Mthfd1l (M. musculus) CCACCCGACCCTGCTTTTAT CTTGACCGCATCTTGCCCAG 
Mthfd2l (M. musculus) GCCGGAGACACGAAGCC GGTGTGGCTTGCTGGGTTAT 
Mthfr (M. musculus) TGAGCAGATCGGGATGAACC GATTCCTGCTGAAGGGTGG 
Mtr (M. musculus) AATACTTGCTGGCTGGAGCA ATCCGGTAGGCCAAGTGTTC 
Polm (C. griseus) CGATCCAAAGGCTTCCGCAT CCACGTGTGTCACCTCTGTA  
 
Polm (M. musculus) TCTCTCCTTCTCCAGAGCGG CAGCAGCTCCTGGATTACTCT 
Rpl13a (C. griseus) CATGCTGCCCCACAAGACTA CCTGGTATTTCCACCCGACC 
Rpl13a (M. musculus) TGACAAGAAAAAGCGGATGGTG GCTGTCACTGCCTGGTACTT 
Shmt1 (M. musculus) GGAGGTGTTGCTGTGGTCA ACTGGTTCAGAGTTGCCTTGT 
Shmt2 (M. musculus) CAGAGATGTGGTCAGCTGGT GCAGAAGTTCTCTGAGGCGA 
Slc25a32 (M. musculus) CGTAGCAGCAACATACCCGT ATGCCTTCTTTCCTCCACGTC 
Wnt1 (C. griseus) AGCTGGGTTTCTGCTACGTT GTTCACGATGCCCCACCATC 
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Table I.1 continued 
 
Wnt10a (C. griseus) CTGTAGGACCAGTGCCAGGA CAACTCCTGGTGCCTCCCAA 
Wnt10b (C. griseus) GGCTTTGTTCACTCGGGCT GGGAAGTTTTAGGCCCAGGAT 
Wnt11 (C. griseus) AAGCCAATAAACTGATGCGG GGCACGTAGAGCCTGTCTCC 
Wnt16 (C. griseus) TCCAGTACGGCATGTGGTT CGACAGCCTGCCTTCCC 
Wnt2 (C. griseus) TCCTCCGAAGTAGTCGGGAAT GGTCACAGGAGCAGGACTTT 
Wnt2b (C. griseus) CCATGCGGTCGCAGCTC TCCCAATATCTCCGTCCCCC 
Wnt3 (C. griseus) GAAAACAGACCTGATGCCCG CAGGATGGTCGTGCGGC 
Wnt3a (C. griseus) GGAAGAACCAAAACGGAGCC CCACAGCTAAAGACCACCAGA 
Wnt4 (C. griseus) GAAAAGTGTGGCTGTGACCG TGGAAACCCTGTGGGCTGAC 
Wnt5a (C. griseus) TACCAGTTTCGGCATCGGAG GTCTCTCTGCTGCCTATTTGC 
Wnt5b (C. griseus) CAACACGTCTGTCTTCGGCA CAGTCTCCCGGCTACCTATC 
Wnt6 (C. griseus) GAGACGATGTGGACTTCGG GCGTGTGCTACGCACCA 
Wnt7a (C. griseus) GCCTGGACGAGTGTCAGTTT CCGGCTCCCCACTTTAAGC 
Wnt7b (C. griseus) GCCAACAGTTCCGATTC GCCTCACGACTCCCTACTCG 
Wnt8a (C. griseus) ATCCCCGTTCACCTCAGTTT TCAGATAGGCCTTGGGACCTG 
Wnt8b (C. griseus) TCGTAGTGCTAACCGGGAGA CGGGAGTCATCACAACA 
Wnt9a (C. griseus) CCGCGCTCAATGGCTCATAG CCTGTTAGCCGGGATCTAGC 




APPENDIX II: SIGNIFICANTLY ALTERED METABOLITES BETWEEN E8.5, E9.5, AND 
E10.5 IN VPA-TREATED EMBRYOS 
Table II.1 Significantly Altered Metabolites Between E8.5, E9.5, and E10.5 in VPA-
treated Embryos 
Fold change (FC) and p values are relative to E8.5. 
Metabolite FC-9.5 FC-10.5 p val-9.5 p val-10.5 
Cytidine 5-Triphosphate 2.11E+05 1.88E+06 1.763E-03 6.948E-07 
Uridine 5-Triphosphate 1.43E+05 1.35E+06 1.992E-03 2.398E-05 
Uridine 5-Diphosphoglucuronic Acid 2.11E+04 2.35E+05 8.375E-04 2.306E-19 
NADH 8.98E+03 2.33E+05 5.643E-03 1.238E-04 
2-Deoxyadenosine 5-Triphosphate 6.83E+03 1.11E+05 1.612E-03 4.236E-08 
Guanosine triphosphate 1.61E+03 2.18E+04 3.058E-03 1.461E-07 
Adenosine 5-Triphosphate 3.06E+02 8.49E+03 1.504E-03 5.382E-07 
NAD 7.21E+02 5.64E+03 6.001E-04 2.205E-11 
Uridine 5-Diphosphogalactose 3.88E+02 2.14E+03 4.393E-04 2.045E-25 
DAMP 2.63E+01 9.32E+02 2.244E-02 4.796E-10 
Uridine 5-Diphospho-N-
Acetylglucosamine 1.50E+02 8.98E+02 4.802E-04 7.068E-26 
Guanosine 5-Diphosphate 1.16E+02 5.19E+02 1.115E-03 2.053E-23 
Adenosine 3,5-Diphosphate 4.89E+01 3.07E+02 7.663E-04 1.216E-21 
CMP 9.86E+00 2.76E+02 2.886E-03 5.415E-08 
3-Hydroxykynurenine 4.53 222.30 2.667E-02 6.682E-14 
Guanosine 5-Monophosphate 2.27 168.77 1.256E-02 1.426E-06 
Adenosine 5-Monophosphate 4.84 142.81 2.429E-02 1.205E-08 
Uridine 5-Diphosphate 44.03 137.15 6.985E-04 1.211E-17 
Fructose 1,6-Biphosphate 21.29 131.76 1.547E-04 1.608E-12 
O-Phospho-Dl-Serine 41.35 118.68 1.922E-06 1.660E-08 
D-Glucosamine 6-Phosphate 7.24 96.68 6.442E-04 1.217E-10 
Oxidized glutathione 6.12 71.49 1.677E-06 2.336E-07 
L-Carnitine 2.77 51.94 8.940E-10 3.803E-10 
Adenosine 5-Diphosphoribose 23.95 51.61 9.943E-04 1.090E-03 
Cytidine 5-Diphosphate 8.93 27.69 1.493E-03 2.302E-16 
Hypotaurine 3.76 26.32 8.670E-10 2.282E-08 
D-Pantothenic Acid 1.93 25.23 1.161E-10 3.874E-11 
Dihydroxyacetone Phosphate 107.83 23.32 4.144E-08 2.301E-08 
5-Aminopentanoate 1.94 22.68 2.944E-07 9.738E-11 
1-Methyladenosine 1.42 15.02 1.861E-08 2.107E-08 
Cis-4-Hydroxy-D-Proline 1.49 14.01 6.058E-13 3.852E-06 
Glutamate 3.61 13.57 8.874E-17 8.241E-12 
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D-Saccharic Acid 3.55 13.04 9.100E-04 3.087E-25 
Adenine 1.08 12.61 7.278E-03 1.452E-20 
N-Methyl-L-Glutamate 3.25 11.69 1.659E-13 2.051E-17 
Creatine Phosphate 15.62 11.50 5.916E-06 5.037E-04 
Ophthalmic Acid 0.88 11.28 7.957E-06 1.009E-07 
5-Hydroxyindoleacetate 0.18 10.98 4.235E-01 3.821E-09 
5-Oxo-L-Proline 2.99 10.21 2.490E-17 1.945E-11 
N-Acetyl-Dl-Glutamic Acid 2.17 9.83 1.230E-14 1.728E-16 
(S)-Dihydroorotate 2.78 9.48 7.688E-03 3.697E-11 
Creatine 2.10 8.96 1.301E-12 1.032E-18 
L-Glutamine 1.41 8.39 1.905E-03 8.740E-15 
Kynurenine 0.15 8.39 2.998E-01 9.835E-11 
5-Methylthioadenosine 1.23 8.25 1.212E-02 2.673E-21 
D-Alanine 2.06 8.25 4.593E-09 1.859E-09 
3-Ureidopropionate 0.79 7.55 1.682E-06 4.322E-08 
O-Succinyl-L-Homoserine 2.28 7.44 2.281E-07 7.025E-17 
S-(5-Adenosyl)-L-Homocysteine 3.35 6.54 2.589E-06 1.059E-13 
D-Tryptophan 0.26 6.46 6.893E-02 1.043E-09 
Maleamate 0.67 6.44 8.916E-04 4.409E-07 
Phospho(Enol)Pyruvic Acid 4.46 6.42 6.349E-04 1.414E-08 
L-Serine 0.77 6.00 1.408E-06 4.373E-09 
Thymidine 5-Monophosphate 0.44 5.44 3.613E-01 8.334E-14 
Adenosine 0.92 5.35 6.980E-02 3.253E-12 
Glycine 0.64 4.72 3.202E-03 1.407E-11 
L-Pipecolic Acid 2.40 4.40 4.626E-03 2.161E-06 
Uridine-5-Monophosphate 0.03 4.36 9.301E-01 3.404E-13 
Nicotinamide 2.07 4.16 2.385E-13 9.482E-16 
L-Proline 1.00 4.00 3.602E-09 1.609E-13 
2-Aminoethyl Dihydrogen Phosphate -0.02 3.70 9.277E-01 4.795E-21 
O-Acetyl-L-Carnitine 0.50 3.45 1.100E-03 3.595E-09 
N-Alpha-Acetyl-L-Asparagine 0.09 3.43 3.050E-01 3.844E-04 
Allantoin 1.10 3.19 1.496E-08 2.138E-15 
N-Acetyl-Dl-Methionine -0.51 2.92 7.572E-02 8.150E-08 
Pyridoxal -0.04 2.90 7.436E-01 2.138E-10 
N-Acetyl-Dl-Serine 1.95 2.87 7.313E-16 2.505E-31 
Isocitric Acid/Citric Acid 0.41 2.54 1.221E-02 4.995E-13 
Leucine/Isoleucine/Norleucine -0.06 2.46 5.881E-01 1.412E-07 
Methionine -0.07 2.42 6.211E-01 2.838E-07 
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L-Threonine/L-Allothreonine 0.56 2.31 2.283E-04 1.855E-06 
Glycerol 2-Phosphate 1.89 1.94 2.991E-06 1.607E-09 
Itaconate 0.44 1.93 5.340E-02 7.674E-18 
Fumarate 0.43 1.91 8.270E-03 2.136E-14 
L-Phenylalanine -0.33 1.60 2.025E-03 6.442E-06 
Gluconic Acid 0.96 1.59 8.051E-10 6.398E-19 
4-Acetamidobutanoate 0.34 1.50 2.162E-01 6.946E-06 
2-Hydroxyglutaric Acid 0.72 1.48 5.224E-02 2.900E-08 
N-Acetyl-L-Phenylalanine -0.16 1.46 1.636E-01 5.612E-08 
Alpha-D-Glucose 1-Phosphate 1.31 1.42 1.323E-02 4.915E-07 
4-Aminobutanoate/Gamma-
Aminobutyric Acid 0.43 1.25 1.377E-03 8.596E-04 
N-Acetylneuraminate 0.50 1.23 1.550E-03 7.909E-14 
Taurine 0.39 1.05 5.043E-05 1.850E-17 
L-Tyrosine -0.23 0.97 3.019E-02 2.083E-05 
2,4-Dihydroxypyrimidine-5-
Carboxylic Acid/Orotic Acid 1.73 0.96 1.710E-04 1.503E-03 
D-Glucose 0.16 0.87 3.859E-01 1.628E-03 
Mannitol 1.46 0.73 1.117E-03 3.081E-04 
Citrulline 0.16 0.69 4.490E-01 2.423E-02 
Guanine 0.28 0.56 3.741E-01 1.536E-03 
N-Acetyl-L-Aspartic Acid 1.69 0.54 2.187E-11 2.460E-03 
5-Deoxyadenosine 2.58 0.54 2.861E-03 1.571E-02 
N-Acetyl-L-Leucine 1.22 0.45 2.716E-01 1.630E-01 
O-Succinyl-L-Homoserine 1.35 0.25 8.517E-11 1.792E-01 
Urocanate 0.49 0.22 3.286E-01 3.030E-01 
N-Acetyl-D-Galactosamine 0.31 0.07 3.159E-01 6.184E-01 
L-Aspartate 0.02 0.03 8.624E-01 8.090E-01 
6-Carboxyhexanoate 0.10 0.02 6.520E-01 8.796E-01 
S-Carboxymethyl-L-Cysteine -0.33 -1.00 1.771E-01 4.607E-08 
Inosine 0.14 -0.96 5.807E-01 8.005E-13 
Diethyl 2-Methyl-3-Oxosuccinate -0.49 -0.96 9.086E-06 7.572E-15 
Suberic Acid -0.65 -0.94 1.387E-07 7.827E-13 
Azelaic Acid -0.60 -0.94 4.699E-06 1.326E-12 
Palatinose/Maltulose -0.50 -0.90 1.647E-03 4.215E-09 
Xanthine 0.67 -0.89 1.310E-01 1.721E-07 
D-Glyceric Acid -0.51 -0.84 5.216E-05 3.748E-11 
Methyl Beta-D-Galactoside -0.53 -0.80 2.886E-04 1.121E-07 
3-Hydroxy-3-Methylglutarate -0.32 -0.79 3.519E-02 1.849E-08 
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2-Oxobutanoate -0.52 -0.75 3.418E-05 2.615E-09 
3-Sulfino-L-Alanine 0.18 -0.71 3.996E-01 8.398E-11 
D-Glucuronic Acid -0.22 -0.71 3.164E-01 5.859E-05 
6-Deoxy-L-Galactose -0.68 -0.70 5.863E-06 6.330E-07 
Nalpha-Acetyl-L-Lysine -0.81 -0.68 1.611E-04 9.104E-04 
Urate -0.61 -0.65 1.971E-03 3.634E-04 
Uridine 0.14 -0.65 6.280E-01 2.974E-06 
2-Oxoadipate -0.14 -0.62 2.429E-01 1.277E-05 
4-Methyl-2-Oxo-Pentanoic Acid -0.70 -0.57 3.545E-07 1.708E-05 
Thymidine -0.01 -0.55 9.513E-01 7.241E-04 
Hypoxanthine 0.65 -0.52 7.892E-02 5.637E-06 
Butanoate -0.33 -0.51 1.585E-04 1.354E-08 
Ll-2,6-Diaminoheptanedioate -0.54 -0.51 2.176E-03 2.373E-03 
D-Ribose 5-Phosphate -0.39 -0.48 8.676E-02 7.388E-04 
L-Cystine 4.08 -0.39 3.286E-05 4.010E-01 
Cytidine 0.43 -0.36 2.339E-01 1.357E-03 
Uracil 0.02 -0.34 9.240E-01 1.086E-02 
Oxaloacetate -0.21 -0.31 2.387E-01 9.243E-02 
Arginine -0.53 -0.30 3.595E-03 6.172E-02 
L-Arabitol -0.60 -0.30 4.506E-04 5.180E-01 
Adipic Acid -0.19 -0.30 1.057E-01 2.051E-02 
Guanosine 0.07 -0.27 8.039E-01 1.045E-01 
Dethiobiotin 0.01 -0.26 9.562E-01 3.449E-02 
4-Guanidinobutanoate 0.17 -0.19 1.545E-01 3.623E-02 
Succinate -0.11 -0.19 3.465E-01 7.704E-02 
Alpha-Ketoglutaric Acid -0.35 -0.17 1.367E-01 5.350E-01 
'4-Hydroxy-2-Quinolinecarboxylic 
Acid/Kynurenic Acid' -0.38 -0.12 2.633E-05 2.442E-01 
Dehydroascorbate -0.36 -0.12 5.409E-03 3.717E-01 
4-Imidazoleacetic Acid 0.45 -0.06 5.239E-02 5.203E-01 




APPENDIX III: METABOLITES OF SIGNIFICANTLY DIFFERENTIAL ABUNDANCE IN VPA-
TREATED E8.5 EMBRYOS 
Table III.1 Metabolites of Significantly Differential Abundance in VPA-treated E8.5 
Embryos 
Fold change (FC) and p values are relative to untreated E8.5 embryos. 
Metabolite FC p value FDR 
2,4-Dihydroxypyrimidine-5-Carboxylic 
Acid/Orotic Acid 231315.2 0.000101 0.000625 
S-Carboxymethyl-L-Cysteine 136441.8 5.96E-06 5.07E-05 
Inosine 388.4198 6.48E-09 2.94E-07 
S-(5-Adenosyl)-L-Homocysteine 90.66007 6.03E-05 0.00039 
Uridine 83.8889 2.05E-07 4.64E-06 
Cytidine 69.24708 1.28E-09 8.7E-08 
Hypoxanthine 67.47478 4.89E-10 6.64E-08 
Guanosine 26.94608 1.05E-06 1.3E-05 
Xanthine 23.79456 4.65E-06 4.21E-05 
Nalpha-Acetyl-L-Lysine 16.10791 0.000147 0.000798 
D-Ribose 5-Phosphate 11.32494 7.91E-07 1.35E-05 
5-Deoxyadenosine 7.836279 1.84E-06 1.92E-05 
Guanine 7.528564 1.01E-06 1.38E-05 
N-Acetyl-Dl-Methionine 7.497179 0.005959 0.01529 
N-Acetyl-D-Galactosamine 4.262983 9.55E-08 2.6E-06 
Maleamate 3.152688 7.61E-09 2.59E-07 
D-Glucuronic Acid 2.843835 0.001308 0.004449 
Uracil 2.503613 0.001081 0.004083 
Leucine/Isoleucine/Norleucine 2.306053 1.18E-05 8.94E-05 
L-Phenylalanine 2.255653 7.68E-06 6.15E-05 
Methionine 2.254925 0.000703 0.002812 
Arginine 2.087436 0.007051 0.017758 
Ophthalmic Acid 2.084014 0.003763 0.010889 
Dethiobiotin 2.048023 0.003993 0.011083 
D-Tryptophan 1.910766 0.001182 0.004346 
L-Aspartate 1.698815 0.000644 0.002653 
L-Tyrosine 1.65908 0.001038 0.004033 
L-Threonine/L-Allothreonine 1.29459 0.014442 0.030217 
2-Deoxyadenosine 5-Triphosphate 0.782845 0.01706 0.03412 
O-Acetyl-L-Carnitine 0.702552 0.007168 0.017724 
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Urocanate 0.694534 0.012178 0.02629 
O-Succinyl-L-Homoserine 0.646731 0.003187 0.009849 
4-Acetamidobutanoate 0.643921 0.012161 0.026675 
N-Acetyl-L-Aspartic Acid 0.635882 0.000459 0.002082 
3-Hydroxy-3-Methylglutarate 0.634816 0.007195 0.017473 
2-Aminoethyl Dihydrogen Phosphate 0.625163 0.003489 0.010315 
Taurine 0.617704 3.4E-05 0.000231 
Isocitric Acid/Citric Acid 0.574861 0.01367 0.029049 
Suberic Acid 0.573524 0.000277 0.001394 
Diethyl 2-Methyl-3-Oxosuccinate 0.556856 0.000549 0.002332 
5-Oxo-L-Proline 0.551748 0.00325 0.009823 
Oxidized glutathione 0.534635 0.015881 0.032237 
Azelaic Acid 0.534056 0.001801 0.005975 
Butanoate 0.532508 0.007509 0.017915 
N-Acetyl-L-Leucine 0.518602 0.018483 0.034912 
Hypotaurine 0.505195 0.005851 0.015302 
L-Glutamine 0.502684 0.003764 0.010665 
Palatinose/Maltulose 0.495823 0.000305 0.00148 
Itaconate 0.489953 2.17E-05 0.000156 
Glutamate 0.472907 0.002128 0.006889 
2-Oxobutanoate 0.468162 0.004097 0.011143 
Oxaloacetate 0.39163 0.010129 0.022959 
Dehydroascorbate 0.38198 0.001215 0.004238 
Glycerol 2-Phosphate 0.372708 0.002176 0.006883 
N-Acetyl-Dl-Serine 0.357209 1.32E-06 1.49E-05 
L-Carnitine 0.308258 0.01757 0.034137 
Creatine Phosphate 0.282662 0.015735 0.032425 
Uridine-5-Monophosphate 0.277163 0.000112 0.000661 
Mannitol 0.271321 2.72E-07 5.28E-06 
Deoxyuridine 0.243961 0.004713 0.012568 
O-Phospho-Dl-Serine 0.215642 0.001186 0.004246 
Cytidine 5-Diphosphate 0.112252 0.007949 0.018639 
L-Cystine 0.069638 0.000528 0.002315 
Adenosine 5-Diphosphoribose 0.033814 0.017072 0.033649 
Uridine 5-Diphosphate 0.030696 0.000141 0.000799 
Guanosine 5-Diphosphate 0.023678 0.026051 0.047877 
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Adenosine 3,5-Diphosphate 0.021049 0.000186 0.000971 
Adenosine 5-Triphosphate 0.007915 0.011116 0.024782 
Uridine 5-Diphospho-N-Acetylglucosamine 0.004405 8E-07 1.21E-05 
Uridine 5-Diphosphogalactose 0.001925 2.23E-06 2.17E-05 
NAD 0.001332 0.000319 0.001498 
Uridine 5-Diphosphoglucuronic Acid 7.5E-05 0.008186 0.01887 
Uridine 5-Triphosphate 2.44E-05 0.02495 0.046482 




APPENDIX IV: METABOLITES OF SIGNIFICANTLY DIFFERENTIAL ABUNDANCE IN 
LIKELY AFFECTED E8.5 EMBRYOS COMPARED TO LIKELY UNAFFECTED E8.5 EMBRYOS 
Table IV.1 Metabolites of Significantly Differential Abundance in Likely Affected E8.5 
Embryos Compared to Likely Unaffected E8.5 Embryos 
Fold change (FC) and p values are relative to likely unaffected E8.5 embryos. 
Metabolite FC p value FDR 
Arginine 3.127258 0.001488 0.01124 
Methionine 2.375961 8.87E-05 0.001341 
D-Tryptophan 2.203482 1.16E-07 1.58E-05 
L-Glutamine 2.053384 1.05E-06 7.15E-05 
L-Phenylalanine 1.829388 3E-05 0.00068 
L-Tyrosine 1.812679 0.0001 0.001362 
Leucine/Isoleucine/Norleucine 1.749528 2.26E-05 0.000614 
L-Serine 1.62573 0.000123 0.001515 
L-Threonine/L-Allothreonine 1.404364 0.000887 0.008042 
D-Alanine 1.380234 0.002674 0.015809 
N-Acetyl-L-Aspartic Acid 0.627777 0.000508 0.00532 
Taurine 0.599058 0.004087 0.021381 
Uridine 5-Diphosphoglucuronic Acid 0.575828 0.002211 0.01432 
3-Sulfino-L-Alanine 0.569848 0.00186 0.012647 
D-Glyceric Acid 0.542208 0.005035 0.025359 
Dehydroascorbate 0.538348 0.001368 0.010947 
Diethyl 2-Methyl-3-Oxosuccinate 0.537697 0.003392 0.018453 
Uracil 0.530414 0.010665 0.04679 
Oxaloacetate 0.523749 0.006177 0.028001 
3-Hydroxy-3-Methylglutarate 0.515073 0.002894 0.016398 
Succinate 0.505727 0.005184 0.02518 
Gluconic Acid 0.488355 5.77E-06 0.000262 
Fumarate 0.472373 0.001598 0.011435 
Itaconate 0.464116 0.000325 0.003679 
Suberic Acid 0.446541 3.54E-05 0.000687 
Azelaic Acid 0.418427 1.58E-05 0.000536 
Allantoin 0.412202 0.000513 0.004987 
6-Deoxy-L-Galactose 0.392875 0.002356 0.014564 
Isocitric Acid/Citric Acid 0.392359 3.79E-05 0.000644 
S-Carboxymethyl-L-Cysteine 0.368204 0.006032 0.02829 
Urate 0.269401 0.000997 0.008476 
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APPENDIX V: LIST OF ACRONYMS 
1-C one-carbon 
AdoMet S-adenosylmethionine 
AED antiepileptic drug  
ALDH aldehyde dehydrogenase  
ALDH1L1 aldehyde dehydrogenase 1-like  
ALDH1L2 aldehyde dehydrogenase 1-like 2  
AMT amino-methyl transferase 
ANOVA analysis of variance 
AP anterior-posterior  
ART antiretroviral therapy  
ATIC inosine monophosphate synthase 
ATP adenosine triphosphate 
BCM Baylor College of Medicine 
Cd Crooked Tail allele 
cDNA complimentary DNA 
CFD cerebral folate deficiency  
CH+-THF  5,10-methenyl- THF 
CH2-THF  5,10-methylene-THF 
CH3-THF 5-methyl-THF 
CHO chinese hamster ovary 
CHO-THF  10-formyl-THF 
CNS central nervous system  
CO2 carbon dioxide 
CRISPR clustered regularly interspaced short palindromic repeats 
CV coefficient of variation  
DHF dihydrofolate 
DHFR dihydrofolate reductase  
DLHP dorsolateral hinge points  
DMEM Dulbecco's modified Eagle's medium 
DMGDH dimethylglycine dehydrogenase 
DNA deoxyribonucleic acid 
DPBS Dulbecco's phosphate buffered saline 
DTG dolutegravir 
EdU ethynyl deoxyuridine 
ELISA enzyme-linked immunosorbent assay  
ES embryonic stem  
 161 
FA folic acid  
FAD+ flavin adenine dinucleotide 
FA-HRP  folic acid-horseradish peroxidase 
FBP folate binding protein 
FBS fetal bovine serum 
FC fold change 
FDA Food and Drug Administration 
FDR false discovery rate 
Fhs 10-formyltetrahydrofolate synthetase (prokaryotic) 
FOLR1 folate receptor 1 
FPGS folylpolyglutamate synthetase  
FR folate receptors 
GABA γ-aminobutyric acid  
GART phosphoribosylglycinamide formyltransferase 
GCS glycine cleavage system  
GLDC glycine decarboxylase 
GMP guanosine monophosphate  
GSEA gene set enrichment analysis  
Hcy homocysteine 
HDAC histone deacetylase 
HFM hereditary folate malabsorption  
HIF1α hypoxia-inducible factor 1α 
HIV human immunodeficiency virus 
HRP horseradish peroxidase 
IACUC Institutional Animal Care and Use Committee  
IR infrared 
KO knockout 
LC-MS liquid chromatrography-mass spectrometry 
L-NAME L-nitro-arginine methyl ester 
LRP2 low-density lipoprotein receptor-related protein 2 
LRP6 low-density lipoprotein receptor-related protein 6 
MAT1A methionine adenosyl transferase 1A 
MEF mouse embryonic fibroblast 
MEM minimal essential medium 
MESDC2 mesoderm development candidate gene 2 
MFT mitochondrial folate transporter  
MHP mediolateral hinge point 
ML mediolateral 
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mLIF mouse leukemia inhibitory factor 
mOCM mitochondrial one-carbon metabolism  
mRNA messenger RNA 
MS mass spectrometry 
MTFMT methionyl-tRNA formyltransferase 
MTHFD 5,10-methylene-THF dehydrogenase 
MTHFD1L methylene-tetrahydrofolate dehydrogenase 1-like 
MTHFR methylene tetrahydrofolate reductase 
MTR methionine synthase  
MTRR methionine synthase reductase  
NAD+ nicotinamide adenine dinucleotide 
NADP+ nicotinamide adenine dinucleotide phosphate 
NaOH sodium hydroxide 
NO nitric oxide 
NOS nitric oxide synthase 
Nrf2 nuclear factor erythroid 2-related factor 2  
NTC neural tube closure 
NTD neural tube defect 
O2 molecular oxygen 
OCM one-carbon metabolism 
PBS phosphate buffered saline 
PC principal component 
PCA principal component analysis 
PCFT proton-coupled folate transporter  
PCR polymerase chain reaction  
p-HWE p-value for Hardy-Weinberg Equilibrium  
PORCN porcupine O-acyltransferase 
PQN probabilistic quotient normalization 
QC quality control 
qPCR quantitative PCR 
RFC reduced folate carrier 
RNA ribonucleic acid 
RPMI Roswell Park Memorial Institute 
SAH S-adenosylhomocysteine  
SAM S-adenosylmethionine  
SARDH sarcosine dehydrogenase 
SEM standard error of the mean 
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SHMT serine hydroxymethyl transferase  
SV40 simian vacuolating virus 40 
SWV swiss-vancouver 
TBS tris buffered saline 
TBS-T tris buffered saline with 0.05% Tween-20 
TCF/LEF T-cell factor/lymphoid enhancer factor 
THF tetrahydrofolate 
tRNA-fMET  N-formylmethionyl-tRNA 
TYMS thymidylate synthase 
UDP uridine diphosphate 
UHPLC ultra high performance liquid chromatography 
VPA valproic acid  
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